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inTRoduCTion
Chronic hepatitis B (CHB) is a major cause of liver disease worldwide despite the 
availability of effective vaccination. There are still more than 350 million people 
chronically infected with the hepatitis B virus (HBV)1 and progression of HBV-related 
liver inflammation to cirrhosis, hepatic decompensation and hepatocellular carcinoma 
(HCC) is estimated to result in up to 1.2 million deaths annually.1
PHASeS of infeCTion
Patients with CHB may present in any one of four, not necessarily sequential, phases 
of infection.2 During the immunotolerant phase, hepatitis B e antigen (HBeAg) is 
detectable and serum HBV DNA level is high (generally >20,000 IU/mL), while serum 
alanine aminotransferase (ALT) is within the normal range and liver histology shows 
minimal inflammation. In the immune clearance phase, the host immune response 
results in a decline in HBV DNA levels, elevated ALT levels and hepatic necroinflam-
mation. During this phase HBeAg loss and seroconversion to anti-HBe can occur. 
HBeAg seroconversion is often followed by an inactive carrier state characterized by 
a low serum HBV DNA level (<2,000 IU/mL) and normalization of ALT. However, in a 
significant proportion of HBeAg-negative patients viral replication recurs or persists 
at higher levels, resulting in active HBeAg-negative CHB. This phase of the infection 
develops through presence of viral strains harbouring mutations in the precore or 
basal core promoter region that reduce or abolish the expression of HBeAg.3 Serum 
levels of hepatitis B surface antigen (HBsAg) also vary across the 4 phases of infection, 
with the highest levels observed in immunotolerant patients, a significant decrease in 
patients progressing to immune clearance, and the lowest levels in patients achieving 
sustained immune control.4
TReATMenT of CHRoniC HePATiTiS B: PARAdigMS And 
RATionAle
Complete eradication of HBV from host hepatocytes cannot be achieved with cur-
rently available agents, due to the persistence of HBV covalently closed circular DNA 
(cccDNA) in host hepatocytes. The main goal of treatment of CHB is therefore to halt 
the progression of liver inflammation to fibrosis, cirrhosis or hepatocellular carcinoma 
(HCC).5 Because these outcomes typically do not occur until after decades of active 
infection, surrogate outcomes are used as measures of therapy efficacy and success. 
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Several independent studies have shown that lower levels of HBV DNA, as well as 
clearance of HBeAg and HBsAg, are associated with a lower risk of cirrhosis, HCC 
and death.6-8 The major endpoints of treatment are therefore a reduction of HBV 
DNA to undetectable levels (virological response), loss of HBeAg with or without the 
appearance of antibodies to HBeAg (anti-HBe, serological response), a reduction 
of ALT to levels considered normal (biochemical response) and a reduction in liver 
necroinflammation with or without an improvement of liver histology.9 Loss of HBsAg 
from serum, accompanied by appearance of anti-HBs, is currently considered the 
optimal surrogate endpoint, although it is rarely achieved.10
TReATMenT of CHRoniC HePATiTiS B
Current guidelines recommend both peginterferon (PEG-IFN), an immune modulator, 
as well as the viral polymerase inhibiting nucleo(s)tide analogues (NA) entecavir and 
tenofovir as first-line treatment options of CHB. The efficacy of treatment is evaluated 
differently for the two treatment modalities, based on their different modes of action. 
In patients treated with NA, on-treatment maintained undetectable HBV DNA level 
is the most important endpoint, because persistently detectable HBV DNA during 
treatment is a major risk factor for the development of viral breakthrough, antiviral 
resistance and progression of liver disease.11-13 While HBeAg seroconversion may 
herald immune control in untreated patients, discontinuation of treatment after NA 
induced HBeAg seroconversion is associated with a high probability of post-treatment 
relapse.14-19 Similarly, discontinuation of NA in patients with HBeAg-negative CHB 
will result in relapse in nearly all patients.20 Continuation of NA therapy until HBsAg 
loss or seroconversion therefore appears to be the most prudent.21
In contrast, PEG-IFN is typically administered for a finite one-year course, after which 
therapy is discontinued. After discontinuation, a subset of patients will develop 
an off-treatment sustained response, assessed at six months post-treatment, and 
require no further therapy. In HBeAg-positive CHB patients treated with PEG-IFN, 
off-treatment sustained loss of HBeAg accompanied by the appearance of anti-HBe 
(HBeAg seroconversion) is frequently used as a definition of sustained response, since 
it is associated with a reduced mortality rate.8, 21 However, a subset of patients will 
have persistently high HBV DNA levels after HBeAg seroconversion, i.e. progress to 
HBeAg-negative CHB, and thus require retreatment.22, 23 The use of a combined sero-
logical and virological endpoint (HBeAg loss or seroconversion with concomitant HBV 
DNA <2,000 IU/mL) therefore seems preferable, since this endpoint is associated with 
a low probability of relapse24, a reduction in the risk of development of HCC7, 25 and a 
high probability of subsequent HBsAg loss and seroconversion.26 In HBeAg-negative 
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CHB patients, prolonged suppression of HBV DNA to low levels (typically below 2,000 
IU/mL), combined with normalization of ALT is currently considered the optimal defini-
tion of response to PEG-IFN27, although late relapse beyond 6 months post-treatment 
has been described.21
CHooSing THe APPRoPRiATe fiRST-line THeRAPy
Both NA and PEG-IFN have substantial advantages and important limitations.28 The 
potent NA entecavir and tenofovir are generally recognised as first line treatment 
options, and may induce and maintain undetectable levels of HBV DNA in nearly 
all patients with limited safety concerns through up to 5 years of treatment.29-31 
Nevertheless, the high rates of relapse observed after discontinuation of NA based 
treatment in both HBeAg-positive and HBeAg-negative CHB patients suggests that 
decades if not lifelong therapy will be necessary in most patients.14, 20 Since a one 
year course of PEG-IFN may induce an off-treatment sustained response in about 
25% of HBeAg-positive patients,28, 32 PEG-IFN may be a valuable treatment option 
for those patients with a high likelihood of response. However, the limited number 
of patients who achieve a response, and the high costs and side-effects associ-
ated with PEG-IFN treatment constrain its clinical use. Selection of patients with the 
highest probability of response is therefore essential for effective use of PEG-IFN 
in clinical practice. Recent studies have shown that response to PEG-IFN depends 
upon the infecting HBV genotype, baseline levels of HBV DNA and ALT, and possibly 
also patient age and sex and previous failure to respond to IFN therapy. However, a 
prediction model incorporating these variables provides only limited discrimination, 
and reliable prediction of response probabilities for individual patients remains a 
challenge.
on-TReATMenT PRediCTion of ReSPonSe To Peg-ifn
Possibly, on-treatment monitoring of viral replication may help identify patients with 
a very high or a very low probability during the first months of treatment. Currently, 
three quantitative markers are available for monitoring HBV replication: serum HBV 
DNA, HBeAg and HBsAg levels. Using data from the PEG-IFN alpha-2a trial, Fried 
et al identified a relationship between on-treatment HBV DNA levels and treatment 
response.33 Patients with HBV DNA levels below 5 log copies/mL at week 24 had a 
53% probability of response, as opposed to a probability of only 14% in patients with 
HBV DNA >9 log copies/mL.33 Nevertheless, the clinical utility of these findings is 
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limited, since a considerable number of future responders would be lost if all patients 
with HBV DNA >9 log copies/mL discontinued therapy.33 Since baseline HBV DNA 
levels are associated with treatment response, combining baseline and on-treatment 
HBV DNA levels may offer advantages. Nevertheless, discrimination between (non-)
responders using modeling of HBV DNA kinetics during PEG-IFN therapy remains 
difficult.34, 35
Other studies have reported on the predictive capabilities of HBeAg levels at week 
24 of therapy.33, 36 Patients who achieved a sustained HBeAg seroconversion show a 
considerably more pronounced on-treatment decline in serum HBeAg levels. Patients 
with the lowest HBeAg levels at week 24 have a 52% probability of sustained HBeAg 
seroconversion, as opposed to a probability of only 4% in patients with the highest 
levels.33 Unfortunately, prediction of response with HBeAg levels must be postponed 
to week 24 of therapy, and reliable assays for quantification of HBeAg are not widely 
available.
Recently, studies with newly available automated quantitative assays showed that 
serum HBsAg levels vary significantly during the different phases of chronic HBV 
infection and are inversely correlated with the immune control of HBV: the higher 
control, the lower HBsAg level.37-40 These findings are consistent with the hypothesis 
that HBsAg serum levels reflect the complex interplay between virus and immune 
system and provide complementary information to viral load as measured using HBV 
DNA levels. Importantly, serum HBsAg levels comprise not only virions (42 nm, Dane 
particles), but mainly the non-infectious HBsAg particles (20 nm diameter filaments 
of variable length and 20-22 nm spheres) which do not contain viral nucleic acids 
and exceed virions by a factor ranging between 102 and 105. HBsAg is secreted from 
the hepatocyte during viral replication as part of the HBV nucleocapsid, or as part 
of noninfectious viral particles.41 Several studies have reported that serum HBsAg 
levels correlate with intrahepatic cccDNA levels in HBeAg-positive patients.42, 43 On-
treatment HBsAg decline may therefore reflect the efficacy of PEG-IFN in decreasing 
intrahepatic cccDNA and consequently predict a sustained response.42, 43
The aims of the current thesis were therefore to (1) identify baseline factors asso-
ciated with an increased likelihood of response to PEG-IFN and (2) to investigate 
whether on-treatment monitoring of HBV replication using HBsAg levels can help 
identify (non-)responders to PEG-IFN therapy.
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1
ABSTRACT
Background & Aims
A limited number of HBeAg-positive patients with chronic hepatitis B respond to 
treatment with peginterferon-alfa (PEG-IFN). We investigated whether IL28B geno-
types are associated with response.
Methods
We studied 205 HBeAg-positive patients who were treated with PEG-IFN (some were 
also treated with lamivudine) at 11 European and Asian hospitals; genotype analysis 
was performed for IL28B rs12980275 and rs12979860. Response was defined as 
HBeAg loss with the appearance of anti-HBe at the end of PEG-IFN therapy (HBeAg 
seroconversion), along with HBeAg seroconversion and HBsAg clearance during 
long-term follow-up.
Results
The patients were infected with hepatitis B virus (HBV) genotypes A (13%), B (20%), 
C (47%), and D (13%). The proportions of IL28B genotypes were 77%, 19%, and 5%, 
for AA/AG/GG at rs12980275 and also for CC/CT/TT at rs12979860, respectively. 
IL28B genotype was significantly associated with HBeAg seroconversion at end 
of treatment (p<0.001); the adjusted odds ratio for seroconversion was 3.16 (95% 
confidence interval [CI], 1.26–8.52; p=0.013) for AA vs AG/GG at rs12980275, after 
adjustment for HBV genotype, age, levels of HBV DNA and alanine aminotransferase, 
and combination therapy. IL28B genotype was independently associated with an 
increased probability of HBeAg seroconversion during long-term follow up (adjusted 
hazard ratio [HR], 2.14; 95% CI, 1.14–4.31; p=0.018 for AA vs AG/GG by Cox regres-
sion analysis). Similar results were obtained for rs12979860. IL28B genotype was also 
associated with HBsAg clearance (HR 3.47 for AA vs AG/GG; 95% CI, 1.04–13.48; 
p=0.042).
Conclusions
Polymorphisms near IL28B are independently associated with serological response 
to PEG-IFN in HBeAg-positive patients with chronic hepatitis B.
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inTRoduCTion
Chronic hepatitis B affects over 350 million people worldwide and is one of the lead-
ing causes of cirrhosis and hepatocellular carcinoma.1 Antiviral therapy with peginter-
feron-alfa (PEG-IFN) results in viral suppression, hepatitis B e antigen (HBeAg) sero-
conversion, hepatitis B surface antigen (HBsAg) clearance, normalization of alanine 
aminotransferase (ALT) and histological improvement.2-4 The long-term therapeutic 
effect of PEG-IFN is durable,5-6 and patients who achieve an IFN induced HBeAg 
seroconversion have a reduced risk of hepatocellular carcinoma and cirrhosis.7-9
However, only 30% to 40% of HBeAg-positive chronic hepatitis B patients treated 
with PEG-IFN achieve HBeAg seroconversion.2-4 Since PEG-IFN treatment is expen-
sive and associated with considerable side effects, selection of patients with the 
highest probability of response is essential for optimal utilization of this agent in 
clinical practice.
Recently, a number of baseline and on-treatment parameters were shown to be 
associated with response to PEG-IFN.10-11 However, a multivariate prediction model 
incorporating these predictors provides only limited discrimination, and considerable 
uncertainty therefore remains on the individual level. It is important to note that most 
described predictors are either virological, or related to the phase of hepatitis B virus 
(HBV) infection.10-11 The influence of host factors on treatment response to PEG-IFN 
in chronic hepatitis B is currently unclear.
Recently, several independent genome-wide association studies have shown that 
genetic polymorphisms at or near the interleukin 28B gene (IL28B; also known as 
IFN-λ-3), including rs12980275 and rs12979860, are associated with higher rates of 
sustained virological response in chronic hepatitis C patients treated with PEG-IFN 
and ribavirin.12-15 The findings have been confirmed in other populations, including 
chronic hepatitis C patients who have undergone liver transplantation.16 While the 
mechanism by which IL28B influences response to PEG-IFN therapy remains elusive, 
it is likely that the relationship is not specific to hepatitis C virus infection. The type 
of IFN coded for by IL28B, IFN-λ, has been shown previously to be active against 
several other viruses, including DNA viruses such as HBV.17-18 Whether IL28B poly-
morphisms are related to response to PEG-IFN in patients with chronic hepatitis B is 
currently unknown.
In this study, we aimed to investigate the effect of IL28B gene polymorphisms on 
PEG-IFN induced serological response at the end of treatment and through long-term 
follow-up in a large global cohort of HBeAg-positive chronic hepatitis B patients.
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MeTHodS
Patients
Consecutive patients with HBeAg-positive chronic hepatitis B who received PEG-IFN 
alfa-2a or PEG-IFN alfa-2b at the liver clinics of 11 European and Asian hospitals were 
enrolled. Patients were treated during various studies from 1988 through 2008 and 
subsequently enrolled in long-term follow-up (LTFU) studies.2-3, 5-6, 9 Host DNA was 
prospectively collected during LTFU. DNA from patients who previously participated 
in the HBV 99-01 study3 was collected during a scheduled long-term follow-up visit 
at selected centers. This LTFU cohort was previously shown to be representative of 
the overall cohort.5 DNA from patients treated with PEG-IFN at the Prince of Wales 
Hospital2, 6 was collected during LTFU visits. Patients previously treated with conven-
tional IFN9 at the Erasmus MC University Medical Center were contacted specifically 
for this study. All patients had positive HBsAg for at least 6 months and were positive 
for HBeAg and negative for antibodies to HBeAg (anti-HBe) at baseline. Short-term 
(maximum two years) concomitant use of nucleos(t)ide analogues was allowed. We 
excluded patients co-infected with hepatitis C virus, delta virus, or human immu-
nodeficiency virus and those who received immunosuppressants, chemotherapy 
or systemic corticosteroids during the study period. Race was determined by the 
local investigator. The study protocol was approved by the ethics committees of the 
participating centres and was consistent with the principles of the declaration of Hel-
sinki. All patients provided written informed consent for participation in the long-term 
follow-up study, and for use of genetic material for this study.
follow-up assessments
The follow-up time was calculated from the starting date of PEG-IFN. For the current 
study, liver biochemistry and hepatitis B virus serology measurements were performed 
at the start of PEG-IFN, during treatment, at the end of treatment and 6 months 
after PEG-IFN discontinuation. Patients were subsequently followed at the outpatient 
clinic every 3-6 months. HBV DNA levels were assessed at therapy initiation, end of 
treatment and at last follow-up date.
endpoints
The primary endpoint was HBeAg seroconversion, defined as negative HBeAg and 
positive anti-HBe in serum. HBeAg seroconversion was assessed at the end of PEG-
IFN treatment to account for differences in post-IFN treatment with nucleo(s)tide 
analogues within the study cohort, and was also investigated through long-term post-
treatment follow-up. At long-term follow-up, HBeAg seroconversion was defined as 
HBeAg seroconversion that was sustained to end of follow-up whether or not followed 
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by HBsAg clearance. In patients retreated with other agents after discontinuation of 
the initial therapy regimen, follow-up was terminated at the start of retreatment, with 
(anti-)HBeAg status before retreatment used as outcome parameter. Other endpoints 
assessed were a combination of HBeAg seroconversion with HBV DNA <2,000 IU/mL, 
and HBsAg clearance. Patients who were retreated were considered non-responders 
for both endpoints.
laboratory tests
Enzyme-linked immunosorbant assay kits were used to test for HBsAg (Roche Diag-
nostics Corp., Indianapolis, IN, USA or AxSYM, Abbott, Abbott Park, IL, USA), HBeAg 
and anti-HBe (Sanofi Diagnostics, Pasteur, France or AxSYM, Abbott, Abbott Park, 
IL, USA). TaqMan real-time polymerase chain reaction assays were used to measure 
HBV DNA levels. HBV genotypes were determined by restriction fragment length 
polymorphism or by INNO-LiPA line-probe assay (Innogenetics, Gent, Belgium).19
IL28B genotyping
TaqMan SNP Genotyping Assays were employed for the detection of the reference 
single nucleotide polymorphisms (SNPs) near the IL28B gene on chromosome 19, 
rs12979860 and rs12980275 (Applied Biosystems, Foster City, CA).12, 20 These SNPs 
were chosen because they were previously reported in two independent studies, 
including mostly Caucasian12 and Asian14 hepatitis C virus infected patients. The 
laboratory procedure was carried out locally in the Erasmus MC University Medical 
Center and the Prince of Wales Hospital following the manufacturer’s instructions. 
Purified genomic DNA of 10 to 20 ng was used for genotyping. After amplification by 
polymerase chain reaction, endpoint plate read was performed using Real-Time PCR 
System (Applied Biosystems). Fluorescence values in each well were read using the 
Sequence Detection System Software.
Statistical analyses
All statistical analysis was performed using SPSS version 16.0 software (SPSS, 
Chicago, IL) and SAS 9.2 (SAS Institute Inc., Cary, NC, USA). Continuous variables 
were expressed as mean ± standard deviation or median (interquartile range (IQR)). 
Group comparison was performed using the Student t test, Mann-Whitney U test, chi-
square test, or Fisher’s exact test as appropriate. Binary logistic regression modelling 
was used to identify independent factors associated with HBeAg seroconversion ± 
HBV DNA <2,000 IU/mL at end of treatment and long-term follow-up. Kaplan-Meier 
analysis and Cox proportional hazard models were used to estimate the association 
between IL28B genotypes and HBeAg seroconversion and HBsAg clearance during 
follow-up. For logistic and Cox regression modelling, the Likelihood Ratio test was 
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used. Statistical significance was taken as a two-sided P value of less than 0.05. The 
proportional hazards assumption was verified using log-minus-log plots and by the 
addition of an interaction term between IL28B genotype and time.
ReSulTS
Patient characteristics
A total of 205 patients, comprising all those with available host DNA, were enrolled 
in the study cohort. All were successfully genotyped at rs12980275 and rs12979860 
near IL28B (table 1). Patients were predominantly male and of either Asian or 
Table 1: Baseline patient characteristics
Characteristics Study Population (n=205)
demography
 Mean (SD) age, years 35.0 (11.4)
 Male 149 (72.7%)
Route of transmission (%)
 Vertical 141 (68.8%)
 Other 64 (31.2%)
Race
 Caucasian 59 (28.8%)
 Asian 133 (64.9%)
 African/other/unknown 13 (6.3%)
Treatment
 PEG-IFN monotherapy 85 (41.5%)
 PEG-IFN + lamivudine 106 (51.7%)
 Conventional IFN 14 (6.8%)
laboratory results
 Mean (SD) ALT* 3.49 (2.74)
 Mean (SD) HBV DNA, logIU/mL 7.70 (1.07)
HBV genotype
 A 26 (12.7%)
 B 41 (20.0%)
 C 96 (46.8%)
 D 27 (13.2%)
 Other/mixed 9 (4.4%)
 Unknown 6 (2.9%)
*multiples of the upper limit of the normal range
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Caucasian origin. All major HBV genotypes were present in the study cohort, with 
HBV genotypes B and C being the most prevalent. The patients enrolled into the 
study were comparable to patients treated at the participating centres who were 
not enrolled with regard to important baseline characteristics. Patients were treated 
with either PEG-IFN monotherapy for one year (n=85)3, PEG-IFN 32 or 52 weeks + 
lamivudine for 52 weeks (n=83)2-3, 6, PEG-IFN for 32 weeks + lamivudine for 96 or 
104 weeks (n=23)6 or conventional IFN for 16-42 weeks (n=14)9. A total of 76 (37%) 
patients were retreated after PEG-IFN therapy. Overall follow-up lasted a median of 
173 (IQR 108 – 356) weeks.
Prevalence of IL28B genotypes
rs12980275 and rs12979860 were in linkage disequilibrium. Only 6 patients were 
classified discordantly. IL28B genotype frequencies were 77%/19%/5%, both for AA/
AG/GG genotypes at rs12980275 and CC/CT/TT genotypes at rs12979860, respec-
tively. Considerable differences were observed concerning the distribution of the 
rs12980275 genotypes for Asians when compared to non-Asians in the study cohort 
(p<0.001, figure 1A), and across HBV genotypes A through D (figure 1B). Similar 
distributions were observed for rs12979860.
Relationship between IL28B genotypes and HBeAg seroconversion 
at end-of-treatment
At the end of PEG-IFN treatment, a total of 90 (44%) patients achieved HBeAg 
seroconversion. HBeAg seroconversion rates varied significantly by IL28B genotype 
(p<0.001, figure 2A). Figures 2B and 2C show the HBeAg seroconversion rates at end 
of treatment by IL28B genotype across HBV genotypes A through D. The relationship 
between IL28B polymorphisms and HBeAg seroconversion at the end of PEG-IFN 
treatment remained statistically significant after adjustment for other baseline pre-
dictors, including age, HBV genotype, combination treatment, HBV DNA level and 
ALT level. The adjusted odds ratio (OR) for HBeAg seroconversion of patients with 
rs12980275 genotype AA versus AG/GG was 3.16 (p=0.013, 95% CI: 1.26-8.52, 
table 2). Similar data were observed for rs12979860 genotype CC versus CT/TT; 
the adjusted OR was 2.89 (p=0.024, 95% CI: 1.15-7.80, table 2). Importantly, the 
relationship between IL28B genotype and HBeAg seroconversion was similar when 
analysed separately for Asians and non-Asians. Combining the genotyping results for 
rs12979860 and rs12980275 into haplotypes was not superior to use of rs12980275 
genotype alone. Since HBV genotype and route of transmission were highly collinear, 
we chose to build the models using HBV genotypes.
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Relationship between IL28B genotype and HBeAg loss with or 
without HBV dnA <2,000 iu/ml at 6 months post-treatment
To allow for comparison with previously published prediction models that defined 
response as HBeAg clearance3 or HBeAg clearance with HBV DNA <2,000 IU/mL 
at 6 months post-treatment10, we also considered these endpoints. The analyses 
at 6 months post-treatment were limited to the 182 (89%) patients who received no 
LAM or LAM for ≤52 weeks. In this population, IL28B genotype was independently 
90%
2%
8%
AA
AG
GG 38%
11%
51%
Asians  (n=133) Non-Asians (n=72)
A
90%
3%
7%
26%
22%
52%
10% 2%
88%
AA
AG
GG
A B
C D
58%
0%
42%
B
figure 1: Distribution of rs12980275 genotypes in Asians versus non-Asians (A, p<0.001), and 
across HBV genotypes A through D (B). Similar frequencies were observed for rs12979860; only 
6 (3%) patients were classified discordantly.
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figure 2: Relationship between rs12980275 and rs12979860 genotype and HBeAg seroconver-
sion at end of PEG-IFN treatment, for the overall cohort (A) and across HBV genotype A through 
D (B and C).
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associated with HBeAg clearance at six months post-treatment (OR for AA vs AG/GG 
3.54 [95% CI: 1.33 – 9.41, p=0.008]; OR for CC vs CT/TT 3.24 [95% CI: 1.21 – 8.69, 
p=0.016]) when adjusting for HBV genotype, baseline levels of HBV DNA and ALT, 
baseline age and previous IFN exposure3. In a model with the same variables, IL28B 
genotype AA (for rs12980275) and CC (for rs12979860) appeared to be associated 
with a higher probability of HBeAg clearance with HBV DNA <2,000 IU/mL, although 
associations were not significant (OR 2.09 [95% CI: 0.76 – 5.75, p=0.139] for AA vs 
AG/GG and OR 1.92 [95% CI: 0.70 – 5.26, p=0.188] for CC vs CT/TT). The relationship 
between IL28B genotype and response was not significant when IL28B genotype was 
added to the previously calibrated PEG-IFN treatment index10: OR for AA vs AG/GG 
1.28 (p=0.588), and OR for CC vs CT/TT 1.03 (p=0.948).
Relationship between IL28B genotypes and HBeAg seroconversion 
through long-term follow-up
A total of 100 (49%) patients achieved HBeAg seroconversion in a median of 93 
(IQR 49 – 192) weeks. Only 15 of 90 (17%) patients with a HBeAg seroconversion at 
end-of-treatment experienced a relapse during follow-up, whereas an additional 25 
achieved HBeAg seroconversion after treatment discontinuation. HBeAg seroconver-
sion at long-term follow-up was associated with IL28B genotype; HBeAg seroconver-
sion rates were 54%/35%/20% in patients with AA/AG/GG genotypes (p=0.005). By 
Kaplan-Meier analysis, AA genotype (versus AG/GG, p=0.006) was associated with a 
higher cumulative probability of HBeAg seroconversion. In a Cox proportional hazards 
model, rs12980275 genotype AA was associated with a higher probability of HBeAg 
seroconversion by Cox regression analysis, when adjusting for HBV genotype, and 
baseline ALT and HBV DNA levels (HR 2.14, 95% CI: 1.14 – 4.31, p=0.018, figure 3A). 
Table 2. Odds ratios for HBeAg seroconversion at end of treatment
rs12980275 rs12979860
Variable oR (95% Ci) p Variable oR (95% Ci) p
AA genotype 3.16 (1.26 – 8.52) 0.013 CC genotype 2.89 (1.15 – 7.80) 0.024
HBV DNA* 0.58 (0.40 – 0.83) 0.003 HBV DNA* 0.57 (0.39 – 0.81) 0.002
HBV Genotype 0.050 HBV Genotype 0.044
 A Reference  A Reference
 B 0.57 (0.15 – 2.05)  B 0.55 (0.15 – 2.02)
 C 0.50 (0.15 – 1.58)  C 0.47 (0.14 – 1.54)
 D 0.15 (0.02 – 0.79)  D 0.14 (0.02 – 0.77)
ALT# 1.06 (0.93 – 1.21) 0.400 ALT# 1.05 (0.93 – 1.20) 0.453
Age 1.04 (1.01 – 1.07) 0.025 Age 1.04 (1.00 – 1.07) 0.026
Monotherapy 0.49 (0.24 – 0.97) 0.040 Monotherapy 0.47 (0.23 – 0.93) 0.030
*as log IU/mL; #as multiples of the upper limit of the normal range.
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figure 3: Cox proportional hazard model survival function of the relationship between rs12980275 
(AA versus AG/GG) (A), rs12979860 (CC versus CT/TT) (B) and HBeAg seroconversion through 
long term follow-up, plotted for the mean values of baseline HBV DNA and ALT and weighted 
by HBV genotype distribution. In retreated patients, follow-up was terminated and (anti)HBeAg 
status before retreatment was used.
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Similar data were observed for rs12979860. CC genotype was associated with a 
higher probability of HBeAg seroconversion when adjusting for the same parameters 
(adjusted hazard ratio (HR) 1.91, 95% CI: 1.03 – 3.78, p=0.041, figure 3B). For both 
analyses, combination treatment (p>0.76) was not a significant predictor of response. 
Stratification by ethnicity revealed no significant differences in the effect estimates for 
Asians versus non-Asians.
Relationship between IL28B genotypes and combined HBeAg 
seroconversion and low HBV dnA levels at long-term follow-up
A total of 57 patients (28%) achieved both sustained HBeAg seroconversion and 
HBV DNA <2,000 IU/mL at long-term follow-up. The differences in the probability of 
combined HBeAg and HBV DNA response across IL28B genotypes was not statisti-
cally significant. By multivariate regression analysis, patients with IL28B genotype AA 
(versus AG/GG) at rs12980275 tended to be more likely to achieve HBeAg serocon-
version with HBV DNA <2,000 IU/ml (OR 2.12, 95% CI: 0.86 – 5.72, p=0.11), when 
adjusting for the only other significant predictor at baseline, HBV genotype. Similar 
data was observed for patients with CC (versus CT/TT) (OR 1.79, 95% CI: 0.73 – 4.78, 
p=0.21).
Relationship between IL28B genotypes and HBsAg clearance 
through long-term follow-up
Overall, 18 (9%) achieved HBsAg clearance through a median of 173 (IQR 108 – 356) 
weeks of follow-up. By univariate analysis, HBsAg clearance was shown to occur in 
patients with all IL28B genotypes. After adjustment for HBV genotype A and ethnicity, 
rs12980275 AA genotype was associated with a higher probability of HBsAg clear-
ance (AA versus AG/GG, HR 3.47, 95% CI 1.04 – 13.48, p=0.042, figure 4). The HR 
for CC versus CT/TT was 2.57 (95% CI: 0.78 – 9.08, p=0.12).
diSCuSSion
In this large international collaborative study, we have shown that polymorphisms 
near IL28B are strong independent predictors of serological response to PEG-IFN 
in HBeAg-positive chronic hepatitis B. Patients with favourable IL28B genotypes 
have an increased probability of achieving HBeAg seroconversion both at the end of 
PEG-IFN treatment and through long-term follow-up, illustrating the importance of 
host factors when aiming to achieve a PEG-IFN induced immune response in HBeAg-
positive chronic hepatitis B.
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PEG-IFN based treatment can induce a durable response in a substantial proportion 
of HBeAg-positive chronic hepatitis B patients,3-5, 21 but the clinical use of PEG-IFN is 
compromised by side-effects,22 costs and the considerable uncertainty as to whether 
an individual patient will achieve such a sustained response. Selection of patients with 
a high probability of response is therefore essential for successful use of this agent 
in clinical practice. We have recently published a baseline prediction model based 
upon a pooled dataset from studies of PEG-IFN for HBeAg-positive chronic hepatitis 
B.10 Unfortunately, discrimination was limited, leaving substantial uncertainty on the 
individual level. Several studies have therefore focused on on-treatment monitoring of 
viral replication, and the formulation of stopping-rules.11, 23-24
Recently, large genome-wide association studies in hepatitis C virus infected patients 
have revealed an association between sustained virological response to PEG-IFN 
and ribavirin treatment and several single nucleotide polymorphisms on chromosome 
19, located near the IL28B gene.12-14, 20 These studies have convincingly shown that 
favorable IL28B genotypes, such as AA for rs12980275, confer increased probabilities 
of sustained virological response, independent of other predictors.20
The exact biological mechanism or pathway of the association between these favor-
able genotypes and response to PEG-IFN remains unclear. IL28B itself is a member 
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figure 4: Cox proportional hazard model survival function of the relationship between rs12980275 
(AA versus AG/GG) and HBsAg clearance through long-term follow-up, weighted by HBV geno-
type and ethnicity. Retreated patients were classified as non-responders.
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of the IFN-λ family, and IFN-λ was recently shown to be active against both RNA 
and DNA viruses.17-18, 25 Indeed, preliminary data from a phase 2 study show that 
treatment with PEG-IFN-λ is effective in HCV infected patients.26 Furthermore, in-
vitro studies have shown that IFN-α, such as administered in the form of PEG-IFN 
in our study, may induce IFN-λ production. Since the two types of IFN, IFN-α and 
IFN-λ, have common downstream signaling pathways, the two types of IFN may act 
synergistically in patients treated with PEG-IFN.27-30
The current study shows that IL28B genotypes also play an important role in respon-
siveness to the immunomodulatory effects of PEG-IFN in chronic hepatitis B. Within 
this global cohort of 205 HBeAg-positive chronic hepatitis B patients, comprising 
both Caucasian and Asian patients infected with all major HBV genotypes, IL28B 
genotype was strongly associated with PEG-IFN induced HBeAg seroconversion, the 
first step towards sustained immune control over HBV. Importantly, the relationship 
between favorable IL28B genotypes, AA for rs12980275 and CC for rs12979860, 
and HBeAg seroconversion was apparent both at the end of PEG-IFN treatment and 
through prolonged off-treatment follow-up. Additionally, the relationship between the 
favorable IL28B genotypes and HBeAg seroconversion was independent of other 
recently published predictors of response.10 It is important to note that viral genotype 
remains a very important determinant for response to PEG-IFN, in addition to IL28B 
genotype. In the current cohort, HBV genotype D was associated with a very low 
probability of response, suggesting that these patients with HBeAg-positive disease 
are poor candidates for PEG-IFN therapy.10 Similarly, the level of HBV DNA at baseline 
is very strongly related to the probability of response. Taken together, these findings 
suggest that IL28B can be a valuable addition when estimating a patient’s probability 
of response, but should be used together with, rather than instead of, previously 
described predictors of response.10
Our findings may have important clinical implications, because sustained HBeAg 
clearance induced by IFN has been proven to reduce the risk of hepatocellular 
carcinoma and to prolong survival.8-9, 31-32 Our finding that host genetic factors are 
strongly related to the occurrence of such a PEG-IFN induced immune response to 
HBeAg-positive HBV provides new insight into the mechanism of action of PEG-IFN 
in chronic hepatitis B, and may aid future selection of patients with a high probability 
of achieving a PEG-IFN induced immune response.
However, recent reports on the long-term prognosis of patients with PEG-IFN induced 
HBeAg clearance have revealed that some patients maintain detectable HBV DNA lev-
els and elevated ALT.5-6 A possible mechanism for these observations is the selection 
of viral strains that have mutations in the pre-core and basal core promoter regions 
that prohibit the synthesis of HBeAg, allowing for persistence of viral replication in 
the face of anti-HBe. 33-34 The data from the current study support the importance of 
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virological factors in the clearance of HBV after a host immune response to HBeAg. 
Despite the overt differences in HBeAg seroconversion rates across IL28B genotypes, 
HBsAg clearance occurs both in patients with favourable and unfavourable IL28B 
genotypes. These findings may be partly explained by HBV genotype distribution in 
this cohort, since HBV genotype A, associated with an increased probability of HBsAg 
clearance5, was also associated with unfavourable IL28B genotypes. In our cohort, 
patients with genotype A had the highest probabilities of response, both overall and 
after stratification for IL28B genotype. This is in line with previous reports,5-6 and is 
despite the relatively low frequency of favourable IL28B genotypes in these patients 
when compared to patients infected with genotype B and C. It should therefore be 
appreciated that HBV genotype remains a very important determinant of the prob-
ability of response to PEG-IFN, irrespective of IL28B genotype. Furthermore, the 
interplay between host factors such as IL28B genotype, and viral factors such as 
HBV genotype, in influencing the outcome of PEG-IFN therapy requires more exten-
sive and prospective investigation. This is especially relevant since IL28B genotype 
appears to be associated with serological responses, whereas a decrease of HBV 
DNA after HBeAg clearance or seroconversion appears to depend on other factors 
beside IL28B genotype. The poor performance of IL28B genotype in predicting a 
combined response of HBeAg clearance with HBV DNA <2,000 IU/mL when added to 
a previously calibrated model suggests that re-establishment of prediction models is 
necessary when IL28B genotype is used to estimate a probability of response.
Possible caveats of the current study relate to the heterogeneity of the study cohort. 
Patients in this study were treated with different types and durations of PEG-IFN with 
or without lamivudine. However, several independent long-term follow-up studies 
have shown that the combination of PEG-IFN with lamivudine provides no advantage 
3, 5-6, and we adjusted for combination therapy in multivariate analysis when neces-
sary. Furthermore, we enrolled a limited number of patients with genotypes other 
than A through D, and only one African patient, and it is therefore unclear whether our 
findings can be extended to these patients. Additionally, DNA samples for this study 
were prospectively collected during follow-up, but not all patients participating in the 
original studies on treatment effects could be enrolled.
Concluding, we have shown that polymorphisms near IL28B, at rs12979860 and 
rs12980275, are strong predictors of PEG-IFN induced HBeAg seroconversion. The 
association is independent of other important predictors, such as HBV genotype and 
baseline HBV DNA and ALT levels, and is apparent both at the end of treatment and 
through long-term post-treatment follow-up. The current study therefore shows that 
host factors are important for the induction of an immune response during antiviral 
therapy of HBeAg-positive chronic hepatitis B.
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ABSTRACT
Background & Aims
Peginterferon (PEG-IFN) treatment of HBeAg-positive chronic hepatitis B (CHB) 
results in HBeAg loss in 30% of patients, but clearance of HBV DNA and HBsAg 
from serum is less often achieved. We aimed to investigate whether the presence 
of precore (PC) and basal core promoter (BCP) mutants before PEG-IFN treatment 
affects serological and virological response.
Methods
A total of 214 HBeAg-positive CHB patients treated with PEG-IFN±lamivudine for 52 
weeks in a global randomized trial were classified at baseline as wildtype (WT) or non-
WT (detectable mutants at PC/BCP) by line-probe assay. Response was assessed at 
6 months post-treatment and through long-term follow-up(LTFU).
Results
Mutants were detected in 64% of patients, in varying frequencies across HBV 
genotypes A through D. Patients with WT had higher baseline HBV DNA, HBeAg 
and HBsAg levels than patients with non-WT. Patients with WT were more likely to 
achieve HBeAg loss with HBV DNA<10,000 copies/mL (response, 34 versus 11%, 
p<0.001) and HBsAg clearance (18 versus 2%, p<0.001) at week 78 than non-WT 
patients. Among WT patients who achieved HBeAg clearance at week 78, 78% had 
undetectable HBV DNA and 61% achieved HBsAg clearance at LTFU (versus 26% 
and 15% in non-WT patients, p<0.001 for both). Presence of WT virus at baseline 
was an independent predictor of response (OR 2.90, 95%CI: 1.15–7.31, p=0.023) and 
HBsAg clearance (OR 5.58, 95%CI: 1.26–24.63, p=0.013) and patients with non-A 
genotypes with detectable mutants had a low probability of response.
Conclusions
Presence of only WT virus at baseline is a strong predictor of response (HBeAg loss 
with HBV DNA <10,000 copies/mL) to PEG-IFN for HBeAg-positive CHB. Patients 
with detectable PC and/or BCP mutants have a lower probability of response and are 
less optimal candidates for PEG-IFN therapy.
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inTRoduCTion
Hepatitis B e Antigen (HBeAg)-positive chronic hepatitis B (CHB) is generally regarded 
as the earliest stage of a four stage disease continuum.1-3 HBeAg does not appear to 
be required for infection with hepatitis B virus (HBV), nor for viral replication, but the 
presence of HBeAg in serum is associated with higher HBV DNA levels and was also 
recently shown to be an independent risk factor for the development of hepatocellular 
carcinoma (HCC).4-5 Clearance of HBeAg (with or without appearance of anti-HBe) 
has therefore been adopted as a primary treatment endpoint for HBeAg-positive 
CHB.1, 3
Current treatment options for CHB result in increased rates of HBeAg clearance when 
compared to placebo treated patients. A one year course of peginterferon (PEG-IFN) 
results in HBeAg clearance in 34% of patients, compared to about 20% in patients 
treated with lamivudine (LAM), entecavir or tenofovir.1, 6 However, emerging data show 
that mere loss of HBeAg from serum may be insufficient to induce disease remission. 
Indeed, among patients who experience HBeAg clearance during nucleo(s)tide ana-
logue (NA) based therapy, a considerable number experience HBeAg reversion or have 
persistently detectable HBV DNA levels after discontinuation of therapy.7 Similarly, 
while HBeAg loss induced by IFN therapy seems to be more durable, a proportion 
of patients continues to have detectable HBV DNA during long-term follow-up.8-11 A 
possible explanation for these observations is the presence of viral strains that have 
mutations in the precore (PC) and basal core promoter (BCP) regions that prohibit 
the synthesis of HBeAg. Presence of these mutants before treatment initiation has 
been shown to predict HBeAg loss after IFN treatment,12 possibly through positive 
selection during antiviral therapy13, but may predispose patients to persistence of 
HBV DNA after HBeAg clearance. 14-15
The aims of the current study were therefore to study the presence and frequency of 
PC and BCP mutants within a cohort of HBeAg-positive CHB patients and to relate 
presence of PC and BCP mutant strains to serological and virological response to 
PEG-IFN therapy.
PATienTS And MeTHodS
Patients
In this study, the presence of PC and BCP mutants was assessed in a cohort of 
HBeAg-positive CHB patients who were previously enrolled in an investigator-initi-
ated multicenter randomized trial and had available HBsAg quantification measure-
ments.6, 8, 16 The inclusion and exclusion criteria for the original study have previously 
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been described elsewhere.6 In summary, patients were eligible if they had been 
HBsAg positive for at least 6 months before randomization, were HBeAg positive, had 
elevated serum alanine aminotransferase (ALT) levels of >2, but <10 times the upper 
limit of normal (ULN), and had a serum HBV DNA concentration of more than 1.0 x 
105 copies/mL. Patients were treated with PEG-IFN alfa-2b 100 μg weekly (PegIntron, 
Schering-Plough, Kenilworth, NJ, USA) in combination with placebo or LAM 100 mg 
(Zeffix, GlaxoSmithKline, Greenford, UK) daily for 52 weeks. The dose of PEG-IFN 
was reduced to 50 μg per week after 32 weeks of treatment to limit the probability of 
treatment discontinuation.
Inclusion criteria for the present analysis were completion of the 26-week follow-up 
phase of the main study, and availability of a baseline serum sample for PC / BCP 
mutation assessment. Of the 266 patients in the initial study, 214 fulfilled these criteria.
The study was conducted in accordance with the guidelines of the Declaration of Hel-
sinki and the principles of Good Clinical Practice. All patients gave written informed 
consent according to standards of the local ethics committees.
laboratory measurements
The presence of PC and BCP mutants was assessed using the INNO-LiPA HBV 
PreCore assay (Innogenetics, Ghent, Belgium). This very sensitive line probe assay 
allows for easy detection of PC (at nucleotide position G1896) and BCP (at nucleotide 
positions A1762 and G1764) mutants, even when only present as minority species.17 
Patients were subsequently classified as wildtype (WT, only WT virus detectable), 
PC (only PC or both PC and WT detectable), BCP (either or both BCP mutations 
detected, with or without WT), or as both when PC and BCP mutants were found. 
Serum HBV DNA, HBeAg and HBsAg was quantified in samples taken at baseline, 
during the treatment period (weeks 4, 8, 12, 24 and 52) and during follow-up (week 
78). HBV DNA quantification was performed using an in-house developed TaqMan 
polymerase chain reaction (PCR) assay (lower limit of quantification 400 copies/mL) 
based on the EuroHep standard.18 HBsAg was measured using the Abbott ARCHI-
TECT HBsAg assay (Abbott laboratories; range 0.05 - 250 IU/mL) and HBeAg with 
the Roche ELECSYS HBeAg assay using a quantitative protocol (Roche Diagnostics, 
range 0.2 – 100 IU/ml).
Statistical analysis
For the current study a composite endpoint of HBeAg loss and HBV DNA level <10,000 
copies/mL (~2,000 IU/mL) was chosen for definition of response at week 78, since 
this endpoint is associated with a low probability of relapse and low risk of disease 
progression.5, 19-20 At long-term follow-up (LTFU), retreated patients were classified 
as non-responders. For multivariate analyses, patients were classified as WT (only 
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WT virus detectable) or non-WT (detectable PC and/or BCP mutants). Associations 
between variables were tested using Student’s t-test, Chi-square, Pearson correlation 
or their non-parametric equivalents when appropriate. To investigate the value of WT/
non-WT status in addition to our previously published PEG-IFN Treatment Index pre-
diction model19, we used a multivariable logistic regression model with the predicted 
probability calculated using the PEG-IFN Treatment Index as a fixed value. The PEG-
IFN treatment index was built using data on HBV genotype, baseline levels of ALT 
and HBV DNA, as well as age, patient gender and previous IFN therapy. The gain of 
adding WT/non-WT status was quantified using the net reclassification improvement 
(NRI), which is the sum of reclassification of subjects with a response and without 
a response, where reclassification is the percentage of patients with an improved 
prediction minus the percentage of patients with a worse prediction.21 SPSS version 
15.0 (SPSS Inc., Chicago, IL, USA) and the SAS 9.2 program (SAS Institute Inc., 
Cary, NC, USA) were used to perform statistical analyses. All statistical tests were 
two-sided and were evaluated at the 0.05 level of significance.
Role of the funding source
Financial support was provided by the Foundation for Liver and Gastrointestinal 
Research (SLO) in Rotterdam, the Netherlands. The funding source did not have influ-
ence on study design, data collection, analysis and interpretation of the data, writing 
of the report nor the decision to submit for publication.
ReSulTS
Patient characteristics
Since treatment outcome did not differ between patients treated with PEG-IFN ± 
LAM, the data of the two treatment arms were pooled for the current analysis. The 
characteristics of the 214 patients are shown in table 1.
Prevalence of PC and BCP mutants at baseline
Within the total cohort, a minority (36%) of patients had only wildtype virus (WT) 
detectable. PC and BCP mutants were detected in 138 (64%) of patients, either alone 
or in combination (table 1). When stratified by HBV genotype, considerable differ-
ences were observed with regard to the frequency and type of detected mutant virus 
(p<0.001). A majority of patients with genotype A harboured only WT virus, whereas 
mutants were often detected in patients with genotypes B, C and D (figure 1).
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Relationship between PC and BCP mutants and HBV serum markers 
at baseline
Considerable differences were observed with regard to baseline HBV DNA, HBeAg and 
HBsAg levels in patients with WT or detectable PC or BCP mutants. After adjustment 
for HBV genotype distribution, patients with WT had higher baseline HBV DNA levels 
(9.20 versus 8.86 log copies/mL, p=0.015), higher HBeAg levels (2.81 versus 2.33 log 
Table 1: Characteristics of the study cohort
Characteristics Study population (n=214)
demography
 Mean (SD) age, years 33.8 (13)
 Male 167 (78%)
Peg-ifn Monotherapy 104 (49%)
Race
 Caucasian 157 (73%)
 Asian 40 (19%)
 Other 17 (8%)
laboratory results
 Mean (SD) ALT* 4.3 (3.0)
 Mean (SD) HBV DNA, log c/mL 9.1 (0.90)
 Mean (SD) HBsAg, log IU/mL 4.4 (0.60)
 Mean (SD) HBeAg, log IU/mL 2.5 (0.70)
HBV genotype
 A 74 (35%)
 B 19 (9%)
 C 29 (14%)
 D 85 (40%)
 Other/mixed 7 (3%)
inno-liPA result
 Wildtype 76 (36%)
 Precore 56 (26%)
 Basal core promoter 47 (22%)
 Precore and basal core 35 (16%)
Response at week 78
 Response# 41 (19%)
 HBeAg loss 77 (36%)
 HBV DNA <10,000 c/mL 43 (20%)
 HBsAg loss 17 (8%)
*Multiples of upper limit of the normal range
#HBeAg loss and HBV DNA <10,000 copies/mL at week 78
41
2
P
reco
re an
d
 co
re p
ro
m
o
ter m
u
tants an
d
 resp
o
n
se to
 p
eg
interfero
n
IU/mL, p<0.001) and higher HBsAg levels (4.53 versus 4.28 log IU/mL, p=0.007) than 
patients with detectable mutants.
Relationship between PC and BCP mutants and treatment response 
at week 78
Among the total population, rates of HBeAg loss were not significantly different 
between patients with WT virus or PC/BCP mutants (figure 2A). However, patients 
with only WT virus were considerably more likely to achieve a response (HBeAg loss 
and HBV DNA <10,000 copies/mL; 34% versus 11%, p<0.001), HBV DNA <10,000 
copies/mL (34% versus 12%, p<0.001), HBV DNA < 400 copies/mL (20% versus 
2%, p<0.001) and HBsAg clearance (18% versus 2%, p<0.001) by week 78, when 
compared to patients with PC/BCP mutants. Patients with both PC and BCP mutants 
had both a very low probability of response and no chance of HBsAg loss.
long-term follow-up of patients with negative HBeAg at week 78
Long-term follow-up (mean 3.0 years, range 1.9 – 5.0) data were available in 50 of 
77 (65%) patients who were HBeAg negative at week 78. The majority of patients 
had sustained HBeAg loss through prolonged follow-up, irrespective of the presence 
of WT or PC/BCP mutants at baseline (Figure 2B). However, patients with only WT 
7%
24%
69%
0%
24%
24%
45%
7% 40%
18%
11%
32%
68%
0% 26%
5%
WT
PC
BCP
Both
A (n=74) B (n=19)
C (n=29) D (n=85)
figure 1: Frequency of PC and BCP mutants in the cohort by HBV genotype.
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figure 2: Relationship between presence of PC and BCP mutants at baseline and response at 
week 78 in the total cohort (n=214) (A) and response at long-term (mean 3.0 years) follow-up 
among patients who were HBeAg negative at week 78 (n=50) (B). Response was defined as 
HBeAg clearance and HBV DNA <10,000 copies/mL at week 78. WT, wildtype; PC, precore; BCP, 
basal core promoter.
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virus at baseline who cleared HBeAg by week 78 had a much higher probability of 
achieving undetectable (<400 copies/mL) HBV DNA levels at long-term follow-up 
when compared to those with mutants (p=0.003, figure 2B). Additionally, patients who 
achieved HBeAg loss at week 78 and had WT virus at baseline had a 61% probability 
being HBsAg negative at long-term follow-up.
Presence of PC and BCP mutants in patients with HBeAg loss with 
HBV dnA >10,000 copies/ml at week 78
Of the 36 patients who cleared HBeAg but had HBV DNA >10,000 copies/mL, serum 
samples and PC/BCP data at week 78 were available in a subset of 29 (81%). All of 
the patients with detectable mutants at baseline had detectable mutants at week 78, 
and 5 of 6 patients with WT at baseline had detectable mutants at week 78 (figure 3).
Wildtype
(n=6)
PC only       
(n=7)
BCP only    
(n=8)
PC and BCP 
(n=8)
Wildtype
(n=1)
PC only       
(n=8)
BCP only    
(n=10)
PC and BCP 
(n=10)
n=1
n=4
n=1
n=4 n=3 n=8 n=1
n=7
Baseline
Week 78
figure 3: Baseline and week 78 INNO-LiPA test results in patients with HBeAg loss and HBV DNA 
>10,000 copies/mL (n=29). WT, wildtype; PC, precore; BCP, basal core promoter.
Relationship between PC/BCP mutants and response; multivariate 
analysis
To account for the differences in PC and BCP mutant distributions across HBV geno-
types, presence of WT/non-WT status was added as an independent determinant 
of response to other previously described predictors, HBV genotype, baseline HBV 
DNA level, ALT and age. Presence of only WT virus remained a strong predictor of 
response (odds ratio (OR) WT versus non-WT: 2.60, 95% CI: 1.05 – 6.42, p=0.037). 
Combination therapy (PEG-IFN + LAM) was not associated with response. Similarly, 
presence of only WT virus at baseline was a significant predictor of HBsAg loss at 
week 78 (OR for WT versus non-WT: 5.58, 95% CI: 1.26 – 24.63, p=0.013), after 
adjustment for other predictors, HBV genotype and age. Flowcharts for treatment 
response for WT versus non-WT by HBV genotype and baseline HBV DNA and ALT 
levels are depicted in Figure 4A and 4B.
We added WT/non-WT status to a model including the previously published PEG-IFN 
treatment index19, and found that it significantly improved prediction of response (WT 
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versus non-WT OR 2.35, 95% CI: 1.06 – 5.19, p=0.033, NRI=0.66). The individual 
patients’ estimated probabilities for the PEG-IFN Treatment Index extended with 
WT/non-WT status are depicted in figure 4C. Re-calibration of the model showed 
that WT/non-WT significantly predicts response to PEG-IFN, independently of HBV 
genotype, baseline ALT and HBV DNA, patient age, and previous IFN therapy failure 
(table 2). An interaction term between HBV genotype and WT/non-WT was not sig-
nificant (p=0.954). Figure 5A shows the estimated probabilities of response from this 
model for WT/non-WT, stratified by HBV genotype. Figure 5B shows the estimated 
probabilities of HBsAg clearance for patients with WT or non-WT, stratified by HBV 
genotype and adjusted for patient age.
WT
ALT≥2 and
HBV DNA<9 
ALT<2 and/or
HBV DNA≥9 
40% (17/43) 63% (5/8)
Non-WT
ALT≥2 and
HBV DNA<9 
ALT<2 and/or
HBV DNA≥9 
18% (2/11) 33% (4/12)
HBeAg(+): 
Genotype A
A
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ALT ≥2 and
HBV DNA<9 
ALT<2 and/or
HBV DNA≥9 
10% (2/20)40% (2/5)
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7% (5/77) 11% (4/37) 
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B
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figure 4: Probability of response (HBeAg loss with HBV DNA <10,000 copies/mL at week 78) 
according to presence of WT or detectable mutants (non-WT) and baseline HBV DNA and ALT 
levels, stratified by genotype A (A) or non-A (B). Grey boxes mark patients groups where pegin-
terferon should be considered based on a probability of more than 30% (19). Panel C shows the 
individual probability of response as estimated by extending the previously published PEG-IFN 
Treatment Index (19) with data on WT/non-WT. WT, wildtype.
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PC and BCP mutants and on-treatment HBV dnA, HBeAg and 
HBsAg levels
To explore the relationship between presence of PC/BCP mutants and on-treatment 
kinetics of HBV DNA, HBeAg and HBsAg, only data from the PEG-IFN monotherapy 
group were analysed, because HBV DNA and HBsAg kinetics differ considerably 
between patients treated with PEG-IFN monotherapy and PEG-IFN + LAM combina-
tion therapy.6, 16 Within the monotherapy cohort, 40 (38%) patients harboured only 
WT virus (WT group), and 64 (62%) had evidence of either PC mutants, BCP mutants 
or both (non-WT group).
HBV DNA
After 52 weeks of treatment, HBV DNA decline from baseline was 2.49 log copies/mL 
in the WT group, compared to 2.22 log copies/mL in patients with non-WT (p=0.60). 
After treatment discontinuation, relapse was observed in patients with mutants, while 
patients with only WT virus at baseline continued to decline. Mean HBV DNA declines 
at week 78 were 2.82 versus 1.77 log copies/mL (p=0.05, figure 6A).
Quantitative HBeAg
HBeAg decline was somewhat more pronounced during the first 8 weeks of therapy in 
patients with PC or BCP mutants, but end of treatment HBeAg declines were similar 
in both groups: 1.07 versus 1.04 log IU/mL in patients with only WT or detectable 
mutants, respectively (p=0.93), as were HBeAg declines at week 78 (p=0.94, figure 
6B).
Table 2. Logistic regression model of probability of response to peginterferon
Variable oR (95% Ci) p
WT 2.90 (1.15 – 7.31) 0.023
HBV Genotype 0.043
 A ref
 B 0.56 (0.14 – 2.21)
 C 0.11 (0.02 – 0.59)
 D 0.35 (0.11 – 1.14)
HBV DNA* 0.58 (0.35 – 0.97) 0.038
ALT# 1.10 (0.95 – 1.26) 0.210
Age 1.04 (1.01 – 1.08) 0.014
No previous IFN 5.20 (1.55 – 17.4) 0.003
*HBV DNA in log copies/mL, #ALT in x ULN.
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Quantitative HBsAg
Patients with only WT virus detectable before therapy had a distinctly steeper HBsAg 
decline than did patients with PC or BCP mutants. End of treatment declines were 
1.46 and 0.43 log IU/mL (p=0.007), and the difference increased through off-treatment 
follow-up to 1.55 versus 0.38 log IU/mL at week 78 (p=0.003, figure 6C).
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figure 5: The estimated probability of response from the model shown in table 2 for WT versus 
non-WT, stratified by HBV genotype (A), and the estimated probability of HBsAg loss at week 78 
by WT/non-WT, adjusted for patient age and stratified by HBV genotype (B).
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figure 6: HBV DNA (A), HBeAg (B) and HBsAg (C) declines among patients with only WT virus, or 
with detectable PC or BCP mutants (non-WT). Analyses were performed in patients treated with 
PEG-IFN monotherapy (n=104). WT, wildtype.
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diSCuSSion
This is the largest study to date investigating the relationship between presence of 
PC and BCP mutants and response to PEG-IFN in HBeAg-positive CHB patients. We 
found that achievement of combined serological and virological response, as well 
as HBsAg seroclearance, is largely confined to patients without detectable PC and 
BCP mutants at baseline. Assessment of WT/non-WT status before therapy thus pro-
vides valuable additional insight into an individual patient’s probability of achieving 
a response to PEG-IFN, and can help optimize patient selection for this burdensome 
treatment modality.
Prolonged presence of HBeAg in serum of CHB patients was recently shown to be 
an independent predictor of emergence of HCC, and clearance of HBeAg, whether 
spontaneous or treatment induced, is therefore considered an important event.1, 3 
However, it has become increasingly clear that a considerable number of patients 
with CHB have persistently detectable HBV DNA levels after HBeAg clearance, pre-
disposing these patients to progression of their liver disease to cirrhosis, HCC and 
premature death.5, 22-23 A possible mechanism for this phenomenon is the selection for 
HBV mutants with mutations in the PC or BCP region, both of which reduce or abolish 
the production of HBeAg and are able to maintain replication despite seroclearance of 
HBeAg.14, 24 Data from the current study now show that these PC and BCP mutants 
may be detected in the majority of HBeAg-positive patients, confirming data from a 
US survey.25 The clinical relevance of these findings, especially in relation to response 
to immunomodulatory treatment of CHB, was however unclear. In patients treated 
with NA, presence of PC or BCP mutants confers an increased probability of HBeAg 
clearance.26 Similarly, several older studies have reported that presence of PC or BCP 
mutants is associated with a higher probability of achieving response to standard 
IFN treatment. 12, 27-28 Response in these studies was commonly defined as HBeAg 
clearance, with or without an HBV DNA undetectability criterion. However, most of 
these studies used HBV DNA assays that were not sensitive enough to detect HBV 
DNA at levels that are currently considered to confer substantial risk for progression 
of liver disease.23 In concurrence with these studies, we found that patients with 
PC or BCP mutants have a good probability of HBeAg clearance, and of remain-
ing HBeAg negative through prolonged follow-up. However, the current study also 
shows that the majority of patients with detectable PC or BCP mutants who achieve 
HBeAg clearance do not achieve HBV DNA levels <10,000 copies/mL, necessitating 
further therapy in these patients according to recent guidelines.1, 3 Furthermore, it is 
important to note that HBeAg clearance alone does not appear to be an appropriate 
marker for immune control in patients with detectable PC or BCP mutants at baseline, 
since HBsAg loss after HBeAg clearance is extremely rare in this group of patients. 
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These observations, along with the high frequency (>60%) of PC and BCP mutant 
strains in our HBeAg-positive cohort, suggest that HBeAg clearance alone is not 
a suitable marker for response to PEG-IFN therapy in the general HBeAg-positive 
patient population, but perhaps only in those with confirmed WT virus at baseline.
We observed considerable differences in the frequency of PC and BCP mutants 
across HBV genotypes A through D. These observations are in line with other reports, 
and may be accounted for by differences in genetic make-up of the respective geno-
types.25 Several recent reports, also from our group, have shown that HBV genotype 
is an important predictor of response to (PEG-)IFN based therapy of CHB.19 The 
current study sheds considerable new light on these observations, since the advan-
tages of patients with genotype A may be partly due to the relatively high frequency 
of WT virus, accounting for the high rates of HBV DNA undetectability and HBsAg 
loss through long-term follow-up in patients with HBV genotype A.8 Nevertheless, 
the advantages of patients with only WT virus over those with detectable PC or BCP 
mutants holds true independent of HBV genotype. Presence of only WT virus is a 
very strong independent predictor of response and HBsAg clearance, when adjusting 
for the other established predictors HBV genotype, baseline HBV DNA level and ALT 
level and age. Importantly, WT/non-WT status adds significantly to our previously 
published PEG-IFN Treatment Index prediction model.19 Extension of this model with 
data on detection of mutants may help optimize prediction of response at baseline 
and help select only those patients who have a very high probability of response 
for PEG-IFN therapy. Moreover, detection of PC or BCP mutants in patients with 
non-A genotypes confers such a low probability of a combined HBeAg and HBV DNA 
response, that in our view PEG-IFN should not be used as a first-line treatment option 
in these patients.
Another important observation is the relationship between the presence of PC and 
BCP mutants and established markers of HBV infection such as HBV DNA, HBeAg 
and HBsAg. We found comparable on-treatment HBV DNA and HBeAg declines in 
patients with only WT or with mutant virus. These findings show the inherent limita-
tions of HBeAg levels in monitoring PEG-IFN therapy efficacy, for they are highly 
influenced by the presence of PC and BCP mutants, and underscore the limitations 
of recent prediction rules for PEG-IFN therapy based on HBeAg thresholds.29 In 
contrast, the current study confirms recent data on the relationship between HBsAg 
decline during PEG-IFN therapy and sustained off-treatment response, for HBsAg 
decline was largely confined to patients with WT virus. 16, 30
Possible limitations of the current study are related to the assay used to classify 
patients as having mutant virus. The INNO-LiPA assay is more sensitive than con-
ventional sequencing technology, and can detect mutant virus at very low levels.17 
However, the prevalence of mutants at baseline may have been underestimated if 
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mutants were only present as minority species (<5%).31 Additionally, the assay can 
only detect known mutations and ignores others. Possible misclassification introduced 
by this limitation may have influenced the results. The current study enrolled patients 
infected with all major HBV genotypes, but only a limited subgroup of patients was 
infected with genotypes B and C. Possibly, this may have resulted in a non-significant 
test for interaction of WT with HBV genotype. Confirmation of our findings in Asian 
patients is therefore required.
Concluding, patients with only WT virus have the highest probability of achieving a 
combined HBeAg and HBV DNA response and HBsAg loss, whereas patients with 
PC or BCP mutants are predisposed to persistent viral replication after HBeAg clear-
ance. This limits the use of HBeAg clearance alone when assessing therapy efficacy 
of PEG-IFN, and potentially other treatment options as well. Patients with WT virus 
appear to be the most suitable candidates for PEG-IFN therapy, irrespective of HBV 
genotype.
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ABSTRACT
Background & Aims
HBeAg seroconversion in chronic hepatitis B (CHB) patients is considered an impor-
tant event as it is associated with better clinical outcome. However, a proportion 
might not achieve immune control after HBeAg seroconversion.
Methods
We determined presence at baseline of precore (PC) and basal core promoter (BCP) 
mutants in 137 consecutive HBeAg-positive patients treated with nucleos(t)ide ana-
logues (NA) by INNO-LiPA HBV PreCore assay (Innogenetics). Baseline HBeAg and 
HBsAg levels were measured using the ELECSYS platform.
Results
The majority (>60%) of patients with genotype B, C and D had PC/BCP mutants 
present at baseline, compared to only 40% of patients with HBV genotype A (p=0.02). 
Patients with mutants had lower HBV DNA (p=0.006), HBeAg (p<0.001) and HBsAg 
(p=0.04) levels compared to patients with wildtype HBV. During a median treatment 
duration of 29 (IQR 18-56) months, 45 patients achieved HBeAg seroconversion. The 
probability of HBeAg seroconversion during therapy was higher in patients with PC/
BCP mutants (HR 2.2, 95% CI: 1.13 - 4.44, p=0.01). After HBeAg seroconversion, 
patients with BCP mutants tended to have a higher probability of HBeAg relapse 
(p=0.07), and detectable PC mutants tended to be associated with a lower probability 
of achieving HBV DNA <2000 IU/mL 1 year after HBeAg seroconversion (p=0.07).
Conclusions
The presence of PC and/or BCP mutants in NA-treated HBeAg-positive patients 
appears an independent predictor of HBeAg seroconversion. However, presence of 
BCP mutants was associated with a higher risk of serological relapse, patients with 
detectable PC mutants tended to have a lower probability of achieving virological 
remission the first year after HBeAg seroconversion.
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inTRoduCTion
Hepatitis B e Antigen (HBeAg)-positive chronic hepatitis B (CHB) is an early stage of 
the disease continuum.1-3 HBeAg does not appear to be required for infection with 
hepatitis B virus (HBV), nor for viral replication, but the presence of HBeAg in serum 
is associated with higher levels of HBV DNA and was shown to be an risk factor 
for the development of hepatocellular carcinoma.4-6 HBeAg clearance has therefore 
been adopted as a treatment endpoint for HBeAg-positive CHB in all major HBV 
guidelines.3, 7
About 20% of patients treated with nucleos(t)ide analogues achieve HBeAg serocon-
version after one year of treatment.7-8 However, emerging data show that mere loss of 
HBeAg from serum may be insufficient to induce disease remission. Indeed, reversal 
to HBeAg positivity is frequently observed after NA-induced HBeAg seroconversion, 
as is persistence of detectable HBV DNA levels after discontinuation of therapy.9 
Similarly, while HBeAg negativity induced by peginterferon (PEG-IFN) therapy seems 
to be more durable, a proportion of patients fail to achieve low levels of HBV DNA and 
HBsAg clearance.10-12 A possible explanation for these observations is the presence of 
viral strains with mutations in the precore (PC) and basal core promoter (BCP) regions 
that prohibit the synthesis of HBeAg.13 In patients treated with PEG-IFN, presence of 
these mutants predisposes to persistent replication after HBeAg clearance, possibly 
through positive selection during antiviral therapy,14 and these mutants may therefore 
also predict persistence of substantial HBV DNA replication after HBeAg clearance in 
patients treated with NA.14-15
The aim of the current study was therefore to investigate the relationship between 
presence of PC or BCP mutants and the probability of NA-induced HBeAg serocon-
version. Secondly, we assessed the relation between these mutants and true disease 
remission after HBeAg seroconversion in patients treated with NA.
PATienTS And MeTHodS
Study population
All consecutive patients who were positive for HBeAg, negative anti-HBe and treated 
with NA therapy for at least 6 months from January 1st 1996 onwards at the Erasmus 
MC University Medical Center in Rotterdam were enrolled. Patients were excluded 
when no stored baseline sample was available for retesting, when co-infected with 
hepatitis C virus, hepatitis D virus or human immunodeficiency virus, when treated 
with peginterferon within 6 months before start of NA therapy or when peginterferon 
was (temporarily) added to the NA regimen.
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follow up evaluation
ALT and virological parameters were assessed at least every 3-6 months. HBeAg 
seroconversion was defined as loss of HBeAg with concurrent appearance of anti-
HBe. HBsAg seroconversion was defined as loss of HBsAg with appearance of anti-
HBs. Serological recurrence was defined as a confirmed reappearance of HBeAg in 
at least 2 consecutive samples after HBeAg seroconversion. Virological remission 
was defined as achieving HBV DNA <80 IU/ml within one year after achieving HBeAg 
seroconversion. In patients in whom treatment was stopped after HBeAg seroconver-
sion accompanied by an HBV DNA <80 IU/mL, relapse was defined as confirmed HBV 
DNA level above 2000 IU/mL and/or restart of antiviral therapy.
laboratory testing
ALT level was measured using automated techniques. The presence of PC and/or 
BCP mutants was assessed at baseline by Innolipa HBV Precore assay (Innogenet-
ics, Ghent, Belgium). This sensitive probe assay allows for detection of PC mutants 
(at nucleotide position G1896) and BCP mutants (at nucleotide positions A1762 and 
G1764), even when a minority species is present.16 Patients were thus classified as 
having wildtype virus (WT, no PC or BCP mutants were detected), PC (PC mutants 
detected with or without WT), BCP (BCP mutants detected with or without WT), or as 
both (both PC and BCP mutants were found). HBV DNA quantification was performed 
using a TaqMan polymerase chain reaction (PCR) assay (lower limit of quantification 
373 copies/mL) based on the EuroHep standard17 or by using the AmpliPrep-COBAS 
TaqMan HBV test (CAP-CTM v 2.0; Roche Molecular Systems, Inc., Branchburg, 
NJ, USA, lower limit of detection 20 IU/mL). HBeAg and HBsAg were quantified at 
baseline using the Roche ELECSYS assay (Roche Diagnostics, Indianapolis, IN, USA) 
using a standardised protocol.
Statistical analysis
Data are presented as either mean (SD) or median (interquartile range, IQR) where 
appropriate. Associations between variables were tested using Student’s t-test, Chi-
square, Pearson correlation or their non-parametric equivalents when appropriate. 
Time-dependent analyses (HBeAg seroconversion, HBeAg seroreversion and virologi-
cal relapse) were performed by Kaplan-Meier survival analysis and Cox’ regression 
analysis. SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) and the SAS 9.2 program 
(SAS Institute Inc., Cary, NC, USA) were used. All statistical tests were two-sided and 
were evaluated at the 0.05 level of significance.
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Role of the funding source
The sponsor of this study was Foundation for Liver and Gastrointestinal Research 
(SLO) in Rotterdam, the Netherlands. Financial support and test kits were provided 
by Innogenetics, Ghent, Belgium. The funding source did not have influence on study 
design, data collection, analysis and interpretation of the data, writing of the report 
nor the decision to submit for publication.
ReSulTS
Patient characteristics
The study population consisted of 137 HBeAg-positive, anti-HBe-negative CHB 
patients (table 1). Median follow up of the study population was 29 (IQR 18-56) 
months from start of NA therapy.
Prevalence of PC and BCP mutants at baseline
Within the total cohort 39% of patients had only WT detectable. PC and/or BCP 
mutants were detected in 84 (61%) of patients (table). After stratification by HBV 
23%
18%
50%
9%
13%16%
37%34%
42%
8%
29%
21%
WT
PC
BCP
Both
A B
C D
4%
60%
29%
7%
figure 1: Frequency of PC and BCP mutants at baseline in the study cohort by HBV genotype.
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genotype, the frequency of PC and/or BCP mutants differed widely (p=0.02, figure 
1). The majority of patients with genotype A had only WT virus (60%) present at start 
of NA therapy. In contrast, patients infected with HBV genotypes B, C and D had 
mutants present in 63 to 82% of patients. Patients with only WT virus at baseline had 
higher levels of HBV DNA, HBsAg and HBeAg compared to patients with PC and/
or BCP mutants (Figure 2). In contrast, ALT levels were comparable between both 
groups.
Table 1. Characteristics of the study cohort
Characteristics Study population (n=137)
demography
 Mean (SD) age, years 36.5 (14.5)
 Male 105 (77%)
Race
 Caucasian 84 (61%)
 Asian 40 (29%)
 Other 13 (9%)
laboratory results
 Median (IQR) ALT* 2.3 (1.3-4.5)
 Mean (SD) HBV DNA, log IU/mL 7.4 (1.6)
 Mean (SD) HBsAg, log IU/mL 4.1 (1.1)
 Mean (SD) HBeAg, log IU/mL 2.1 (1.0)
HBV genotype
 A 45 (33%)
 B 24 (18%)
 C 22 (16%)
 D 38 (28%)
 Other/mixed 8 (6%)
inno-liPA result
 Wildtype 53 (39%)
 Precore 24 (18%)
 Basal core promoter 33 (24%)
 Precore and basal core 27 (20%)
nucleos(t)ide analogue regimen
 Lamivudine 52 (38%)
 Entecavir 41 (30%)
 Adefovir** 32 (23%)
 Tenofovir** 12 (9%)
*Multiples of upper limit of the normal range. **Adefovir+lamivudine in 2 and tenofovir+lamivudine 
in 3.
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Relationship between PC and BCP mutants and serological 
response
A total of 45 (33%) patients achieved HBeAg seroconversion after a median of 76 
(28-137) weeks (Figure 3). Patients with PC/BCP mutants present at baseline had a 
higher probability of achieving HBeAg seroconversion compared with WT patients 
(HR 2.20, 95% CI: 1.13 - 4.44, p=0.01, figure 4). In univariate analysis, higher baseline 
ALT was also associated with a higher probability of achieving HBeAg seroconversion 
(HR 1.05, 95% CI 1.02 – 1.07, p=0.002). In contrast, higher levels of HBV DNA (HR 
0.87, 95% CI: 0.74 – 1.01, p=0.08) and HBsAg (HR 0.84, 95% CI 0.71 - 1.00, p=0.05) 
were associated with a lower probability of HBeAg seroconversion. Baseline HBeAg 
(HR 0.93, 95% CI 0.68 – 1.26, p=0.62) levels were not associated with probability of 
achieving HBeAg seroconversion. After adjustment for baseline HBV DNA, HBsAg, 
HBeAg, HBV genotype and ALT within a Cox regression model, the presence of PC/
BCP mutants at baseline remained independently associated with a higher probability 
of achieving HBeAg seroconversion (95% CI 1.11-6.15, p=0.03). Only 7 (16%) patients 
achieved HBV DNA negativity before achieving HBeAg seroconversion. Probability of 
achieving HBV DNA negativity did not differ between patients with or without HBeAg 
seroconversion (p=0.29 by log rank). HBsAg seroconversion was achieved in only 
6 (4%) patients and did not differ between patients with WT and PC/ BCP mutants 
(p=0.99).
7.9
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p=0.006
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figure 2 Relationship between presence of PC and/ or BCP mutants at baseline and virological 
and biochemical parameters of CHB infection. The y-axis represents mean values for: HBV DNA 
log IU/mL, HBsAg log IU/mL, HBeAg log IU/mL, and median for ALT xULN.
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figure 3 Study flow chart of 137 HBeAg-positive patients.
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figure 4 Cumulative probability of achieving HBeAg seroconversion during NA therapy up to 
192 weeks of continuous therapy. Comparison between patients with WT virus and patients with 
detectable PC/BCP mutants at baseline.
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follow-up after HBeAg seroconversion
After achieving HBeAg seroconversion, 15 of 45 (33%) patients had HBeAg serorev-
ersion (HBeAg reappearance confirmed in a consecutive sample). In 11 of these 15 
(73%) patients HBeAg relapse occurred before cessation of therapy. HBeAg serorev-
ersion tended to occur more frequently in patients with BCP mutants (HR 2.69, 95% 
CI 0.86-8.49, p=0.07, figure 5). Eight of these 11patients (73%) remained HBeAg-
positive during prolonged follow up. Fifteen (33%) patients experienced confirmed 
anti-HBe relapse after achieving HBeAg seroconversion, but this was not related to 
the presence of mutants.
A total of 33 (73%) patients (17 LAM, 6 ADV, 9 ETV and 1 TDF) achieved virological 
remission (HBV DNA <80 IU) within one year after HBeAg seroconversion. After exclu-
sion of 7 patients with documented genotypic resistance to their current NA regimen 
(6 LAM and 1 ADV), the presence of PC mutants at baseline remained associated 
with a lower probability of achieving virological remission within one year after HBeAg 
seroconversion compared with patients without PC mutants (73% versus 96%, 
p=0.07). Importantly, type of therapy was not a significant predictor for achieving this 
endpoint (p=0.39).
NA therapy was stopped after at least 6 (median 18, IQR 10-48) months of consolidation 
therapy in 9 patients (7 LAM, 1 ETV and 1 ADV) who achieved HBeAg-seroconversion 
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figure 5 Comparison between patients with BCP mutants and patients without BCP mutants at 
baseline for confirmed reappearance of HBeAg after achieving HBeAg seroconversion (n=45).
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and HBV DNA <80 IU/mL. Two of these 9 (22%) patients had WT virus at baseline. 
However, after cessation of therapy within this group, 5 (56%) patients had virological 
relapse (confirmed HBV DNA >2000 IU/mL or restart of NA therapy) after a median 
follow up of 25 (15-157) weeks. Probability of virological relapse was not significantly 
influenced by the presence of PC and/or BCP mutants (p=0.63 by log rank), by type 
of therapy (p=0.55 by log rank) or by length of consolidation therapy (p=0.43 by log 
rank).
diSCuSSion
This study shows that the presence of PC/BCP mutants in HBeAg-positive patients is 
HBV genotype dependent and associated with a higher rate of HBeAg-seroconversion 
during NA therapy. However, after HBeAg seroconversion there was a trend towards 
a higher rate of HBeAg relapse in patients with BCP mutants and a lower rate of 
virological remission in patients with PC mutants.
HBeAg seroconversion during the natural course of CHB is associated with disease 
remission. However, it has become increasingly clear that a substantial proportion of 
patients develops active HBeAg-negative CHB after HBeAg seroconversion and thus 
remains at risk for clinical progression of liver disease.5, 18-19 Current data indicate a 
possible role for mutations within the PC or BCP region for developing active HBeAg-
negative CHB. Mutations in both of these regions are associated with higher levels of 
viral replication after achieving HBeAg seroconversion.14, 20-21 In this study we showed 
that these mutants are already detectable in a considerable number of HBeAg-positive 
patients at initiation of therapy, particularly in non-genotype A patients.
In addition, we showed that the presence of these mutants is predictive for achiev-
ing HBeAg seroconversion during NA-therapy. This is supported by previous studies 
showing that a PC mutant at position 1896 results in a stopcodon and thus cannot 
produce HBeAg and that BCP mutants show a diminished precore mRNA and HBeAg 
production.22-23 Despite this higher rate of serological response, patients with BCP 
mutants have a higher likelihood of HBeAg seroreversion, and those with PC mutants 
of maintaining high serum HBV DNA levels.
BCP mutants are still able to produce HBeAg at a lower level and it was suggested 
that an accumulation of additional mutations could cause relapse of HBV DNA.15, 21 
Further evidence that achieving HBeAg seroconversion in these patients does not 
confer real immune control over the virus is supported by our finding that they have 
a low probability of achieving HBsAg seroconversion. These findings are important 
because stopping of NA therapy is still a major point of discussion in current HBV 
treatment guidelines.7, 24
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Possible limitations of our study are the retrospective design and the heterogeneity 
of the cohort. However, the rate of HBeAg seroconversion does not vary across the 
different NA, and the current design enabled us to include a substantial number of 
HBeAg positive patients with long-term follow up.25-26 Furthermore, the INNO-LiPA 
assay can only detect mutations at positions 1896 (PC), 1762 and 1764 (BCP), which 
are the most established mutated positions.13 However, this assay is more sensitive 
than conventional sequencing, and can thus detect mutant virus at lower levels.16
In conclusion, the presence of PC and/or BCP mutants in HBeAg-positive patients 
was HBV genotype dependent, and independently associated with a higher prob-
ability of achieving HBeAg seroconversion during long-term NA therapy. However, 
after HBeAg-seroconversion patients with BCP mutants frequently have serological 
relapse while patients with PC mutants often do not achieve a complete virological 
response. HBsAg seroconversion was rare and not affected by the presence of PC 
and/or BCP mutants.
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ABSTRACT
Background & Aims
Serum levels of interferon-gamma inducible protein 10 (IP-10) are a marker for 
immune activity, and may predict response to peginterferon (PEG-IFN) therapy in 
chronic hepatitis B.
Methods
IP-10 was measured at baseline and on-treatment week 12 in 210 HBeAg-positive 
patients treated with PEG-IFN for 52 weeks. Response to treatment was assessed 
at 6 months post-treatment and defined as HBeAg loss, combined response (HBeAg 
loss with HBV DNA <10,000c/mL) or HBsAg loss.
Results
Median baseline IP-10 levels were 158.2 pg/mL. Higher baseline IP-10 was associ-
ated with more HBV DNA, HBeAg and HBsAg decline from week 4 onwards, and IP-10 
was higher in patients who achieved HBeAg loss (p=0.001) and combined response 
(p=0.052). A combination of high IP-10 (>150 pg/mL) with absence of precore (PC) 
and core promoter (BCP) mutants strongly predicted combined response and HBsAg 
loss: 48% of patients with high IP-10 and no detectable mutants achieved a com-
bined response (p<0.001). IP-10 decline from baseline to week 12 was very limited, 
but more pronounced in patients who achieved HBeAg loss (0.05 log pg/mL, versus 
an increase of 0.05 in patients without HBeAg loss, p=0.04).
Conclusions
Higher pre-treatment IP-10 levels are associated with an increased probability of 
HBeAg loss after PEG-IFN therapy. A combination of high baseline IP-10 and absence 
of PC and BCP mutants identified patients with the highest probability of combined 
response and HBsAg loss.
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inTRoduCTion
Peginterferon (PEG-IFN) is a first-line treatment option for chronic hepatitis B (CHB), 
because a finite treatment course may result in a sustained response in about 25% 
of patients.1-3 In HBeAg-positive patients, HBV genotype, patient age, low baseline 
HBV DNA and high baseline ALT are independent predictors of response to PEG-IFN 
therapy.4 Another recent study suggests that host IL28B genotype may also influence 
the probability of serological response to PEG-IFN,5 while absence of precore (PC) 
and basal core promoter (BCP) mutants may predict virological response after HBeAg 
clearance.6 The association of both high ALT and IL28B genotype with response to 
PEG-IFN suggests that successful induction of an immune response with PEG-IFN 
depends upon a susceptible host in combination with an active immune response, 
and biomarkers of immune activity may therefore predict response to treatment.
The interferon-gamma inducible protein 10 (IP-10), also known as chemokine C-X-C 
motif ligand (CXCL-)10, targets the CXC3 receptor, attracts T-lymphocytes and influ-
ences T-cell as well as natural killer cell adhesion.7-9 Therefore, serum levels of IP-10 
may be a marker for immune activity.10 Pre-treatment IP-10 levels appear to predict 
response to PEG-IFN therapy in chronic hepatitis C patients,10-13 independent of other 
known predictors, such as viral load, HCV genotype and stage of liver disease.10, 12, 13 
Moreover, recent studies have shown that quantification of IP-10 may add substantially 
to IL28B genotyping when aiming to predict a sustained response in hepatitis C patients, 
possibly through an association with interferon stimulated gene expression.14-16
Although the precise role of IP-10 in CHB remains unclear, one previous study showed 
that IP-10 kinetics are associated with the occurrence of flares in CHB patients. 
These findings suggest that serum levels of IP-10 could reflect the immune activity of 
patients, and consequently predict response to PEG-IFN therapy.17
The aim of the current study was therefore to investigate the relationship between 
serum levels of IP-10 and response to PEG-IFN in HBeAg-positive CHB patients.
PATienTS And MeTHodS
Patients
In this study, serum levels of IP-10 were measured before treatment initiation and 
at week 12 of treatment in 210 HBeAg-positive CHB patients treated with PEG-IFN 
alfa-2b within an investigator-initiated multicenter randomized trial.1, 18, 19 The inclu-
sion and exclusion criteria for this study have previously been described elsewhere.1 
In summary, patients were eligible if they had been HBsAg positive for at least 6 
months before randomization, were HBeAg positive, had elevated serum alanine 
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aminotransferase (ALT) levels of >2, but <10 times the upper limit of normal (ULN), 
and had a serum HBV DNA concentration of more than 100,000 copies/mL. Patients 
were treated with PEG-IFN alfa-2b 100 μg weekly (PegIntron, Schering-Plough, 
Kenilworth, NJ, USA) in combination with placebo or lamivudine (LAM) 100 mg (Zeffix, 
GlaxoSmithKline, Greenford, UK) daily for 52 weeks. Inclusion criteria for the present 
analysis were completion of the 26-week post-treatment follow-up phase of the main 
study, data on PC / BCP mutants at baseline, and available serum for IP-10 assess-
ment at baseline. Of the 266 patients in the initial study, 210 fulfilled these criteria.
The study was conducted in accordance with the guidelines of the Declaration of Hel-
sinki and the principles of Good Clinical Practice. All patients gave written informed 
consent according to standards of the local ethics committees.
laboratory measurements
Serum IP-10 was assessed at baseline and at week 12 of treatment using a com-
mercially available ELI+SA kit (Alta Analytical Laboratory, San Diego, USA) in samples 
that were stored at -80° Celcius since the original studies. The presence of PC and 
BCP mutants was assessed using the INNO-LiPA HBV PreCore assay (Innogenetics, 
Ghent, Belgium). This very sensitive line probe assay allows for easy detection of PC 
(at nucleotide position G1896) and BCP (at nucleotide positions A1762 and G1764) 
mutants.20 Patients were classified as wildtype (WT, only WT virus detectable), or as 
non-WT (when PC, BCP or both mutants were detected). Serum HBV DNA, HBeAg and 
HBsAg were quantified in samples taken at baseline, during the treatment period and 
at 6 months post-treatment. HBV DNA was measured using an in-house developed 
TaqMan polymerase chain reaction (PCR) assay (lower limit of quantification 400 cop-
ies/mL).21 HBsAg was measured using the Abbott ARCHITECT HBsAg assay (Abbott 
laboratories; range 0.05 - 250 IU/mL) and HBeAg with the Roche ELECSYS HBeAg 
assay using a quantitative protocol (Roche Diagnostics, range 0.2 – 100 IU/ml).
Statistical analysis
Response was assessed at 6 months post-treatment (week 78) and was defined 
as either HBeAg loss, HBeAg loss with HBV DNA <10,000 copies/mL (combined 
response) or HBsAg loss. Associations between variables were tested using Stu-
dent’s t-test, Chi-square, Pearson correlation or their non-parametric equivalents 
when appropriate. SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) and the SAS 9.2 
program (SAS Institute Inc., Cary, NC, USA) were used to perform statistical analyses. 
All statistical tests were two-sided and were evaluated at the 0.05 level of significance.
Role of the funding source
Financial support was provided by the Foundation for Liver and Gastrointestinal 
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Research (SLO) in Rotterdam, the Netherlands. The funding source did not have influ-
ence on study design, data collection, analysis and interpretation of the data, writing 
of the report nor the decision to submit for publication.
ReSulTS
Patient characteristics
The characteristics of the enrolled patients are shown in table 1. Overall, 75 (36%) 
cleared HBeAg, 39 (19%) achieved a combined response and 17 (8%) cleared HBsAg. 
Table 1: Characteristics of the study cohort
Characteristics
demography
 Mean (SD) age, years 33.7 (12)
 Male 164 (78%)
Previous ifn therapy 38 (18%)
Peg-ifn Monotherapy 102 (49%)
Race
 Caucasian 153 (73%)
 Asian 40 (19%)
 Other 17 (8%)
laboratory results
 Mean (SD) ALT* 4.3 (3.0)
 Mean (SD) HBV DNA, log c/mL 9.1 (0.89)
 Mean (SD) HBsAg, log IU/mL 4.4 (0.60)
 Mean (SD) HBeAg, log IU/mL 2.5 (0.70)
 Median (range) IP-10, pg/mL 158.2 (6.6-1500)
HBV genotype
 A 73 (35%)
 B 19 (9%)
 C 29 (14%)
 D 82 (39%)
 Other/mixed 7 (3%)
inno-liPA result
 Wildtype 76 (36%)
 Precore 54 (26%)
 Basal core promoter 45 (21%)
 Precore and basal core 35 (17%)
*Multiples of upper limit of the normal range
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Since combination treatment with lamivudine did not influence response rates1, data 
from the monotherapy and combination arms were pooled for the current analysis. 
Treatment allocation was controlled for in multivariate analyses whenever applicable. 
Median baseline level of IP-10 was 158.2 pg/mL (range: 6.6 – 1500 pg/mL). IP-10 
levels were logarithmically transformed for further analysis, and also divided into 
quartiles: quartile 1 (<2.02 log pg/mL), quartile 2 (2.02 – 2.20 log pg/mL), quartile 3 
(2.20 – 2.42 log pg/mL) and quartile 4 (>2.42 log pg/mL).
Relationship between iP-10 levels and baseline characteristics
Baseline IP-10 levels did not significantly differ across the HBV genotypes A through 
D, across patients with different ethnicities, nor among patients with only WT virus 
versus those with detectable PC and/or BCP mutants. Baseline IP-10 level did not 
correlate with baseline HBV DNA, HBeAg, or HBsAg levels, but was significantly 
associated with patient age (r=0.23, p=0.001) and correlated strongly with baseline 
ALT (r=0.45, p<0.001).
Association of baseline iP-10 with on-treatment decline of HBV 
dnA, HBeAg and HBsAg
Higher baseline IP-10 level was associated with more HBV DNA (p=0.001), HBeAg 
(p<0.001) and HBsAg decline (p=0.028) at 6 months after PEG-IFN discontinuation 
(week 78). Figure 1A-C shows the on-treatment declines in HBV DNA, HBeAg and 
HBsAg stratified by a baseline IP-10 level of 150 pg/mL (~median). Importantly, a 
baseline IP-10 level >150 pg/mL independently predicted HBsAg decline at week 78 
when adjusted for HBV genotype, presence of only WT virus and baseline HBsAg. 
Adjusted HBsAg decline for patients with an IP-10 >150 pg/mL was 1.38 log IU/mL, 
compared to 0.89 for those with an IP-10 <150 pg/mL (p=0.034). In similar models, 
baseline IP-10 level > 150 pg/mL was associated with more HBeAg decline (1.35 vs. 
0.83 log IU/mL, p=0.002) and HBV DNA decline (3.00 vs. 1.96 log c/mL, p=0.002). 
Combination therapy did not predict HBsAg, HBeAg or HBV DNA decline at week 78 
in these models (p≥0.370). Importantly, the association between high IP-10 level at 
baseline (>150 pg/mL) and more pronounced on-treatment decline was apparent as 
soon as week 4 of treatment for HBsAg (p<0.001), HBeAg (p=0.002) and HBV DNA 
(p<0.001), when adjusting for HBV genotype, presence of only WT virus, baseline 
level and combination therapy.
Baseline iP-10 levels and response at 6 months post-treatment
Baseline IP-10 level was higher in patients who cleared HBeAg by week 78 when 
compared to those who did not (2.34 vs. 2.17 pg/mL, p=0.001), as was the case for 
patients who achieved a combined response versus those who did not (2.32 vs. 2.21 
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figure 1. Relationship between baseline IP-10 level and on-treatment viral decline. Decline of 
serum HBV DNA (A), HBeAg (B) and HBsAg (C) during treatment by baseline IP-10 level (n=210).
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log pg/mL, p=0.052). The association between baseline IP-10 level (in quartiles) and 
probability of response at 6 months post-treatment is shown in figure 2. In multivariate 
analysis, IP-10 levels at baseline were significantly associated with the occurrence 
of HBeAg clearance (adjusted OR: 3.60, 95% CI: 1.15 – 11.22, p=0.024, table 2) 
when adjusting for HBV genotype, presence of only WT virus, baseline age, HBV DNA 
and ALT and previous IFN treatment failure. Of note, presence of PC and/or BCP 
mutants was not an independent predictor of HBeAg loss after PEG-IFN therapy, nor 
was combination therapy. Interestingly, serum IP-10 at baseline was not significantly 
associated with the occurrence of a combined response (adjusted OR: 2.48, 95% CI: 
0.59 – 10.48, p=0.21, table 2).
A combination of iP-10 and presence of only WT virus identifies 
patients with a high likelihood of response
Since baseline levels of IP-10 was associated with HBeAg loss, but not combined 
response, whereas presence of only WT virus was previously shown to be associ-
ated with achievement of low HBV DNA levels after HBeAg clearance6, we explored 
the interplay between these two variables. In a model for combined response, an 
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interaction term between WT virus and baseline IP-10 level was highly significant 
(p=0.002), indicating that the association of IP-10 levels with response is not the same 
for patients with WT virus compared to those with detectable mutants at baseline. A 
similar interaction was also found for WT virus and baseline ALT (p=0.030). Such an 
interaction was not found when HBeAg loss was considered (p=0.15 for interaction 
of IP-10 and WT, p=1.0 for ALT and WT). Figure 3 shows the estimated probability of 
combined response as predicted by the prediction model shown in table 2, with addi-
tion of an interaction term of WT with IP-10. The probability of response for patients 
with only WT virus strongly improved with increasing IP-10 level, and similar findings 
were obtained with ALT. In contrast, patients with detectable PC and/or BCP mutants 
did not benefit from higher IP-10 or ALT levels. A combination of baseline IP-10 >150 
pg/mL and absence of PC and BCP mutants could identify patients with a very high 
likelihood of response (figure 4). Furthermore, it can also be inferred from figure 4 that 
high IP-10 level at baseline predisposes to HBeAg clearance after PEG-IFN therapy, 
but that this did not translate to increased combined response rates or HBsAg loss if 
PC and/or BCP mutants were present.
on-treatment iP-10 and response to treatment
IP-10 levels remained stable from baseline to week 12; a minimal non-significant 
decline was observed of 0.015 log pg/mL (p=0.52 compared to baseline). IP-10 
decline was more pronounced in patients who achieved HBeAg loss (0.05 log pg/
mL decline, versus an increase of 0.05 in patients without HBeAg loss, p=0.04), and 
Table 2. Logistic regression model of probability of response to peginterferon in HBeAg-positive 
patients
HBeAg loss week 78 Combined Response week 78
Variable oR (95% Ci) p Variable oR (95% Ci) p
IP-10* 3.60 (1.15 – 11.2) 0.024 IP-10* 2.48 (0.59 – 10.5) 0.209
Wildtype 1.11 (0.50 – 2.46) 0.799 Wildtype 3.45 (1.30 – 9.18) 0.011
HBV Genotype 0.001 HBV Genotype 0.048
 A Reference  A Reference
 B 0.62 (0.18 – 2.13)  B 0.52 (0.12 – 2.19)
 C 0.10 (0.03 – 0.37)  C 0.11 (0.02 – 0.61)
 D 0.45 (0.18 – 1.14)  D 0.33 (0.10 – 1.12)
ALT# 1.11 (0.99 – 1.25) 0.081 ALT# 1.06 (0.90 – 1.25) 0.528
Age 1.02 (0.99 – 1.05) 0.280 Age 1.04 (1.00 – 1.07) 0.036
HBV DNA** 0.58 (0.38 – 0.88) 0.010 HBV DNA** 0.55 (0.32 – 0.94) 0.031
No previous IFN 3.74 (1.50 – 9.32) 0.003 No previous IFN 5.07 (1.49 – 17.3) 0.004
Combined response was defined as HBeAg loss with HBV DNA <10,000 c/mL at 6 months post-
treatment. *IP-10 in log pg/mL, **HBV DNA in log copies/mL, #ALT in x ULN.
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the proportion of patients who achieved a decline of IP-10 from baseline was higher 
among patients with HBeAg loss (59 versus 42%, p=0.024) and combined responders 
(60 versus 45%, p=0.11). Patients with an IP-10 decrease at week 12 achieved more 
HBV DNA decline (2.55 versus 1.85 log c/mL, p=0.06), HBeAg decline (1.24 versus 
0.84 log IU/mL, p=0.029) but not HBsAg decline (1.04 versus 0.75, p=0.26).
diSCuSSion
This is the first study to describe the association of IP-10 level and response to PEG-
IFN therapy in CHB. In our study, higher baseline level of IP-10 strongly predicted 
HBeAg loss after PEG-IFN therapy, and a combination of high IP-10 and presence of 
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stratified by presence of precore and/or core promoter mutants
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only WT virus identified patients with a high likelihood of combined serological and 
virological response.
PEG-IFN is a valuable treatment option for CHB, for it is the only agent that can 
be expected to induce a sustained off-treatment response after a finite treatment 
course.22 However, the limited response rates observed in the general CHB patient 
population necessitate careful selection of patients.23 Our group recently published 
a baseline prediction model that can help clinicians identify HBeAg-positive patients 
with a high likelihood of response4, and extensions with host and viral factors have 
been proposed.5, 6, 24 The current study shows that response to PEG-IFN in HBeAg-
positive patients also depends upon pre-treatment serum level of IP-10. Importantly, 
the association of IP-10 with response to treatment is already apparent from week 4 
of therapy, as shown by the more pronounced HBV DNA, HBeAg and HBsAg decline 
observed in patients with higher levels of IP-10 at baseline. Given the strong associa-
tion of IP-10 with ALT, high levels of IP-10 may be a proxy for an active host immune 
response, resulting in more active liver inflammation.25 Importantly, blocking the 
effects of IP-10 may reduce liver damage in mice,26 further supporting the association 
of IP-10 with immune activity. These findings are corroborated by recent data from 
Cornberg et al, showing more pronounced HBsAg decline in nucleo(s)tide analogue 
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treated patients with high IP-10 levels.27 The association with immune activity is 
further strengthened by the observation that IP-10 levels decline during PEG-IFN 
therapy in patients who achieve a response, mimicking reductions in intrahepatic 
inflammation previously observed in responders to PEG-IFN.1 Previous studies have 
shown that a pre-existing immune response may be a pre-requisite for response to 
PEG-IFN therapy,4, 28 and the current study shows that serum levels of IP-10 may help 
identify patients with such favourable characteristics. Nevertheless, the observed 
IP-10 decline in responders is very limited, restraining the use of IP-10 as an on-
treatment predictor of response to PEG-IFN therapy in HBeAg-positive CHB. Fur-
thermore, recent studies in HCV infected patients treated with PEG-IFN have shown 
that a slight increase in IP-10 levels may be observed after PEG-IFN dosing, which 
may also reduce the reliability of IP-10 quantification during treatment. The current 
study therefore does not support the use of IP-10 for on-treatment decision-making 
in HBeAg-positive CHB patients treated with PEG-IFN.12
It should be appreciated that baseline and on-treatment IP-10 levels appear to be 
mainly associated with the probability of HBeAg clearance after PEG-IFN therapy, 
and less so with a combined serological and virological response. Persistence of 
viral replication after HBeAg loss may be accounted for by the presence PC and 
BCP mutants, which can be detected in a considerable proportion of HBeAg-positive 
patients.6 Combining levels of IP-10 and presence of PC and BCP mutants showed 
that both contribute to the achievement of a combined serological and virological 
response; patients with both a high baseline level of IP-10 and absent mutants 
achieved high rates of combined response, whereas patients with a high IP-10 level 
with detectable mutants progressed to active HBeAg-negative CHB. A similar asso-
ciation was found if a combination of baseline ALT and presence of mutants was 
explored, further illustrating the importance of active inflammation. Based on these 
findings, we propose that combined serological and virological response to PEG-IFN 
in HBeAg-positive CHB requires both a susceptible host (high IP-10, high ALT), as 
well as a susceptible virus (absence of PC and BCP mutants).
Concluding, high levels of IP-10 predict HBeAg loss, and a combination of high 
IP-10 and absent PC and BCP mutants predicts combined serological and viro-
logical response to PEG-IFN in HBeAg-positive CHB. There appears little use for 
on-treatment quantification of IP-10 for prediction of response to PEG-IFN in CHB.
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ABSTRACT
Background & Aims
HBeAg and HBsAg clearance are associated with an improved prognosis in chronic 
hepatitis B patients (CHB). These endpoints are more often achieved with a one year 
course of peginterferon (PEG-IFN) compared with one year of nucleos(t)ide analogue 
(NA) therapy. However, prolonged NA therapy may result in comparable serological 
response rates as with PEG-IFN.
Methods
We compared serological and virological response rates among HBeAg-positive CHB 
patients treated with long-term continuous entecavir (ETV) (n=91) for a median of 92 
(IQR 50-132) weeks or one year of PEG-IFN (n=266) with comparable follow up.
Results
Finite PEG-IFN therapy resulted in significantly higher rates of HBeAg seroconversion 
(adjusted hazard ratio (HR): 3.16, p<0.001) and HBsAg clearance (HR 5.66, p=0.027) 
when compared to prolonged ETV treatment, whereas ETV resulted in higher rates of 
HBV DNA undetectability (OR 31.14, p<0.001) also after adjustment for HBV genotype 
and other relevant baseline factors.
Conclusions
Our study shows that finite PEG-IFN is associated with a higher probability of sero-
logical, but not virological, response for HBeAg-positive chronic hepatitis B patients 
when compared to prolonged ETV, even after correction for baseline differences.
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inTRoduCTion
Prolonged infection with the hepatitis B virus (HBV) may ultimately result in severe 
liver-related morbidity and mortality, and treatment of CHB is therefore indicated in 
patients with persistent liver inflammation.1-4 Hepatitis B e Antigen (HBeAg)-positive 
CHB is regarded as the earliest stage of a four stage disease continuum.1, 3-4 HBeAg 
seroconversion (HBeAg clearance with positive anti-HBe) and Hepatitis B surface 
Antigen (HBsAg) seroclearance are important treatment end-points in HBeAg-positive 
CHB,3-4 since they are associated with disease remission, a reduced risk of hepatocel-
lular carcinoma and an improved prognosis.5-6 These serological endpoints are more 
often achieved with a one year course of peginterferon (PEG-IFN) when compared 
to one year of nucleo(s)tide analogues (NA), but prolonged NA therapy may result 
in serological response rates approximating those achieved with PEG-IFN.7-8 Cur-
rent treatment guidelines recommend both treatment modalities as first-line therapy 
options in HBeAg-positive CHB.3-4 However, head-to-head comparisons of finite 
PEG-IFN versus long-term NA therapy have not been performed, and differences 
in baseline characteristics prohibit direct comparison of previously published study 
results. We therefore aimed to compare rates of HBeAg seroconversion and HBsAg 
clearance, as well as HBV DNA undetectability, in HBeAg-positive CHB patients 
treated with continuous entecavir (ETV) monotherapy or one year of PEG-IFN with 
subsequent off-treatment follow-up.
MeTHodS
Patients
A total of 266 HBeAg-positive CHB patients were treated with PEG-IFN alfa-2b 
(PegIntron, Schering-Plough, Kenilworth, NJ, USA) daily for 52 weeks ± lamivudine 
(LAM, Zeffix, GlaxoSmithKline, Greenford, UK) for one year.8 Patients were subse-
quently followed-up for another 6 months off-treatment and were enrolled in a long-
term follow-up study.9 Key inclusion criteria for this study were: HBsAg positive for at 
least 6 months before randomization, HBeAg positivity, elevated serum alanine ami-
notransferase (ALT) levels <10 times the upper limit of normal (ULN), and serum HBV 
DNA of more than 1.0 x 105 copies/mL. Another 91 consecutive NA-naïve patients 
were treated with ETV 0.5 mg daily as recommended by current treatment guidelines 
and were followed-up at the outpatient clinic at least every 3-6 months. The study 
was conducted in accordance with the guidelines of the Declaration of Helsinki and 
the principles of Good Clinical Practice. All patients gave written informed consent 
according to standards of the local ethics committees.
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laboratory assays
(anti-)HBeAg and HBsAg tests were performed using commercially available ELISA 
kits. HBV DNA was measured at baseline using real-time Taqman based methods.8 
ALT was measured locally and was expressed as multiples of the upper limit of nor-
mal (ULN). HBV genotype was assessed by line-probe assay (Innogenetics, Ghent, 
Belgium).
Statistical analysis
HBeAg seroconversion (HBeAg negativity with anti-HBe) and HBsAg clearance rates 
were compared by Kaplan-Meier and Cox-proportional hazard analyses. Rates of 
HBV DNA undetectability were evaluated at week 78 (i.e. 6 months post-treatment for 
patients treated with PEG-IFN) and at last follow-up evaluation. The analysis at last 
follow-up was limited to patients treated with ETV for ≥78 weeks. Follow-up time was 
calculated from start of treatment, and is expressed as median with the interquartile 
range (IQR). Follow-up was terminated in patients retreated after PEG-IFN and sero-
logical status before retreatment used as outcome parameter. SPSS version 15.0 
(SPSS Inc., Chicago, IL, USA) and the SAS 9.2 program (SAS Institute Inc., Cary, NC, 
USA) were used to perform statistical analyses. All statistical tests were two-sided 
and were evaluated at the 0.05 level of significance.
ReSulTS
Study Cohort
Treatment outcomes did not differ between patients treated with PEG-IFN ± LAM, 
and patients were therefore pooled for this analysis.8-9 Median follow-up was 92 
weeks (IQR 78–198) for patients treated with PEG-IFN, and 92 (IQR 50-132) weeks 
for patients treated with ETV. HBV genotype distributions among patients treated with 
PEG-IFN were A/B/C/D/other in 34%, 9%, 15%, 39% and 4%, compared to 27%, 
8%, 21%, 33% and 11% in the ETV group (p=0.11). The PEG-IFN and ETV groups 
were also well-balanced with regard to age (34.95 versus 36.93 years, p=0.21), sex 
(78% male versus 75%, p=0.55) and previous IFN therapy (both 21%, p=0.97). Base-
line HBV DNA levels were higher in patients treated with PEG-IFN (9.06 versus 7.98 
log copies/mL, p<0.001) as were ALT levels (4.30 versus 3.05 times the upper limit of 
normal, p=0.004).
HBeAg seroconversion
A total of 114 (32%) patients achieved HBeAg seroconversion in a median of 78 
weeks (IQR 52–120). By Kaplan-Meier analysis, the cumulative probability of HBeAg 
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seroconversion was higher in patients treated with PEG-IFN for one year versus those 
treated with ETV (p=0.007). PEG-IFN therapy remained an independent determinant 
of HBeAg seroconversion in a Cox proportional hazard model; the hazard rate (HR) 
for PEG-IFN versus ETV was 3.16 (95% CI: 1.64 – 6.75, p<0.001), after adjustment for 
HBV genotype, baseline ALT and baseline HBV DNA (figure 1A).
HBsAg loss
A total of 30 (8%) patients cleared HBsAg in 92 (IQR 78–170) weeks. By Kaplan-Meier 
analysis, cumulative HBsAg clearance rates were higher in patients receiving PEG-
IFN therapy compared to patients treated with ETV (p=0.032). In a Cox proportional 
hazards model, PEG-IFN therapy was independently associated with HBsAg clear-
ance, with a HR of 5.66 (95% CI: 1.17 – 101.80, p=0.027) after adjustment for HBV 
genotype, age and previous IFN exposure (figure 1B).
HBV dnA undetectability
At week 78, a total of 69 (21%) patients had undetectable HBV DNA. HBV DNA 
undetectability was achieved in 77% of ETV treated patients, compared to only 8% 
of patients treated with PEG-IFN (p<0.001). At last follow-up evaluation, 90 (39%) 
of patients achieved undetectable HBV DNA, comprising 92% of patients on ETV, 
and 19% of PEG-IFN treated patients (p<0.001). In a logistic regression model, ETV 
therapy (OR 31.14, 95% CI: 13.30 – 72.90, p<0.001), HBV genotype A (OR 3.54, 95% 
CI: 1.58 – 7.95, p=0.002) and log HBV DNA (OR 0.65, 95% CI: 0.48 – 0.89, p=0.007) 
but not ALT (p=0.74) were independently associated with HBV DNA undetectability 
at week 78. An interaction term of HBV genotype and therapy was non-significant 
(p=0.26).
diSCuSSion
This is the first study to compare a finite course of PEG-IFN to prolonged potent NA 
therapy for serological and virological response rates. We found that PEG-IFN results 
in higher rates of HBeAg seroconversion and HBsAg seroclearance than continu-
ous ETV therapy, and this difference remained after adjustment for baseline factors. 
Nevertheless, HBV DNA undetectability was achieved in only a minority of PEG-IFN 
treated patients, whereas most patients on ETV achieved this endpoint.
PEG-IFN and the NA have distinctly different modes of action in CHB.10 PEG-IFN is 
an immunomodulator with limited direct antiviral efficacy that is able to induce a host 
immune response in a subset of patients.11 NA competitively inhibit HBV polymerases 
and thus HBV DNA production. Several studies have shown that currently approved 
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figure 1: Cox-proportional hazard plots of the probability of HBeAg seroconversion (A) and 
HBsAg clearance (B) in patients treated with PEG-IFN (± LAM) or ETV.
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potent NA ETV and TDF can induce and maintain undetectable HBV DNA levels for 
prolonged therapy duration with a low risk of viral resistance or complications.7, 12 
However, relapse is common after discontinuation of therapy.13 HBeAg seroconver-
sion has previously been shown to be associated with an improved prognosis 5-6, and 
is considered a first step towards immune control over HBV. The current study shows 
that this endpoint is more often achieved with a finite course of PEG-IFN than with 
prolonged ETV therapy, suggesting that immune control can more often be achieved 
with PEG-IFN. However, long-term follow-up studies of patients treated with PEG-IFN 
have revealed that some patients maintain elevated HBV DNA levels after HBeAg 
seroconversion.9, 14 Similarly, in patients treated with NA, viral rebound is frequently 
observed when therapy is discontinued after HBeAg seroconversion.15
Furthermore, our study also shows that a finite course of PEG-IFN results in superior 
rates of HBsAg seroclearance, the closest outcome to clinical cure one can hope to 
achieve in CHB.3-4 HBsAg clearance is highly durable, confers an excellent long-tem 
prognosis and is associated with a low probability of HBV reactivation in immune 
competent patients 5, 16. Although HBsAg clearance is only rarely achieved with cur-
rently available agents, particularly in patients treated with NA, we showed that a 
substantial proportion of patients treated with PEG-IFN may achieve this end-point 
during treatment and long-term off-treatment follow-up. This is in line with recent 
studies showing increased decline of HBsAg levels in patients treated with PEG-IFN, 
particularly in responders, when compared to patients treated with ETV.17-18
Nevertheless, serological response is only achieved in a limited subset of patients 
treated with PEG-IFN, and persistence of HBV DNA after PEG-IFN is a reality in the 
majority of patients.9, 14 In contrast, nearly all patients on ETV achieved HBV DNA 
undetectability, and thus disease remission, while on-treatment. Taking into consider-
ation the considerable side-effects of PEG-IFN and the limited response rates, PEG-
IFN therapy should be limited to those patients with the highest chances of achieving 
both serological and virological response, whereas ETV is a powerful treatment option 
for the vast majority of patients.
Although the current study was not randomized, we conducted a thorough multivari-
ate analysis including all major determinants of serological response.19 Of note, the 
HBV genotype distribution was comparable in the two cohorts, and we adjusted for 
baseline ALT and HBV DNA levels, age, sex, presence of cirrhosis and previous IFN 
exposure when necessary. We also pooled the results of patients treated with PEG-
IFN ± LAM to increase power. Importantly, several independent randomized studies 
and a meta-analysis have revealed no benefits of combination therapy.8, 13-14, 19
In conclusion, our study shows that a finite course of one year PEG-IFN results in 
superior rates of HBeAg seroconversion and HBsAg seroclearance, but not HBV DNA 
undetectability, when compared to prolonged ETV monotherapy.
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ABSTRACT
Background & Aims
Serum hepatitis B surface antigen (HBsAg) decline during treatment may reflect the 
immunomodulatory efficacy of peginterferon (PEG-IFN). We aimed to investigate 
within a large randomised trial whether quantitative HBsAg levels predict response to 
PEG-IFN in HBeAg-positive chronic hepatitis B patients.
Methods
Serum HBsAg was measured in samples taken at baseline, week 4, 8, 12, 24, 52 and 
78 of 221 patients treated with PEG-IFN alfa-2b ± lamivudine for 52 weeks. HBsAg 
decline was compared between treatment arms and between responders and non-
responders. Response was defined as HBeAg loss with HBV DNA <10,000 copies/mL 
at 26 weeks post-treatment (week 78).
Results
Forty-three of 221 (19%) patients achieved a response. One year of PEG-IFN ± 
lamivudine resulted in a significant decline in serum HBsAg, which was sustained 
post-treatment (decline 0.9 log IU/mL at week 78, P<0.001). Patients treated with 
combination therapy experienced a more pronounced on-treatment decline, but 
relapsed subsequently. Responders experienced a significantly more pronounced 
decline in serum HBsAg compared to non-responders (decline at week 52: 3.3 versus 
0.7 log IU/mL, P<0.001). Patients who achieved no decline at week 12 had a 97% 
probability of non-response through post-treatment follow-up and no chance of 
HBsAg loss. In a representative subset of 149 patients similar results were found for 
prediction through long-term (mean 3.0 years) follow-up.
Conclusions
PEG-IFN induces a significant decline in serum HBsAg in HBeAg-positive patients. 
Patients who experience no decline from baseline at week 12 have little chance of 
achieving a sustained response and no chance of HBsAg loss and should be advised 
to discontinue therapy with PEG-IFN.
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inTRoduCTion
Chronic hepatitis B (CHB) is a major health problem, affecting more than 350 million 
people worldwide. Prolonged infection with the hepatitis B virus (HBV) may ultimately 
result in severe liver-related morbidity and mortality, and treatment of CHB is there-
fore indicated in patients with persistent liver inflammation.1-4 The ideal outcome of 
treatment of CHB would be complete eradication of HBV, but this is only scarcely, 
if ever, achieved, for HBV covalently closed circular DNA (cccDNA) persists in host 
hepatocytes.5 Therefore, the main goal of therapy is to halt the progression of liver 
inflammation to fibrosis, cirrhosis or hepatocellular carcinoma.6-7
Current treatment options for CHB consist of nucleo(s)tide analogues (NA) and 
(pegylated) interferons (PEG-IFN). Antiviral treatment with NA aims at inhibiting viral 
polymerase activity,8 and the most recently approved NA can effectively maintain 
suppression of HBV DNA levels for prolonged periods of time in the vast majority of 
patients.9-11 Nevertheless, PEG-IFN remains an important first-line treatment option 
for CHB, especially in hepatitis B e antigen (HBeAg)-positive disease, since a long-
term off-treatment sustained response can be achieved in about 25% of patients after 
a finite treatment course12-14. Response to IFN-based therapy in these patients is 
accompanied by high rates of hepatitis B surface antigen (HBsAg) seroconversion,15 
a reduced incidence of hepatocellular carcinoma and prolonged survival.16-17
The development of a durable off-treatment response is attributed to the immuno-
modulatory effect of PEG-IFN,18 which results in a decrease in intrahepatic cccDNA.19 
CccDNA levels at the end of therapy are indeed predictive of a sustained off-treatment 
response,20 but since these can only be assessed invasively the clinical utility is lim-
ited. Recent studies report an excellent correlation between decline in intrahepatic 
cccDNA and serum HBsAg levels in HBeAg-positive patients.5, 21 A decline in serum 
HBsAg levels may therefore reflect the efficacy of PEG-IFN in decreasing intrahepatic 
cccDNA and consequently predict a sustained off-treatment response.
The aims of our study were to investigate the effects of one year of PEG-IFN ± lami-
vudine (LAM) therapy on serum HBsAg levels in HBeAg-positive CHB patients, and 
to describe the relationship between on-treatment HBsAg decline and a sustained 
off-treatment response.
MeTHodS
Patients
In this study serum HBsAg levels were assessed in HBeAg-positive CHB patients who 
were previously enrolled in an investigator-initiated multicenter randomized controlled 
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trial and a subsequent long-term follow-up (LTFU) study.12-13 Patients were eligible 
for the initial study if they had been HBsAg positive for at least 6 months prior to 
randomization, were HBeAg positive on two occasions within 8 weeks prior to ran-
domization, had elevated serum alanine aminotransferase (ALT) levels of 2 - 10 times 
the upper limit of normal (ULN), and had a serum HBV DNA concentration above 1.0 
x 105 copies/mL. Key exclusion criteria were: antiviral therapy within 6 months prior 
to randomization, presence of viral co-infections, pre-existing cytopenia or decom-
pensated liver disease. Treatment comprised of PEG-IFN alfa-2b 100 μg weekly 
(PegIntron, Schering-Plough, Kenilworth, NJ, USA) in combination with placebo or 
LAM (Zeffix, GlaxoSmithKline, Greenford, UK) 100 mg daily for 52 weeks. To limit the 
probability of early treatment discontinuation, the dose of PEG-IFN was reduced to 
50 μg per week after 32 weeks of treatment. Patients attended the outpatient clinic 
at least every 4 weeks for routine examinations and laboratory assessments during 
both the treatment and the post-treatment follow-up phase of the initial study. For the 
LTFU study, patients were re-evaluated at one additional visit at the local participating 
center. The mean duration of follow-up was 3 years.12
Inclusion criteria for the present analysis were completion of the 26-week follow-up 
phase of the main study and availability of a baseline serum sample for HBsAg quan-
tification. Of the 266 patients in the initial study, 221 fulfilled these criteria. Of these 
patients, 149 participated in the associated LTFU study.12 The study was conducted 
in accordance with the guidelines of the Declaration of Helsinki and the principles 
of Good Clinical Practice. All patients gave written informed consent according to 
standards of the local ethics committees.
laboratory measurements
Serum HBsAg was quantified in samples taken at baseline, during the treat-
ment period (weeks 4, 8, 12, 24 and 52) and during follow-up (week 78) using the 
ARCHITECT HBsAg assay (Abbott laboratories; range 0.05 - 250 IU/mL).22 HBV 
DNA quantification for the initial study was performed with 4-week intervals using 
an in-house developed TaqMan polymerase chain reaction (PCR) assay (lower limit 
of quantification 400 copies/mL) based on the EuroHep standard.23 For the LTFU 
study, HBV DNA was measured with the Cobas TaqMan HBV assay (Roche Molecular 
Systems, Branchburg, NJ, USA), with a dynamic range of quantification of 174 - 6.4 x 
108 copies/mL (30 - 1.1 x 108 IU/mL). It has previously been demonstrated that there 
is an excellent correlation between the two assays.12 HBeAg was assessed using EIA 
(AxSYM, Abbott, Abbott Park, IL, USA) or ELISA (DiaSorin SpA, Saluggia, Italy). ALT 
was measured locally in accordance with standard procedures and is presented as 
multiples of the upper limit of normal (ULN). HBV genotype was assessed using the 
INNO-LiPA assay (Innogenetics).
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Statistical analysis
For the current study a composite endpoint of HBeAg loss and HBV DNA level 
<10,000 copies/mL was chosen for definition of response.24 Patients who were 
retreated after the initial study were considered non-responders at LTFU. Associations 
between variables were tested using Student’s t-test, Chi-square, Pearson correla-
tion or their non-parametric equivalents when appropriate. The differences in HBsAg 
decline between treatment arms and (non-)responders were analysed using repeated 
measurement models with an unstructured covariance allowing heterogeneity across 
compared groups. Discrimination, or the ability of HBsAg concentration and decline 
at various time-points to distinguish patients who will develop a response from those 
who will not, was quantified by the area under the receiver-operating characteristic 
curve (AUC). Our aim was to use on-treatment HBsAg levels to identify a stopping 
rule that would enable a clinician to discontinue patients who had a very low chance 
of response as early as possible, while maintaining >90% of responders on treatment. 
The optimal cut-off in HBsAg decline was identified using a grid-search of possible 
cut-off points at weeks 4, 8, 12, and 24. For each cut-off point the chi-square test was 
calculated together with the sensitivity and the negative predictive value (NPV). The 
highest chi-square identified the optimal cut-off point. 25 SPSS version 15.0 (SPSS 
Inc., Chicago, IL, USA) and the SAS 9.2 program (SAS Institute Inc., Cary, NC, USA) 
were used to perform statistical analyses. All statistical tests were two-sided and 
were evaluated at the 0.05 level of significance.
ReSulTS
Patient characteristics
The characteristics of the 221 patients are shown in table 1 according to assigned 
treatment regimen. Patients were comparable across both groups with regard to age, 
race, HBV genotype distribution, baseline prevalence of cirrhosis and ALT and HBV 
DNA levels. Overall, 43 (19%) patients had a response at week 78, and these patients 
were distributed equally across the two study arms. Baseline mean serum HBsAg 
was 4.4 log IU/mL in both treatment groups. Serum HBsAg was positively correlated 
with HBV DNA (r = 0.66, p<0.01) and inversely correlated with age (r = -0.16, P = 0.02) 
but did not correlate with ALT. Variation was observed in pre-treatment HBsAg levels 
between genotypes, with the highest baseline levels in genotypes A and D (mean 
4.5 log IU/mL for both) and lower levels in genotypes B (mean 4.3 log IU/mL) and C 
(mean 3.8 IU/mL) (P<0.001 for genotype C versus other genotypes with Bonferroni 
correction).
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on-treatment HBsAg decline according to treatment regimen
Overall, HBsAg levels decreased significantly through 52 weeks of therapy (mean 
decline 1.2 log IU/mL, P <0.001), and the decrease was sustained after 26 weeks 
of follow-up (mean decline compared to baseline 0.9 IU/mL, P<0.001). Patterns of 
HBsAg decline for both treatment groups are depicted in figure 1. Declines were 
similar in both treatment arms at weeks 4, 8 and 12, but slightly more pronounced 
in the combination (PEG-IFN + LAM) compared to the monotherapy group (PEG-IFN 
+ placebo) at week 24 (mean decline 1.0 log IU/mL versus 0.6 log IU/mL, P = 0.04) 
and at week 52 (mean decline 1.46 and 0.87 log IU/mL for combination therapy and 
monotherapy, respectively, P = 0.04). This difference was not sustained through post-
treatment follow-up (mean decline of 0.98 and 0.86 log IU/mL for combination and 
Table 1: Patient characteristics according to treatment regimen
Characteristics Peg-ifn
and placebo
(n=111)
Peg-ifn
and lamivudine 
(n=110)
P
demography
 Mean (SD) age, years 34 (13) 33 (12) 0.52
 Male 90 (81%) 83 (75%) 0.33
 BMI 24.2 (3.4) 25.1 (4.5) 0.10
Race 0.31
 Caucasian 80 (72%) 80 (73%)
 Asian 25 (23%) 19 (17%)
 Other 6 (5%) 11 (10%)
laboratory results
 Mean (SD) ALT* 4.3 (3.0) 4.2 (3.0) 0.75
 Mean (SD) HBV DNA, log copies/mL 9.1 (0.8) 9.1 (1.0) 0.87
 Mean (SD) HBsAg, log IU/mL 4.4 (0.6) 4.4 (0.7) 0.74
HBV genotype 0.52
 A 40 (36%) 34 (31%)
 B 10 (9.0%) 10 (9.1%)
 C 18 (16%) 14 (13%)
 D 41 (37%) 46 (42%)
 Other/mixed 2 (1.8%) 6 (5.5%)
Response at week 78
 Response# 20 (18 %) 23 (21%) 0.61
 HBV DNA <400 copies/mL 9 (8.1%) 13 (12%) 0.38
 HBeAg loss 43 (39%) 41 (37%) 0.89
 HBsAg loss 8 (7.3%) 11 (10%) 0.48
*Multiples of upper limit of the normal range
#HBeAg loss and HBV DNA <10,000 copies/mL
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monotherapy at week 78, respectively, P = 0.63). Considering the equal response 
rates and HBsAg levels at week 78 in the two treatment groups, we analysed the 
relationship between HBsAg decline and treatment response in all 221 patients.
HBsAg decline according to treatment response at week 78
Baseline mean HBsAg levels were comparable in the 43 patients who achieved a 
response at week 78 and those who did not; 4.4 versus 4.3 log IU/mL in non-respond-
ers and responders, respectively (P = 0.19). Mean HBsAg declines from baseline for 
responders and non-responders at week 78 are shown in figure 2. Non-responders 
showed a modest decline through 52 weeks of therapy (0.69 log IU/mL, P <0.001), 
and relapsed during follow-up (decline from baseline at week 78 was 0.35 log IU/mL, 
P <0.001 compared to week 52). Mean decline from baseline in responders was 3.3 
log IU/mL at week 52 and 3.4 at week 78 (P<0.001 for both when compared to base-
line). Responders thus showed a more vigorous decline in HBsAg starting at week 4, 
and this difference increased through 52 weeks of therapy and was sustained during 
post-treatment follow-up (P<0.005 for week 4 and P≤0.001 for all other time-points 
compared to non-responders).
Prediction of response
Since HBsAg decline patterns differed depending on treatment response, we inves-
tigated the discriminatory capabilities of HBsAg decline at weeks 4, 8, 12 and 24 for 
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Figure 1
figure 1: Mean change in serum HBsAg from baseline in patients treated with monotherapy 
(PEG-IFN + placebo) and combination therapy (PEG-IFN + LAM).
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predicting response. Using ROC analysis, areas under the curve (AUC) were 0.70, 
0.76, 0.75 and 0.78 for decline at week 4, 8, 12 and 24, respectively, for predict-
ing response at week 78. We also investigated the discriminatory values of absolute 
HBsAg levels (in log IU/mL) and HBV DNA decline, but these proved inferior to HBsAg 
declines.
Next, we proceeded to investigate the optimal cut-off point, according to our pre-
set criteria, in HBsAg decline at week 4, 8, 12 and 24 for prediction of response. 
A cut-off of any decline in serum HBsAg level from baseline (i.e. the HBsAg level 
on-treatment was lower than the level measured at baseline: log(HBsAgon-treatment) − 
log(HBsAgbaseline) < 0) proved superior. Subsequently, prediction of response at weeks 
12 and 24 was superior to weeks 4 and 8 since it allowed for more patients to be 
stopped, while maintaining >90% of responders on-treatment (Figure 3). In addition, 
week 12 was superior to week 24 because it allowed for earlier discontinuation of 
therapy, while maintaining high predictive values for both response and HBsAg loss 
(Table 2).
At week 12, 69% of patients achieved a decline in HBsAg when compared to base-
line. Of the 31% who did not only 3% achieved a response at week 78. Consequently, 
the negative predictive value (NPV) of the presence of any decline in HBsAg at week 
12 is 97% for prediction of response at week 78. Comparable NPVs were found for 
prediction of response at week 24 (Table 2, figure 4). Of those patients that achieved a 
decline at week 12, 25% achieved a response at week 78, and 12% achieved HBsAg 
loss.
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figure 2: Mean change in serum HBsAg from baseline in patients who achieved a response 
(HBeAg loss and HBV DNA <10,000 copies/mL) at week 78 and those who did not.
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Prediction of response through lTfu
Of the 149 patients with LTFU data available, 36 (24%) had a response at LTFU. 
Similar decline patterns were observed for responders and non-responders at LTFU 
when compared to (non-)responders at week 78; responders showed a steeper 
on-treatment decline. Declines were 0.53 log IU/mL versus 2.76 log IU/mL at week 
52, for (non-)responders, respectively (P=0.007 for weeks 4 and 8, P≤0.002 for all 
other time-points), and the difference was sustained post-treatment. Furthermore, 
of the patients who did not achieve a decline through 12 weeks of therapy, only 5% 
achieved a sustained response through LTFU and none lost HBsAg (table 3).
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figure 3: Individual HBsAg declines at week 12, stratified by response at week 78. All but two 
patients who achieved a response at week 78 experienced a decline in HBsAg from baseline to 
week 12. Lines represent median decline.
Table 2: Positive and negative predictive values for any HBsAg decline at week 12 and 24 for 
prediction of response and HBsAg loss at week 78
Response week 78* HBsAg loss week 78
no yes PPV nPV no yes PPV nPV
Any decline week 12 Yes 104 35 25% – 122 17 12% –
 No 61 2  – 97% 63 0  – 100%
Any decline week 24 Yes 122 36 23% – 140 18 11% –
 No 47 4  – 92% 51 0  – 100%
PPV, positive predictive value; NPV negative predictive value;
* Response is defined as HBeAg loss and HBV DNA < 10,000 copies/mL
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Yes
202 patients
139 patients
63 patients
35 patients
104 patients
2 patients
61 patients
No
Yes
No NPV 97%
PPV 25%
Decline
Response
Yes
No
Yes
209 patients
158 patients
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36 patients
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4 patients
47 patients
No
Yes
No NPV 92%
PPV 23%
Decline
Response
Yes
No
A Week 12
B Week 24
figure 4: Flowcharts for any decline in serum HBsAg levels from baseline at weeks 12 (A) or 24 
(B) in relation to sustained off-treatment response at week 78.
Table 3: Positive and negative predictive values for any HBsAg decline at week 12 and 24 for 
prediction of response and HBsAg loss at LTFU
Response lTfu * HBsAg loss lTfu
no yes PPV nPV no yes PPV nPV
Any decline week 12 Yes 65 29 31%  – 80 14 15% –
 No 42 2  – 95% 44 0  – 100%
Any decline week 24 Yes 76 30 28%  – 90 16 15% –
 No 32 3  – 91% 35 0  – 100%
PPV, positive predictive value; NPV negative predictive value;
* Response is defined as HBeAg loss and HBV DNA < 10,000 copies/mL
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diSCuSSion
We report the first large study on serum HBsAg decline during PEG-IFN treatment for 
HBeAg-positive CHB in relation to a sustained off-treatment response. One year of 
therapy with PEG-IFN significantly reduced serum HBsAg levels, and the decrease 
was sustained through post-treatment follow-up. HBsAg decline was significantly 
more pronounced in patients who achieved a response (HBeAg loss and HBV DNA 
<10,000 copies/mL). Furthermore, we found that reliable prediction of non-response 
to PEG-IFN is possible as early as week 12 of therapy, based on the absence of a 
decline in serum HBsAg. Patients who do not experience a decline in serum HBsAg 
from baseline to week 12, comprising 31% of our study population, have a minimal 
chance of achieving a sustained off-treatment response. Our results can help clini-
cians in their decision of whether to continue PEG-IFN therapy based on an individual 
patient’s probability of non-response.
PEG-IFN can induce an off-treatment sustained response in a substantial propor-
tion of HBeAg-positive CHB patients,12-15 but its clinical use is compromised by the 
frequent occurrence of side-effects26 and the uncertainty as to whether a patient will 
actually benefit from this therapy. Reliable prediction of non-response at baseline or 
during the first weeks of therapy is therefore essential to optimal utilization of this 
agent. Recently, a baseline prediction model has been published, based upon data 
from the two largest studies involving PEG-IFN in HBeAg-positive chronic hepatitis 
B.24 The model enables the clinician to predict response (HBeAg loss and HBV DNA < 
2,000 IU/mL (~10,000 copies/mL)) of HBeAg-positive patients to PEG-IFN, based on 
readily available data, such as HBV genotype, HBV DNA and ALT levels, age and sex. 
While the model provides considerable support when considering a patient for PEG-
IFN therapy, substantial uncertainty remains as to whether an individual patient will 
respond to a one year course of PEG-IFN. On-treatment monitoring of viral replication 
using HBV DNA, HBeAg and HBsAg levels may aid decision-making and frequent 
HBV DNA monitoring is therefore recommended in treatment guidelines3. However, 
modeling of HBV DNA kinetics during PEG-IFN therapy has shown only limited clini-
cal utility,27-28 and reliable prediction of non-response is only possible at week 24 of 
therapy (negative predictive value (NPV) 86%).29
Recent technical advances have allowed for the quantitative assessment of HBsAg 
in serum. HBsAg is secreted from the hepatocyte during viral replication as part of 
the HBV nucleocapsid, or as part of noninfectious viral particles.30 Several studies 
have reported that serum HBsAg levels correlate with intrahepatic cccDNA levels in 
HBeAg-positive patients.21, 31 On-treatment HBsAg decline may therefore reflect the 
efficacy of PEG-IFN in decreasing intrahepatic cccDNA and consequently predict a 
sustained response.21, 31 This hypothesis was first tested in HBeAg-negative patients, 
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and it was found that patients with low HBsAg levels at the end of treatment had the 
highest probability of achieving a sustained off-treatment response.32 Furthermore, 
another study showed that patients who did not achieve a 0.5 log decline in serum 
HBsAg from baseline to week 12 of therapy had only 10% probability of achieving a 
response (NPV 90%).33
Our observations in HBeAg-positive patients corroborate these results on the excel-
lent predictive capabilities of on-treatment HBsAg decline. In our study population, 
patients who did not achieve a decline in serum HBsAg concentration from baseline 
to week 12 of therapy had only 3% chance of achieving a sustained off-treatment 
response. The resulting NPV of 97% is superior to that achieved using HBV DNA and 
comparable to HBeAg monitoring.29 Furthermore, our findings indicate that prediction 
of non-response to PEG-IFN is possible as early as week 12, as opposed to week 24 
when using serum HBV DNA or HBeAg levels29 and that prediction of non-response 
using HBsAg decline can accurately indentify those patients with a low probability 
of sustained response through 3 years of post-treatment follow-up. Furthermore, if 
our on-treatment stopping-rule was applied combined with the baseline prediction 
model.24 the AUC increased from 0.75 for the stopping-rule alone to 0.79 for the 
combination, showing that application of both two models to guide therapy decisions 
may be beneficial.
Other studies have reported that HBsAg levels of <1500 IU/mL at week 12 or week 
24 of therapy were highly predictive of sustained HBeAg seroconversion 6 months 
post-treatment34. We found comparable positive predictive values (PPVs) for HBsAg 
levels <1500 IU/mL at week 12 for response at LTFU (PPV: 55%) and for loss of 
HBsAg at LTFU (PPV: 35%). Prediction did not improve at week 24, with PPVs of 53% 
for response at LTFU, and 41% for HBsAg loss at LTFU. Anyhow, these results have 
limited clinical significance, since even patients with HBsAg levels >1500 IU/mL at 
either of these time-points have a considerable probability of response. If one were to 
discontinue therapy all patients with HBsAg >1500 IU/mL at week 24, one would miss 
out on 48% of patients with a response at LTFU in our study population.
A possible caveat of our study is that we pooled data from the two treatment arms 
for the formulation of our stopping-rule. Patients who received combination therapy 
experienced a somewhat larger decline from week 24 to week 52. To account for this, 
we validated our stopping-rule in both treatment groups, and found that it performed 
equally well in both populations. Sensitivity analysis confirmed that a cut-off of any 
decline was superior in both groups. Additionally, our LTFU population comprised 
only a subgroup of the total study group (149 out of 221). However, it was previously 
shown that the LTFU group was representative of the entire study cohort 12, and we 
confirmed these findings (data not shown). Also, the cut-off of any decline performed 
well in both groups (tables 2 and 3). Furthermore, one could argue that we should 
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have chosen a different definition of response. In this study, we defined response as 
off-treatment sustained HBeAg loss combined with HBV DNA <10,000 copies/mL 
(~2000 IU/mL), since HBeAg loss 6 months post-treatment has been reported to be 
highly durable12 and since patients with low HBV DNA levels are less likely to develop 
HBV related liver complications or require antiviral therapy according to recent guide-
lines.3, 35-37 Moreover, this end-point is in line with other recently published papers 
on response to PEG-IFN in HBeAg-positive CHB,24 and the high negative predictive 
values were maintained if HBeAg seroconversion combined with HBV DNA <10,000 
copies/mL was applied as end-point.
Concluding, a one year course of PEG-IFN results in a significant decline in serum 
HBsAg in HBeAg-positive CHB patients. The decline is considerably more pro-
nounced in patients who achieve a response (HBeAg loss and HBV DNA <10,000 
copies/mL) when compared to non-responders. Patients who do not experience a 
decline in HBsAg levels through 12 weeks of therapy have a low chance of achieving 
a sustained off-treatment response (<5%) and no chance of HBsAg loss, and should 
therefore be considered for treatment discontinuation.
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ABSTRACT
Background & Aims
On-treatment decline of serum Hepatitis B surface Antigen (HBsAg) may reflect the 
immunomodulatory effect of peginterferon (PEG-IFN) for HBeAg-positive chronic 
hepatitis B (CHB). We aimed to compare HBsAg decline across HBV genotypes 
between combined responders (HBeAg loss and HBV DNA <10,000 copies/mL at 
week 78), HBeAg responders (HBeAg loss with HBV DNA >10,000 copies/mL) and 
nonresponders.
Methods
HBsAg was measured at baseline, on-treatment and 6 months post-treatment in 221 
HBeAg-positive CHB patients treated with PEG-IFN±lamivudine for 52 weeks, and 
in a representative subgroup of 142 patients at long-term follow-up (LTFU; mean 
follow-up 3.0 years).
Results
On-treatment HBsAg decline significantly varied according to HBV genotype (A and 
B more than C and D, p<0.001). On-treatment HBsAg decline also differed between 
patients with a combined response (n=43) and those without (n=178, 3.34 versus 
0.69 logIU/mL decline at week 52; p<0.001). Among patients without a combined 
response, no difference was observed between HBeAg responders (n=41) versus 
nonresponders (n=137). HBsAg decline was sustained in combined responders and 
progressed to 3.75 logIU/mL at LTFU. Patients with a combined response achieved 
pronounced HBsAg declines, irrespective of HBV genotype, and those who achieved 
HBsAg levels <1,000 IU/mL at week 78 had a high probability of a sustained response 
and HBsAg clearance through LTFU.
Conclusions
On-treatment HBsAg decline during PEG-IFN therapy for HBeAg-positive CHB 
depends upon HBV genotype. Patients with a combined response to PEG-IFN 
achieve a pronounced HBsAg decline, irrespective of HBV genotype, which is sus-
tained through 3 years of off-treatment follow-up.
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inTRoduCTion
Chronic hepatitis B (CHB) is an important global health problem, with over 350 million 
people being chronically infected.1 Prolonged liver inflammation due to infection with 
the hepatitis B virus (HBV) may progress to cirrhosis, liver failure and hepatocel-
lular carcinoma (HCC).1-2 Hepatitis B e Antigen (HBeAg)-positive CHB is generally 
regarded as the earliest phase of infection in what is essentially a four phase disease 
continuum.2 Current treatment guidelines recommend both pegylated interferon (PEG-
IFN) and nucleos(t)ide analogues (NA) for the treatment of HBeAg-positive patients.2-3 
A one year course of PEG-IFN results in an off-treatment sustained response, defined 
as HBeAg loss and HBV DNA <10,000 copies/mL at 6 months post-treatment, in 
around 25 percent of patients. 4-5 Response to IFN-based therapy has been reported 
to be associated with a lower incidence of HCC and prolonged survival. 6-8
Covalently closed circular DNA (cccDNA) is the main replication template of HBV 9 
and low cccDNA levels following antiviral therapy have been shown to be predictive 
of a sustained response.10 Intrahepatic cccDNA can only be assessed invasively, but 
it has recently been demonstrated that serum levels of hepatitis B surface antigen 
(HBsAg) reflect intrahepatic cccDNA levels in HBeAg-positive CHB patients and may 
consequently predict a sustained response.11-13
PEG-IFN induces a strong decline in serum HBsAg levels in both HBeAg-positive 
and HBeAg-negative patients.14-18 Patients who achieve a sustained response to 
PEG-IFN exhibit a steeper HBsAg decline compared with non-responders. A recent 
study among HBeAg-negative patients suggested that the degree of HBsAg decline 
may be influenced by the infecting HBV genotype as well.19 Given these findings, 
a durable suppression of HBsAg may reflect immunological control over the virus. 
The long-term sustainability of PEG-IFN induced HBsAg decline is however currently 
unknown. The aims of our study were therefore to investigate (1) which factors are 
associated with HBsAg decline induced by PEG-IFN for HBeAg-positive CHB and (2) 
whether HBsAg decline is durable through long-term follow-up.
MeTHodS
Patients
Serum HBsAg levels were assessed in 221 HBeAg-positive CHB patients who were 
previously enrolled in an investigator-initiated multicenter randomized controlled trial 
and a subsequent long-term follow-up (LTFU) study.4, 20 The in- and exclusion criteria 
for this study have been described elsewhere. In short, patients were eligible if they 
had been HBsAg positive for at least 6 months prior to randomization, were HBeAg 
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positive twice within 8 weeks prior to randomization, had elevated serum alanine ami-
notransferase (ALT) levels of 2 - 10 times the upper limit of normal, and had a serum 
HBV DNA level above 1.0 x 105 copies/mL. Exclusion criteria were antiviral therapy 
within 6 months prior to randomization, viral co-infections, pre-existing cytopenia 
and/or decompensated liver disease. Patients were treated with PEG-IFN alfa-2b 100 
μg weekly (PegIntron, Merck, Whitehouse Station, NJ, USA) in combination with a 
placebo or lamivudine (LAM) 100 mg (Zeffix, GlaxoSmithKline, Greenford, UK) daily 
for 52 weeks. The PEG-IFN dose was reduced to 50 μg per week after 32 weeks of 
therapy to limit the probability of early treatment discontinuation. Patients attended 
the outpatient clinic every 4 weeks for routine examinations and laboratory assess-
ments during both the treatment and the post-treatment follow-up phase of the study. 
For the LTFU study, patients were re-evaluated at one additional visit at the local 
participating center. The mean duration of follow-up was 3.0 years.20
Inclusion criteria for the present study were: completion of the 26-week follow-up 
phase of the main study and availability of a baseline serum sample for HBsAg 
quantification. Of the 266 patients in the initial study, 221 fulfilled these criteria. Of 
these patients, 142 participated in the associated LTFU study and had LTFU samples 
available for HBsAg quantification.20
The study was conducted in accordance with the guidelines of the Declaration of Hel-
sinki and the principles of Good Clinical Practice. All patients gave written informed 
consent according to standards of the local ethics committees.
laboratory measurements
Serum HBsAg was quantified in samples taken at baseline, during the treatment 
period (weeks 4, 8, 12, 24 and 52), during follow-up (week 78) and at LTFU using the 
ARCHITECT HBsAg assay (Abbott laboratories, Abbott Park, IL; range 0.05 - 250 IU/
mL). HBV DNA quantification was performed using an in-house developed TaqMan 
polymerase chain reaction (PCR) assay (lower limit of quantification 400 copies/mL) 
based on the EuroHep standard.21 For the LTFU study, HBV DNA was measured with 
the Cobas TaqMan HBV assay (Roche Molecular Systems, Branchburg, NJ, USA), 
with a dynamic range of quantification of 174 - 6.4 x 108 copies/mL (30 - 1.1 x 108 IU/
mL). There is an excellent correlation between the two assays.20 ALT was measured 
locally in accordance with standard procedures and is presented as multiples of the 
upper limit of normal (ULN). HBV genotype was assessed using the INNO-LiPA assay 
(Innogenetics, Gent, Belgium).
Statistical analysis
Response to treatment was assessed at week 78 in all patients. A composite endpoint 
of HBeAg loss and HBV DNA level <10,000 copies/mL was chosen for definition of 
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combined response, 5 and patients who achieved HBeAg loss but failed to achieve 
HBV DNA <10,000 copies/mL were considered HBeAg responders. All others were 
non-responders. Associations between variables were tested using Student’s t-test, 
Chi-square, Pearson correlation or their non-parametric equivalents when appropri-
ate. SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) and the SAS 9.2 program (SAS 
Institute Inc., Cary, NC, USA) were used to perform statistical analyses. All statistical 
tests were two-sided and were evaluated at the 0.05 level of significance.
ReSulTS
Patient characteristics
A total of 221 patients were included in this study. The mean age of the total study 
population was 34 years at the start of therapy, patients were predominantly male 
(78%), and of Caucasian origin (72%). HBV genotypes A and D were most prevalent 
in the study cohort (34% and 39%), followed by C (15%) and B (9%). Mean baseline 
ALT levels were 4.2 times ULN, HBV DNA levels were 9.1 log copies/mL and HBsAg 
levels were 4.4 log IU/mL (Table 1). Of the 221 patients, 43 (19%) achieved a com-
bined response (HBeAg negativity and HBV DNA <10,000 copies/mL at week 78). 
An additional 41 patients were HBeAg responders (HBeAg loss with HBV DNA levels 
>10,000 copies/mL), and 19 patients (9%) lost HBsAg.
A total of 142 patients had serum available at LTFU (mean follow-up 3.0 years). The 
characteristics of the main study population and the LTFU cohort were fully compa-
rable with regard to baseline HBV DNA, ALT and HBsAg levels, and HBV genotype 
distribution (table 1). Follow-up duration was similar in responders and non-respond-
ers. Importantly, only one patient with a combined response at week 78 experienced 
HBeAg relapse, and 54% of combined responders at week 78 was HBsAg negative 
at LTFU.
HBsAg decline on-treatment
One year of treatment with PEG-IFN resulted in a mean decline in serum HBsAg levels 
of 1.17 log IU/mL. This decline was sustained through 6 months of post-treatment 
follow-up: the mean decline from baseline was 0.92 log IU/mL at week 78. At base-
line, only age (p<0.01) and HBV genotype (p<0.01) were related to HBsAg decline at 
week 78 by univariate analysis. Combination therapy, ALT, log HBV DNA, sex and race 
were all not associated with HBsAg decline at week 78. By multivariate analysis, HBV 
genotype, age and log HBV DNA level at baseline were related to HBsAg decline at 
week 78.
110
7
HBsAg decline according to HBV genotypes
Baseline HBsAg levels were significantly different in genotypes A through D. Mean 
HBsAg levels were 4.53 log IU/mL in patients with genotype A, 4.33 in genotype 
B, 3.79 in genotype C, and 4.51 in genotype D (p<0.001 for genotype C versus 
other genotypes). Furthermore, considerably different HBsAg decline patterns were 
observed in the respective genotypes. While patients with genotype D experienced a 
slight increase during the first 12 weeks of therapy, patients with genotypes A and B 
showed a strong initial decline (figure 1). At the end of treatment, patients infected with 
genotypes A and B had a significantly more pronounced HBsAg decline (mean 1.90 
and 2.17 log IU/mL, respectively), when compared to patients harbouring genotypes 
C or D (0.59 and 0.55, respectively; p<0.001 for A and B versus C and D). Through 
Table 1: Patient characteristics
Characteristics Main study
population (n=221)
lTfu study
population (n=142)
P
demography
 Mean (SD) age, years 34 (12) 34 (12) 1.0
 Male 173 (78%) 115 (81%) 0.60
 BMI 25 (4.0) 25 (4.2) 0.66
Monotherapy 111 (50%) 75 (53%) 0.63
Race 0.83
 Caucasian 160 (72%) 99 (70%)
 Asian 44 (20%) 30 (21%)
 Other 17 (8%) 13 (9%)
laboratory results
 Mean (SD) ALT* 4.2 (3.0) 4.6 (3.4) 0.31
 Mean (SD) HBV DNA, log copies/mL 9.1 (0.89) 9.1 (0.80) 1.0
 Mean (SD) HBsAg, log IU/mL 4.4 (0.64) 4.3 (0.69) 0.26
HBV genotype 0.78
 A 74 (34%) 41 (29%)
 B 20 (9%) 12 (9%)
 C 32 (15%) 27 (19%)
 D 87 (39%) 56 (39%)
 Other/mixed 8 (4%) 6 (4%)
Response at week 78
 Combined response# 43 (19%) 24 (17%) 0.58
 HBeAg loss 84 (38%) 49 (35%) 0.51
 HBsAg loss 19 (9%) 10 (7%) 0.69
*Multiples of upper limit of the normal range
#HBeAg loss and HBV DNA <10,000 copies/mL
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post-treatment LTFU, considerable relapse was observed in patients with genotype 
B (decline at LTFU 1.24 log IU/mL), whereas HBsAg levels in patients with genotype 
A continued to decrease (decline at LTFU 2.46 log IU/mL). HBsAg levels remained 
stable through LTFU in patients infected with genotypes C and D.
HBsAg decline according to treatment response
Pre-treatment HBsAg levels were comparable in patients who achieved a combined 
response and in those who did not; 4.29 versus 4.43 log IU/mL (p=0.19). However, 
on-treatment HBsAg kinetics clearly differed between patients with a combined 
response and those without. Combined responders exhibited a decline of 3.34 log 
IU/mL, compared to 0.69 in all other patients (p<0.001, figure 2). Within the group 
who failed to achieve a combined response, no significant difference was observed 
between patients who achieved a HBeAg response (n=41) versus those who remained 
HBeAg positive (n=137); mean declines were 0.90 and 0.62 log IU/mL at week 52, 
respectively (p=0.17). The HBsAg decline induced by PEG-IFN was sustained in 
patients with a combined response, and declined further through LTFU to 3.75 log 
IU/mL (p=0.27 versus end of treatment). In those who were HBeAg positive at week 
78, mean HBsAg decline at LTFU was 0.51 log IU/mL, (figure 2, p<0.001 compared to 
combined responders), while the HBeAg responders achieved a decline of 0.86 log 
IU/mL at LTFU (p=0.35 versus those with positive HBeAg).
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figure 1: HBsAg decline in all patients according to HBV genotype. Differences between patients 
with genotype A or B versus C or D were statistically significant from week 24. Error bars repre-
sent the standard error of the mean.
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HBsAg decline according to treatment response and HBV genotype
Of the 43 combined responders, 42 were infected with genotype A through D (28 
(65%) genotype A, 5 (12%) genotype B, 3 (7%) C and 6 (14%) D). Of the 41 HBeAg 
responders, 9 (22%) were infected with genotype A, 5 (12%) with B, 5 (12%) with C 
and 18 (44%) with D. Similar to the overall population, combined responders infected 
with genotypes A through D achieved more HBsAg decline than did patients with the 
same genotype who were HBeAg responders or who remained HBeAg positive (figure 
3A-D).
Combined responders experienced marked declines in HBsAg levels from baseline to 
end of treatment (genotype A 3.81, genotype B 2.98, genotype C 1.47 and genotype 
D 2.68 log IU/ml; p=0.59). At LTFU, declines were 4.18, 2.38, 1.87 and 3.09 log IU/mL 
in combined responders with genotypes A, B, C and D, respectively (p=0.56).
In contrast, on-treatment decline in the HBeAg responders (patients who cleared 
HBeAg but did not achieve HBV DNA <10,000 copies/mL) significantly varied accord-
ing to HBV genotype; patients with genotype A and B achieved declines of 2.02 and 
1.56 log IU/mL at week 52, compared to 0.50 and 0.43 log IU/mL in patients with C 
and D (P=0.02 for A and B versus C and D). At LTFU, declines were 3.33, 0.92, 0.09 
and 0.22 in HBeAg responders with genotypes A through D, respectively (p=0.03).
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figure 2: HBsAg decline in patients with a combined response (HBeAg loss and HBV DNA 
<10,000 copies/mL) versus patients with an HBeAg response (HBeAg loss but HBV DNA >10,000 
copies/mL) or no response. Response was assessed at week 78. Differences between patients 
with a combined response versus those with no response or HBeAg response were significant 
from week 8 of treatment. Error bars represent the standard error of the mean.
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Relationship between HBsAg levels at week 78 and response at 
lTfu
Thirty-three of 142 (23%) patients with HBsAg data at LTFU achieved a combined 
response at LTFU. Analysis was limited to the 141 with available HBsAg levels at 
week 78. Probabilities of achieving a combined response at LTFU in relation to HBsAg 
levels and decline at week 78 are shown in table 2, both for the overall population 
(n=141) and for patients with a combined response at week 78 with available LTFU 
data (n=23). Importantly, no patient without a decline at week 78 achieved HBsAg 
clearance by LTFU, whereas patients with an HBsAg level <1,000 IU/mL at week 
78 (n=28) had a probability of HBsAg clearance of 46% (13/28). Only 2 of 113 (2%) 
patients with HBsAg ≥1,000 IU/mL achieved HBsAg clearance at LTFU. Among 
patients with a combined response, those with HBsAg <1,000 IU/mL achieved HBsAg 
negativity at LTFU in 73% (11/15), compared to 25% (2/8) in those with HBsAg ≥1,000 
IU/mL.
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Figure 3D
figure 3: HBsAg decline in patients with a combined response (HBeAg loss and HBV DNA 
<10,000 copies/mL at week 78) versus patients with an HBeAg response (HBeAg loss but HBV 
DNA >10,000 copies/mL at week 78) or no response for genotypes A (A), B (B), C (C) and D (D). 
Error bars represent the standard error of the mean.
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diSCuSSion
In this large study we show that on-treatment HBsAg decline is a sensitive marker for 
response to PEG-IFN, showing a steep decline in patients who achieved a combined 
response (defined as HBeAg loss and HBV DNA <10,000 copies/mL), irrespective of 
HBV genotype. A very limited decline was observed in patients who remained HBeAg 
positive or those who cleared HBeAg but progressed to active HBeAg-negative CHB, 
and patients without an HBsAg decline at week 78 have a very limited probability 
of response at LTFU. Furthermore, HBsAg decline was sustained in patients with a 
combined response through 3 years of follow-up, reflecting a long-term sustained 
suppression after therapy discontinuation.
The HBV replication pathway that produces HBsAg is separate from the pathway 
that produces HBV DNA. HBsAg is transcribed and subsequently translated from the 
HBV envelope gene, and produced as small, medium or large HBsAg proteins.22-23 
Synthesized HBsAg proteins may then be incorporated into mature HBV nucleocap-
sids, and subsequently secreted from the hepatocyte. However, HBsAg production 
far exceeds that required for the production of HBV virions and HBsAg is therefore 
also secreted in the form of non-infectious particles. Commercially available HBsAg 
quantification assays probably detect all forms of HBsAg, 24 but the clinical relevance 
of the different HBsAg forms is so far unclear.
HBsAg levels in the sera of patients with CHB depend on the phase of infection. 
Patients classified as being in the immune tolerant and immune clearance phases 
of the disease have the highest HBsAg levels, whereas HBsAg is lowest in inactive 
carriers. 24-26 Furthermore, patients classified as inactive carriers who experienced a 
subsequent HBV DNA increase (reactivation) had higher HBsAg levels compared to 
those who did not.25 A post-treatment sustained reduction in HBsAg levels achieved 
with PEG-IFN therapy may therefore signify an immunological response, resulting in 
Table 2. HBsAg level and decline at week 78 and response at LTFU.
All patients* (n=141) Combined response 78# (n=23)
Combined response lTfu no yes nPV PPV no yes nPV PPV
HBsAg level week 78 <1,000 11 17  – 61% 0 15   – 100%
 ≧1,000 98 15 87% – 4 4  50%   –
Any decline week 78 Yes 71 31  – 30% 3 19   –  86%
 No 38 1 97% – 1 0 100%   –
* All patients with HBsAg levels at week 78 and at LTFU. #Patients with a combined response at 
week 78. Combined response was defined as HBeAg negativity with HBV DNA <10,000 copies/
mL. NPV, negative predictive value; PPV, positive predictive value.
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transition to the inactive carrier state. 26 In our study, one year of PEG-IFN therapy 
induced a pronounced decline in serum HBsAg levels, particularly in patients who 
achieved HBeAg loss and HBV DNA <10,000 copies/mL at week 78. Importantly, 
the decline achieved in these combined responders was durable through LTFU. This 
implies not only long-term sustained disease remission with a very low probability of 
relapse,25 but also reflects the high probability of subsequent HBsAg loss as described 
previously in HBeAg-positive responders to (PEG-)IFN.20, 27 Furthermore, we found 
that patients who achieved a combined response (HBeAg clearance with HBV DNA 
<10,000 copies/mL at week 78) with concomitant HBsAg levels <1,000 IU/mL did 
not experience relapse during off-treatment follow-up and were very likely to clear 
HBsAg. Conversely, patients who failed to achieve an HBsAg decline from baseline 
by week 78 had little chance of combined response, and no chance of HBsAg loss, 
suggesting the necessity of retreatment with other agents.
The current study also shows that baseline HBsAg levels and on-treatment HBsAg 
decline in HBeAg-positive patients are dependent upon HBV genotype. These findings 
are in line with a report on HBeAg-negative subjects,19 and may reflect a difference 
in transcription efficacy between respective genotypes. 28 However, the differences 
observed in HBsAg decline according to genotype may also be a reflection of the 
variance in the efficacy of PEG-IFN across the genotypes. Among HBeAg responders, 
those with genotypes C and D experienced only a limited reduction in HBsAg levels, 
and these patients were reported to have a high probability of HBeAg seroreversion 
and persistently detectable HBV DNA through LTFU.20, 29 Conversely, HBeAg respond-
ers infected with genotype A experienced a pronounced decline in HBsAg levels, and 
also had the highest probability of losing HBsAg through LTFU. 20 Interestingly, we 
found detectable precore and/or core promoter mutants by INNO-LiPA line-probe 
assay in all but one of the HBeAg responders with available serum, irrespective of 
HBV genotype (n=29, data not shown). This suggests that the differences in HBsAg 
decline across genotypes are not due to the presence or absence of these mutants.
In contrast to the genotype specific differences among HBeAg responders, all 
combined responders experienced pronounced HBsAg declines. This shows that, 
irrespective of HBV genotype, a combined response is associated with a sustained 
reduction in HBsAg levels and a high probability of HBsAg loss through long-term 
follow-up.27 Taken together, these observations corroborate recent data highlighting 
the influence of HBV genotype on response to PEG-IFN, and show that a combined 
response of HBeAg loss and HBV DNA < 10,000 copies/mL is the most appropriate 
marker for response to PEG-IFN, especially in patients with non-A genotypes.5, 20
Recent studies among HBeAg-positive18 and HBeAg-negative14, 30 patients treated 
with PEG-IFN have shown that HBsAg levels during therapy may be used to predict 
response to treatment. However, the current study now shows that HBsAg decline 
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during PEG-IFN treatment for HBeAg-positive CHB depends upon HBV genotype as 
well, and the differences in HBsAg decline suggest that genotype specific thresholds 
may be required when using HBsAg to guide PEG-IFN based therapy.
A possible caveat of our study is that we pooled data from the two treatment arms 
of the original trial. Combination therapy of PEG-IFN and LAM is known to cause a 
slightly steeper on-treatment HBsAg decline. However, this effect of LAM was the 
same regardless of treatment response or HBV genotype, and was not sustained 
post-treatment. Furthermore, we found no difference in any of the outcomes when 
we analyzed the treatment arms separately. Response rates were similar in patients 
treated with PEG-IFN monotherapy versus the combination with LAM (18 versus 21%, 
p=0.61), as were HBsAg decline at week 78 (0.86 versus 0.98 log IU/mL, p=0.63) and 
at LTFU (0.93 versus 1.32, p=0.22). A subgroup of non-responders was retreated after 
the initial study. Retreatment did not affect HBsAg kinetics during LTFU.
In conclusion, HBeAg-positive CHB patients who achieve a combined response 
(HBeAg loss and HBV DNA <10,000 copies/ml) to PEG-IFN therapy achieve a pro-
nounced decline in HBsAg levels, irrespective of HBV genotype. In contrast, patients 
who clear HBeAg but have HBV DNA levels >10,000 copies/mL experience a limited 
decline, showing that HBeAg loss alone may be a suboptimal marker for response to 
PEG-IFN in patients with non-A genotypes. The HBsAg decline achieved in patients 
with a combined response is sustained through 3 years of post-treatment follow-up 
reflecting a durable response with a low chance of relapse and a high probability of 
subsequent HBsAg loss.
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ABSTRACT
Background & Aims
On-treatment levels of hepatitis B surface antigen (HBsAg) may predict response to 
peginterferon (PEG-IFN) therapy in chronic hepatitis B (CHB), but previously proposed 
prediction rules have shown limited external validity.
Methods
We analysed 803 HBeAg-positive patients treated with PEG-IFN in 3 global studies 
with available HBsAg measurements. A stopping-rule based on absence of a decline 
from baseline was compared to a prediction-rule that uses HBsAg levels of <1500 IU/
mL and >20,000 IU/mL to identify patients with high and low probabilities of response.
Results
Patients with an HBsAg level <1,500 IU/mL at week 12 achieved response (HBeAg 
loss with HBV DNA <2,000 IU/mL at 6 months post-treatment) in 45%. At week 12, 
patients without a decline in HBsAg achieved a response in 14%, compared to only 
6% of patients with HBsAg >20,000 IU/mL, but performance varied across HBV 
genotype. In patients treated with PEG-IFN monotherapy (n=465), response rates 
were low in patients with genotypes A or D if there was no decline of HBsAg by week 
12 (negative predictive value [NPV]: 97-100%), and in patients with genotypes B or 
C if HBsAg at week 12 was >20,000 IU/mL (NPV: 92-98%). At week 24, nearly all 
patients with HBsAg >20,000 IU/mL failed to achieve a response, irrespective of HBV 
genotype (NPV for response and HBsAg loss 99% and 100%).
Conclusions
HBsAg is a strong predictor of response to PEG-IFN in HBeAg-positive CHB. HBV 
genotype specific stopping-rules may be considered at week 12, but treatment dis-
continuation should be considered in all patients with HBsAg >20,000 IU/mL at week 
24, irrespective of HBV genotype.
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inTRoduCTion
Chronic hepatitis B (CHB) affects over 350 million people and is one of the leading 
causes of cirrhosis and hepatocellular carcinoma.1 Antiviral treatment with peginter-
feron-alfa (PEG-IFN) may result in suppression of HBV DNA, hepatitis B e antigen 
(HBeAg) loss and hepatitis B surface antigen (HBsAg) clearance.2-5 Response to 
PEG-IFN therapy is durable, and patients with a sustained response have a reduced 
risk of developing hepatocellular carcinoma.6-8
However, clinical application of PEG-IFN is compromised by the limited response 
rates and the occurrence of side-effects.3-5 Careful selection of patients with the 
highest probabilities of response to PEG-IFN therapy is therefore essential. Several 
studies have shown that response rates are higher in patients with HBV genotypes A 
or B versus C or D,3, 5, 9 and in patients with higher levels of ALT5, 9 and lower levels of 
HBV DNA.9 Recent studies also suggest that host factors such as IL28B genotype, as 
well as viral characteristics such as absence of precore and/or core promoter mutants 
also influence response probabilities.10, 11
Nevertheless, prediction models incorporating these variables have only limited 
discriminatory capabilities. Recent studies have shown that serum levels of HBsAg 
correlate with intrahepatic cccDNA concentrations, and that achievement of a decline 
in HBsAg may herald induction of immune-control.12, 13 HBsAg levels during treatment 
with PEG-IFN can be used to identify patients with very high or very low probability 
of response,5, 14 but interpretation of the findings is hampered by the use of differ-
ent definitions of response across the studies. Furthermore, the external validity of 
proposed stopping-rules was shown to be limited,15 which may be accounted for by 
the influence of HBV genotype on HBsAg levels and kinetics.16 Since HBV genotype 
distribution differed considerably across the different study cohorts, only a combined 
analysis of individual patient data would allow for adequate assessment of the perfor-
mance of the prediction rules across patients with different HBV genotypes.
The aim of the current study was therefore to evaluate the performance of two recently 
proposed prediction rules for HBeAg-positive CHB patients treated with PEG-IFN 
in a pooled dataset of patients participating in 3 of the largest randomized studies 
conducted worldwide.3-5
PATienTS And MeTHodS
Patients
In this study serum HBsAg levels were assessed in HBeAg-positive CHB patients who 
were previously enrolled in 3 separate pivotal multicenter randomized controlled trials 
122
8
on PEG-IFN therapy: the PEG-IFN alfa-2a Phase 3 study,4 the HBV 99-01 study,3, 14 
and the Neptune study.5 The PEG-IFN alfa-2a Phase 3 study compared PEG-IFN 
alfa-2a alone, lamivudine alone, or the two combined for a treatment duration of 48 
weeks.4 The HBV 99-01 study compared PEG-IFN alfa-2b alone with PEG-IFN alfa-2b 
combined with lamivudine for 52 weeks.3 The Neptune study compared 48 weeks 
of PEG-IFN alfa-2a at the full dose of 180ug/week for 48 weeks or 24 weeks, with 
a reduced dose of 90 ug/week for 48 or 24 weeks.5 Only patients from the Neptune 
study randomized to the full dose for 48 weeks of PEG-IFN alfa-2a were eligible for 
participation in the current study. Response to treatment was assessed at 6 months 
post-treatment in all 3 studies, corresponding to study week 72 for the PEG-IFN 
alfa-2a Phase 3 and Neptune studies, and week 78 for the HBV 99-01 study. Inclu-
sion criteria for these studies have been published previously, but in short: patients 
were positive for HBsAg for at least six months, positive for HBeAg, had an elevated 
ALT between 1 and 10 times the upper limit of normal (ULN) and HBV DNA levels 
exceeding 1.0 × 105 copies/mL. Exclusion criteria included co-infection with hepatitis 
C virus, hepatitis delta virus or human immunodeficiency virus, decompensated liver 
disease, previous antiviral therapy within six months and pre-existing neutropenia or 
thrombocytopenia.
Patients were eligible for the current analysis if they were infected with HBV genotypes 
A through D, had available HBsAg measurements at baseline, available HBsAg mea-
surements at week 12 and/or week 24, and available data on treatment outcome at 
6 months post-treatment. Out of a total of 899 patients with available data (PEG-IFN 
alfa-2a Phase 3: n=542; HBV 99-01: n=221; Neptune: n=136), 803 patients complied 
with these criteria. Of the excluded 96 patients, 17 were infected with HBV genotypes 
other than A through D, 38 patients did not have available HBsAg levels at baseline 
and week 12 and/or 24, and 41 did not have available outcome data on (anti-)HBe, 
HBV DNA levels or HBsAg at 6 months post-treatment.
laboratory measurements
Serum HBsAg was quantified in samples taken at baseline, during the treatment 
period and during follow-up. HBsAg was measured using the Architect (Abbott, 
Abbott Park, IL, USA17) in patients from the PEG-IFN alfa-2a Phase 3 and the HBV 
99-01 studies, and using the Elecsys HBsAg II (Roche Diagnostics, Indianapolis, IN, 
USA) for patients enrolled in the Neptune study. A large previous study has shown a 
high correlation and close agreement between the two assay and demonstrated that 
prediction rules derived from measurements conducted with one platform may be 
confidently used on the other.18 HBV DNA quantification was performed on Taqman 
based PCR assays with a lower limit of detection <400 copies/mL. ALT was measured 
locally in accordance with standard procedures and is presented as multiples of the 
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upper limit of normal (ULN). HBV genotype was assessed using the INNO-LiPA line 
probe assay (Innogenetics, Ghent, Belgium).
Statistical analysis
Response to treatment was defined as a composite endpoint of HBeAg loss with 
an HBV DNA level <2,000 IU/mL (~10,000 copies/mL)9 or HBsAg loss. The predic-
tion rules evaluated in the current analysis included the stopping-rule proposed by 
Sonneveld et al., which recommended treatment discontinuation if there is no decline 
of serum HBsAg levels from baseline to weeks 12 or 24,14 and a prediction-rule identi-
fied previously by Piratvisuth et al. on the PEG-IFN alfa-2a Phase 3 dataset, which 
used HBsAg levels of <1500 IU/mL and >20,000 IU/mL at weeks 12 and 24 to identify 
patients with a high and low probability of response, respectively.19 The validity of 
these cut-offs was confirmed in the pooled dataset using logistic regression analysis 
fitting a spline with 5 knots. The optimal cut-point was chosen based on a sensitiv-
ity of at least 95% and the highest negative predictive value (but always >90%) for 
response and HBsAg loss. SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) and the 
SAS 9.2 program (SAS Institute Inc., Cary, NC, USA) were used to perform statistical 
analyses. All statistical tests were two-sided and were evaluated at the 0.05 level of 
significance.
ReSulTS
Patient characteristics
A total of 803 patients were analysed, 104 (13%) treated with PEG-IFN alfa-2b alone, 
100 (13%) treated with PEG-IFN alfa-2b with LAM, 361 (45%) treated with PEG-IFN 
alfa-2a alone and 238 (30%) treated with PEG-IFN alfa-2a with LAM. The character-
istics of the 803 enrolled patients are shown in table 1 by assigned therapy regimen. 
Overall, 182 (23%) achieved a response (HBeAg loss with HBV DNA <2,000 IU/mL) 
and 39 (5%) cleared HBsAg by 6 months after PEG-IFN discontinuation.
HBsAg decline according to therapy regimen and HBV genotype
Baseline HBsAg levels significantly varied across HBV genotype, baseline levels 
were 4.59, 4.23, 3.91, and 4.53 log IU/mL for patients with genotypes A, B, C, and 
D(p<0.001 by ANOVA). Mean HBsAg decline at six months post-therapy was 0.73 
log IU/mL. HBsAg decline during treatment varied significantly by therapy regimen; 
patients treated with combination therapy (n=338) achieved an end of treatment 
decline of 1.37 log IU/mL, compared to 0.92 in patients treated with PEG-IFN 
monotherapy(p<0.001). However, HBsAg declines at 6 months post-treatment did not 
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differ: declines were 0.68 and 0.80 log IU/mL for patients treated with PEG-IFN alone 
versus PEG-IFN with LAM(p=0.293). HBsAg decline during treatment also varied 
across the HBV genotypes (figure 1). At six months post-treatment, mean declines 
were 1.60 and 0.96 log IU/mL for patients with genotypes A or B, versus 0.46 and 
0.39 log IU/mL for patients infected with genotypes C or D(p<0.001).
HBsAg decline according to response: overall and by HBV genotype
A decline of HBsAg levels was most pronounced in patients who achieved a response 
(figure 2A). HBsAg declines at end of treatment and at six months post-treatment 
were 2.39 and 1.98 log IU/mL in responders, compared to 0.73 and 0.34 log IU/mL 
in non-responders (p<0.001 for responders versus non-responders). Similar patterns 
were observed across the HBV genotypes (figures 2B-E). Responders achieved more 
HBsAg decline by 6 months post-treatment than non-responders, also when adjusting 
for combination therapy and HBV genotype: 2.05 versus 0.50 log IU/mL (p<0.001).
Table 1: Characteristics of the study cohort
Characteristics Peg-ifn alone
(n=465)
Peg-ifn + lAM
(n=338)
p
demography
 Mean (SD) age, years 33.0 (10.5) 32.0 (10.6) 0.161
 Male 349 (75%) 255 (75%) 0.899
Race 0.202
 Caucasian 100 (22%) 88 (26%)
 Asian 347 (75%) 233 (69%)
 Other 18 (4%) 17 (5%)
Previous ifn 47 (10%) 46 (14%) 0.126
laboratory results
 Mean (SD) ALT* 3.76 (3.5) 4.01 (3.2) 0.294
 Mean (SD) HBV DNA, log c/mL 9.35 (1.8) 9.84 (1.7) <0.001
 Mean (SD) HBsAg, log IU/mL 4.11 (0.73) 4.23 (0.66) 0.019
HBV genotype 0.299
 A 58 (13%) 45 (13%)
 B 122 (26%) 82 (24%)
 C 230 (50%) 156 (46%)
 D 55 (12%) 55 (13%)
Response at week 78
 Response# 109 (23%) 73 (22%) 0.538
 HBsAg loss 18 (4%) 21 (6%) 0.127
*Multiples of upper limit of the normal range
#HBeAg loss and HBV DNA <2,000 IU/mL at 6 months post-treatment
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on-treatment prediction of response using HBsAg levels at weeks 
12 and 24
Of the 803 enrolled patients, 779 (97%) had available HBsAg levels at week 12, and 
788 (98%) had HBsAg levels at week 24. Analysis of the association between HBsAg 
levels and declines at weeks 12 and 24 and response to treatment showed that the 
previously identified cut-offs from the respective studies (<1,500 for identification of 
patients with a high likelihood of response, >20,000 IU/mL or absence of a decline for 
identification of non-responders) were valid also in the pooled dataset.
At week 12, patients with HBsAg levels <1500 IU/mL had a probability of response of 
45%, compared to 6% in patients with HBsAg >20,000 IU/mL (NPV: 94%, p<0.001, 
figure 3A). The probability of HBsAg loss was 15% for patients with an HBsAg level 
<1500 IU/mL at weeks 12 or 24. However, 6 patients with HBsAg >20,000 IU/mL at 
week 12 achieved HBsAg loss by 6 months post-treatment (6 out of 38 with HBsAg 
loss, or 16%). At week 24, only 4 of 162 patients with HBsAg >20,000 IU/mL achieved 
a response, and none cleared HBsAg (NPVs 98% and 100%, figure 3B).
Of patients who did not achieve a decline in HBsAg levels from baseline to week 12, 
14% achieved a response (NPV 86%, p=0.001, figure 3C) and 2 cleared HBsAg (5% 
of all patients with HBsAg loss). Similar observations were made when decline was 
assessed at week 24 (Figure 3D).
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figure 1: Change in serum HBsAg from baseline during treatment and 6 months of off-treatment 
follow-up across HBV genotypes A through D.
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on-treatment prediction of response at week 12 or 24 across HBV 
genotypes
The performance of the prediction rules varied across HBV genotypes A through D 
(table 2A and table 2B). At week 12, patients with HBV genotypes A, B or C with 
HBsAg levels <1500 IU/mL had a high probability of response (42% - 86%), whereas 
such low HBsAg levels were hardly ever achieved in genotype D patients. Further-
more, application of the two stopping-rules (absence of a decline from baseline or 
an HBsAg level >20,000 IU/mL) yielded varying results across the HBV genotypes. In 
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figure 2: Mean change in serum HBsAg from baseline in patients with a response (HBeAg loss 
with HBV DNA <2,000 IU/mL) in the overall cohort (A) and by HBV genotype A through D (B-E).
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patients with genotype A, relatively high negative predictive values for response (83 
and 88%) were achieved with both stopping-rules. However, 4 of 38 (10%) genotype 
A patients with an HBsAg >20,000 IU/mL would subsequently achieve HBsAg loss 
(20% of all genotype A patients with HBsAg loss), compared to none of the patients 
without a HBsAg decline at week 12. Discontinuation of PEG-IFN in genotype A 
patients with HBsAg >20,000 IU/mL is therefore not indicated.
In patients with genotypes B and C, an HBsAg level >20,000 IU/mL at week 12 
accurately identified patients with a low likelihood of response and HBsAg loss. In 
patients with HBV genotype D, very few patients achieved a response, and absence 
of a decline at week 12 best identified non-responders.
At week 24, an HBsAg level of >20,000 IU/mL accurately identified patients with a 
low likelihood of response and HBsAg loss (figure 3B) across all genotypes (NPVs for 
genotype A, B, C and D were 94%, 100%, 100% and 97% for response, respectively, 
and 100% for HBsAg loss among all HBV genotypes).
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figure 3: Application of the prediction rules based on HBsAg levels at week 12 (A) and 24 (B) and 
HBsAg declines at weeks 12 (C) and 24 (D).
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Performance of the stopping-rules in patients treated with Peg-ifn 
monotherapy
Based on the varying performance of the stopping-rules across the HBV genotypes 
when applied at week 12, we compared the use of a stopping-rule based on an HBsAg 
level >20,000 IU/mL with a genotype specific approach (application of no decline for 
genotypes A and D and >20,000 IU/mL for genotypes B and C). A grid-search of cut-off 
Table 2A. Observed response rates according to HBsAg level at week 12 stratified by HBV geno-
type. Response was defined as HBeAg loss with HBV DNA <2,000 IU/mL.
genotype A (n=98) genotype B (n=199)
Response <1500 1500-20000 >20000 <1500 1500-20000 >20000
no 2 (14%) 25 (60%) 35 (83%) 35 (58%) 75 (74%) 35 (92%)
yes 12 (86%) 17 (41%) 7 (17%) 25 (42%) 26 (26%) 3 (8%)
HBsAg loss <1500 1500-20000 >20000 <1500 1500-20000 >20000
no 3 (21%) 38 (91%) 38 (91%) 57 (95%) 100 (99%) 38 (100%)
yes 11 (79%) 4 (10%) 4 (10%) 3 (5%) 1 (1%) 0 (0%)
genotype C (n=377) genotype d (n=105)
Response <1500 1500-20000 >20000 <1500 1500-20000 >20000
no 52 (58%) 178 (81%) 66 (99%) 2 (100%) 26 (93%) 72 (96%)
yes 37 (42%) 43 (20%) 1 (2%) 0 (0%) 2 (7%) 3 (4%)
HBsAg loss <1500 1500-20000 >20000 <1500 1500-20000 >20000
no 78 (87%) 219 (99%) 67 (100%) 2 (100%) 28 (100%) 73 (97%)
yes 11(12%) 2 (1%) 0 (0%) 0 (0%) 0 (0%) 2 (3%)
Table 2B. Observed response rates according to HBsAg decline at week 12 stratified by HBV 
genotype. Response was defined as HBeAg loss with HBV DNA <2,000 IU/mL.
genotype A (n=98) genotype B (n=199)
Response decline no decline decline no decline
no 47 (58%) 15 (88%) 130 (73%) 15 (68%)
yes 34 (42%) 2 (12%) 47 (27%) 7 (32%)
HBsAg loss decline no decline decline no decline
no 62 (76%) 17 (100%) 173 (98%) 22 (100%)
yes 19 (24%) 0 (0%) 4 (2%) 0 (0%)
genotype C (n=377) genotype d (n=105)
Response decline no decline decline no decline
no 203 (77%) 93 (83%) 49 (93%) 51 (98%)
yes 62 (23%) 19 (17%) 4 (8%) 1 (2%)
HBsAg loss decline no decline decline no decline
no 253 (96) 111 (99%) 52 (98%) 51 (98%)
yes 12 (5%) 1 (1%) 1 (2%) 1 (2%)
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points showed that the genotype specific approach at week 12 was superior to the 
use of an HBsAg >20,000 for all patients. At week 24, all patients with an HBsAg level 
>20,000 had a very low probability of response, irrespective of HBV genotype and it 
was therefore applied to all patients. The proposed algorithm performed excellently 
when applied on the patients treated with PEG-IFN monotherapy (table 3 and figure 
4). Figure 4 shows the probability of response according to HBsAg level at week 24, 
stratified by HBV genotype.
Genotype A 
1500-20000 >20000 <1500 
47% 1% 86% 
0% 0% 64% 
HBsAg level 
Response 
HBsAg loss 
Genotype B 
1500-20000 >20000 <1500 
22% 0% 45% 
0% 0% 2% 
Genotype C 
1500-20000 >20000 <1500 
17% 0% 40% 
0% 0% 9% 
HBsAg level 
Response 
HBsAg loss 
Genotype D 
1500-20000 >20000 <1500 
15% 0% 0% 
8% 0% 0% 
figure 4: Relationship between HBsAg level (in IU/mL) at week 24 of treatment and response 
(HBeAg loss with HBV DNA <2,000 IU/mL) and HBsAg loss at 6 months off-treatment.
Table 3. Performance of proposed stopping-rules at week 12 and 24 for response (HBeAg loss 
with HBV DNA <2,000 IU/mL) and HBsAg loss across the HBV genotypes in patients treated with 
peginterferon monotherapy for one year.
Week HBV genotype Applied rule n identified nPV response nPV HBsAg loss
W
ee
k 
12
A (n=55) No decline 13 (24%) 100% 100%
B (n=120) >20,000 IU/mL 24 (20%) 92% 100%
C (n=225) >20,000 IU/mL 45 (20%) 98% 100%
D (n=54) No decline 33 (61%) 97% 97%
W
ee
k 
24
A (n=55) >20,000 IU/mL 24 (44%) 96% 100%
B (n=122) >20,000 IU/mL 16 (13%) 100% 100%
C (n=224) >20,000 IU/mL 27 (12%) 100% 100%
D (n=53) >20,000 IU/mL 36 (68%) 100% 100%
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diSCuSSion
This study shows that quantification of HBsAg in HBeAg-positive patients receiv-
ing PEG-IFN may help individualise on-treatment decision-making. At week 24, 
all patients with HBsAg levels >20,000 IU/mL have a low probability of response, 
irrespective of HBV genotype, and PEG-IFN discontinuation is indicated. Use of HBV 
genotype specific stopping-rules may also be considered at week 12.
PEG-IFN is a powerful treatment option for HBeAg-positive CHB, but the limited 
response rates achieved in the general patient population, as well as the frequent 
side-effects, prohibit wide-spread use.20 Previous studies have used serum levels of 
HBV DNA and HBeAg during PEG-IFN therapy to identify patients with a low prob-
ability of response.21-23 HBeAg levels yielded higher negative predictive values than 
did HBV DNA levels, but both could only be confidently used after at least 24 weeks 
of therapy.24 Unfortunately, HBeAg levels in serum are also influenced by presence of 
precore and core promoter mutants, which may impair the reliability of prediction.10 
Recent studies have therefore focussed on the use of serum HBsAg levels for monitor-
ing of PEG-IFN efficacy. The current study, a pooled analysis of 803 patients from 3 of 
the largest global cohorts and treated with both formulations of PEG-IFN alfa, shows 
that HBsAg decline during PEG-IFN therapy is strongly associated with the occurrence 
of a response to treatment. Importantly, the pronounced HBsAg decline observed in 
responders was apparent across all major HBV genotypes. Given the association of 
HBsAg kinetics with response, several of us have attempted to use HBsAg levels at 
weeks 12 and 24 of treatment to estimate the probability of response. Sonneveld et 
al. showed that in a cohort of predominantly Caucasian patients, absence of a HBsAg 
decline from baseline at week 12 identified patients with a low likelihood of response. 
Conversely, Piratvisuth et al. found that only few patients with HBsAg >20,000 IU/mL 
at the same time-point achieved a response.19 Subsequent studies have shown the 
suboptimal external validity of these prediction rules.15, 16 Interpretation was further 
hampered by the use of different definitions of response; HBeAg loss with HBV DNA 
<10,000 copies/mL in one study and HBeAg seroconversion in others.14, 19
The current study finally resolves these issues by providing a pooled analysis of the 
patients enrolled in the previous studies, allowing for careful stratified analysis across 
HBV genotypes and using a clinically relevant definition of response. We defined 
response as HBeAg loss with HBV DNA <2,000 IU/mL, since this endpoint is highly 
durable7, 16 and since patients with low HBV DNA levels are less likely to develop HBV 
related liver complications or require antiviral therapy.25-29 Our results indicate that, 
when assessed at week 12, both an HBsAg level >20,000 IU/mL as well as absence of 
a decline from baseline may identify non-responders to PEG-IFN, but the differences 
in performance across HBV genotypes warrant careful application. The requirement 
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for different HBsAg cut-offs across HBV genotypes at week 12 of treatment may 
partly reflect the differences in baseline HBsAg levels; patients with HBV genotypes A 
had substantially higher levels than those with genotype B or C, which may account 
for the observation that patients with genotypes A with HBsAg levels >20,000 IU/
mL at week 12 may still achieve a response and HBsAg loss. Furthermore, a recent 
study in a cohort of mostly patients with genotypes A and D showed that HBeAg-
positive patients with only detectable wildtype virus (ie. no detectable precore and/
or core promoter mutants) have both higher baseline levels of HBsAg and a higher 
probability of HBsAg loss after PEG-IFN therapy.10 The high rate of response and 
HBsAg loss observed in genotype A patients with HBsAg >20,000 IU/mL at week 12 
(17% and 10%, respectively) is an important finding, and shows that HBV genotyping 
is essential if a week 12 prediction-rule is to be used in areas where HBV genotype 
A is prevalent.
Fortunately, an HBsAg level >20,000 IU/mL at week 24 may be confidently used as a 
stopping-rule for all patients with high NPVs for response and HBsAg loss, irrespec-
tive of HBV genotype. Given the wide availability of HBsAg quantification platforms, 
the low cost of the test, and the excellent predictive performance observed in the cur-
rent study, assessment of the HBsAg concentration at week 24 should be considered 
a vital part of optimal PEG-IFN therapy.
Side-effects and patient preferences should also be taken into consideration, and the 
performance of the prediction algorithm should be re-evaluated when data becomes 
available on extension of PEG-IFN therapy beyond 48 weeks or when a combination 
with nucleo(s)tide analogues other than LAM is used. Nevertheless, HBsAg based 
response-guided therapy is a valuable tool for optimization of PEG-IFN therapy, and 
can help with achieving higher response rates for every therapy course completed. 
Early identification of non-responders may help make this treatment modality more 
acceptable to patients, physicians and healthcare policy makers and possibly 
increase the cost-effectiveness of PEG-IFN in HBeAg-positive CHB.
In conclusion, the current study shows that HBsAg levels can be confidently used to 
guide therapy decisions in HBeAg-positive patients treated with PEG-IFN. Discon-
tinuation of PEG-IFN treatment is indicated in all patients with HBsAg levels >20,000 
IU/mL after 24 weeks of PEG-IFN therapy.
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ABSTRACT
Background & Aims
ALT flares occur frequently during peginterferon(PEG-IFN) therapy. We related occur-
rence of flares to presence of precore(PC) and/or core promoter(BCP) HBV mutants 
and studied kinetics of HBeAg and HBsAg levels during flares.
Methods
Fifty of 214(23%) patients treated with PEG-IFN±lamivudine for 52 weeks experienced 
flares during treatment or 6 months off-treatment follow-up. Flares were host-induced 
(ALT elevation followed by HBV DNA decline,n=19), virus-induced (HBV DNA increase 
with subsequent ALT elevation,n=17) or indeterminate(n=14). Presence of wildtype 
(WT) or non-WT (detectable PC/BCP mutants) was studied by lineprobe assay.
Results
Fifty-eight percent of host-induced flares occurred in WT HBV patients, whereas 
94% virus-induced flares occurred in patients with PC and/or BCP mutants(p=0.003). 
HBsAg loss was only achieved in patients with a host-induced flare, and WT patients 
with a host-induced flare cleared HBsAg in 64%. Analysis of individual patient data 
revealed that serum HBsAg levels only declined after a host-induced flare, whereas 
virus-induced flares were accompanied by stable or increasing levels of HBsAg. 
Patients with a host-induced flare achieved a mean HBsAg reduction of 3.24 logIU/
mL by 6 months post-treatment, compared to 0.25 logIU/mL in virus-induced flares 
(p<0.001). Patients who achieved a decline in HBsAg of more than 0.5 logIU/mL 
within four weeks after the flare cleared HBsAg in 64% (7/11), increasing to 75% (6/8) 
in patients with a decline >1 logIU/mL (p<0.001).
Conclusions
Host-induced flares are associated with WT virus and may result in decline and clear-
ance of HBV DNA, HBeAg and HBsAg. Monitoring of HBsAg levels during and after 
flares may help predict a favourable treatment outcome.
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inTRoduCTion
Pegylated interferon (PEG-IFN) is a first-line treatment option for HBeAg-positive 
chronic hepatitis B (CHB), but results in a response in only a limited number of 
patients.1-3 Spontaneous elevations of ALT, or flares, are a well-recognised phe-
nomenon in patients treated with PEG-IFN, although the pathogenesis is not well 
understood.4 Flares may occur in up to 25% of patients treated with a one year 
course of PEG-IFN, and have been associated with an increased probability of sero-
logical response.5, 6 However, flares can also have considerable detrimental effects, 
and may result in hepatic decompensation and death in patients with advanced cir-
rhosis.7 We previously recognised different types of flares during PEG-IFN therapy of 
HBeAg-positive CHB.5, 8 In that study, host-induced flares, characterised by an ALT 
flare followed by a decline in HBV DNA, were associated with response to treatment, 
whereas virus-induced flares, ALT elevations that were preceded by an increase in 
HBV DNA, were not.5 Why some patients develop host-induced flares where others 
experience virus-induced flares is currently unclear. Acute flares in untreated CHB 
patients were recently shown to be associated with presence of precore (PC) and 
basal core promoter (BCP) mutant virus.9 These mutants are associated with impaired 
or absent production of HBeAg, and may be less susceptible to an immune response 
against HBeAg. Since ALT flares that are preceded by an increase in HBV DNA levels 
do not trigger an effective immune response,10 it is possible that these virus-induced 
flares during PEG-IFN therapy are associated with presence of PC and BCP mutant 
virus.
It has recently become clear that serum levels of HBsAg reflect intrahepatic cccDNA 
and may be a marker for response to PEG-IFN.11-14 Possibly, monitoring of serum 
HBsAg levels may therefore provide additional insight into the differences of host 
versus virus-induced flares and may help identify patients with a high likelihood of a 
favourable outcome after flares.
The aims of the current study were therefore to (1) relate presence of PC and BCP 
mutants before PEG-IFN therapy to occurrence of host or virus-induced flares, (2) to 
study the kinetics of HBeAg and HBsAg levels during these flares, and (3) investigate 
whether ALT and HBsAg monitoring can help predict therapeutic outcome.
PATienTS And MeTHodS
Patients
Patients treated with PEG-IFN alfa-2b alone or in combination with lamivudine (LAM) 
in an investigator-initiated multicenter randomized trial were enrolled into the current 
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study.1, 14, 15 The inclusion and exclusion criteria for the original trial have previously 
been described elsewhere.1 Patients were HBsAg positive for at least 6 months before 
randomization, were HBeAg positive, had elevated serum alanine aminotransferase 
(ALT) levels of >2, but <10 times the upper limit of normal (ULN), and had a serum 
HBV DNA concentration of more than 1.0 x 105 copies/mL. Patients were treated with 
PEG-IFN alfa-2b 100 μg weekly (PegIntron, Schering-Plough, Kenilworth, NJ, USA) 
in combination with placebo or LAM 100 mg (Zeffix, GlaxoSmithKline, Greenford, 
UK) daily for 52 weeks. Of the 266 patients in the original study, 214 had available 
data on baseline presence of PC and/or BCP mutants. The study was conducted in 
accordance with the guidelines of the Declaration of Helsinki and the principles of 
Good Clinical Practice. All patients gave written informed consent according to the 
standards of the local ethics committees.
laboratory measurements
Presence of PC and BCP mutants was assessed using the INNO-LiPA HBV PreCore 
assay (Innogenetics, Ghent, Belgium). This line probe assay allows for easy detection 
of PC (at nucleotide position G1896) and BCP (at nucleotide positions A1762 and 
G1764) mutants, even when only present as minority species.16 Patients were sub-
sequently classified as wildtype (WT, only WT virus detectable), or non-WT (PC, BCP 
or both mutants detectable). Serum HBV DNA, HBeAg and HBsAg were quantified 
in samples taken at baseline, during treatment, and during 6 months of off-treatment 
follow-up. Patients were seen at the outpatient clinic at least every 4 weeks during 
the study. HBV DNA quantification was performed using an in-house developed Taq-
Man polymerase chain reaction (PCR) assay (lower limit of quantification 400 copies/
mL) based on the EuroHep standard.17 HBsAg and HBeAg were measured using the 
Roche ELECSYS assay using a quantitative protocol (Roche Diagnostics).
Classification of flares
A flare was defined as a threefold increase in serum ALT compared with baseline 
levels.5 The time point of the flare was defined as the time of the peak level of serum 
ALT. If a patient experienced multiple flares, the first was used for classification. Two 
types of flares were recognized, as described previously by Flink et al.5 A flare was 
designated as virus-induced when the ALT peak was preceded by at least a 1 log 
increase in HBV DNA levels within four months. Host-induced flares were character-
ized as an ALT peak, without a preceding increase in HBV DNA, and were typically 
followed by a subsequent decrease in HBV DNA of at least 1 log within the next 4 
months. Flares that could not be classified were designated indeterminate.5
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Statistical analysis
Associations between variables were tested using Student’s t-test, Chi-square, Pear-
son correlation or their non-parametric equivalents when appropriate. SPSS version 
15.0 (SPSS Inc., Chicago, IL, USA) and the SAS 9.2 program (SAS Institute Inc., 
Cary, NC, USA) were used to perform statistical analyses. All statistical tests were 
two-sided and were evaluated at the 0.05 level of significance.
Role of the funding source
Financial support was provided by the Foundation for Liver and Gastrointestinal 
Research (SLO) in Rotterdam, the Netherlands. The funding source did not have influ-
ence on study design, data collection, analysis and interpretation of the data, writing 
of the report nor the decision to submit for publication.
ReSulTS
Patient characteristics
Flares occurred in 50 of 214 patients with available PC/BCP data (23%). The char-
acteristics of patients with a host-induced, virus-induced or indeterminate flare are 
shown in table 1. The frequency of flares was similar for patients with WT when 
compared to those with PC and/or BCP mutants (25 versus 23%, p=0.675).
Relationship between type and timing of flare and presence of PC 
and BCP mutants
The type of flare differed according to presence of mutants; host flares occurred 
predominantly in patients with WT virus (58%), whereas virus-induced flares almost 
always occurred in patients with non-WT (16/17, or 94%). Of the 76 patients with 
WT, 11 (14%) experienced a host-induced flare, compared to 6% of patients with 
non-WT (p=0.033). Conversely, 12% of non-WT patients experienced a virus-induced 
flare, versus only 1 of 76 (1%) of WT patients (p=0.008). Of the 25 (50%) flares that 
occurred during treatment, 15 (60%) occurred in patients with WT virus. Interestingly, 
the timing of the flare was also associated with presence of WT or non-WT (p=0.004, 
figure 1). Presence of PC and/or BCP mutants at baseline was independently asso-
ciated with the occurrence of a virus induced flare, also after adjustment for HBV 
genotype, patient age and use of combination therapy (adjusted odds ratio for virus 
induced flare: 7.04, p=0.024).
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Relationship between type of flare, presence of mutants and 
response at week 78
Host-induced flares resulted more frequently in HBeAg loss than virus induced flares 
(58% versus 12%, p=0.001). HBeAg loss with HBV DNA levels <10,000 copies/mL 
and HBsAg clearance were achieved in 42% of patients with a host-induced flare, 
and in none of the patients with virus-induced or indeterminate flares (p<0.001). HBV 
DNA undetectability was observed in 5 (26%) of patients with a host induced flare, 
Table 1: Characteristics of the study cohort
Characteristics flare no flare
(n=164)
p
Host
(n=19)
Virus
(n=17)
indeterminate
(n=14)
demography
 Mean (SD) age, years 42 (12.8) 27 (9.8) 34 (11.4) 33.5 (12.4) 0.005
 Male 15 (79%) 14 (82%) 12 (86%) 126 (77%) 0.846
Peg-ifn Monotherapy 7 (37%) 3 (18%) 14 (100%) 80 (49%) <0.001
Race 0.221
 Caucasian 15 (79%) 14 (82%) 8 (57%) 120 (73%)
 Asian 1 (5%) 1 (6%) 4 (29%) 34 (21%)
 Other 3 (16%) 2 (12%) 2 (14%) 10 (6%)
laboratory results
 Mean (SD) ALT* 3.1 (1.3) 3.2 (1.7) 2.6 (1.0) 4.7 (3.3) 0.005
 Mean (SD) HBV DNA, log c/mL 9.3 (0.5) 9.2 (1.1) 9.3 (0.6) 9.1 (0.9) 0.505
 Mean (SD) HBsAg, log IU/mL 4.6 (0.4) 4.4 (0.7) 4.4 (0.5) 4.4 (0.6) 0.375
 Mean (SD) HBeAg, log IU/mL 2.5 (0.9) 2.2 (0.8) 2.6 (0.6) 2.5 (0.7) 0.546
HBV genotype 0.038
 A 12 (63%) 2 (12%) 5 (36%) 55 (34%)
 B 2 (11%) 2 (12%) 0 (0%) 15 (9%)
 C 0 (0%) 1 (6%) 4 (29%) 24 (15%)
 D 4 (21%) 12 (71%) 4 (29%) 65 (40%)
 Other/mixed 1 (5%) 0 (0%) 1 (7%) 5 (3%)
Previous ifn therapy 3 (16%) 5 (29%) 2 (14%) 28 (17%) 0.615
inno-liPA result 0.007
 Wildtype 11 (58%) 1 (6%) 7 (50%) 57 (35%)
 Non-wildtype 8 (42%) 16 (94%) 7 (50%) 107 (65%)
Response
 HBeAg loss 11 (58%) 2 (12%) 1 (7%) 63 (38%) 0.003
 Combined response 8 (42%) 0 (0%) 0 (0%) 33 (20%) 0.003
 HBsAg loss 8 (42%) 0 (0%) 0 (0%) 9 (6%) <0.001
*Multiples of upper limit of the normal range
#HBeAg loss and HBV DNA <10,000 copies/mL at week 78
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compared to none of patients with other types of flares (p=0.011). Importantly, in 
the subgroup of WT patients with a host-induced flare (n=11), HBsAg clearance was 
achieved in 64% (7 / 11, p<0.001).
Monitoring of HBeAg and HBsAg levels during flares in individual 
patients
We analysed individual patients’ changes in ALT, HBV DNA, HBeAg and HBsAg 
monthly during PEG-IFN therapy and up to 6 months post-treatment. As shown 
in figure 2A and 2B, host-induced flares were characterised by a steep ALT flare, 
followed by pronounced declines of HBV DNA, HBeAg and HBsAg. In contrast, virus-
induced flares typically showed an increase in HBV DNA before ALT elevation, and 
serum levels of HBeAg and HBsAg remained either stable (figure 2C) or temporarily 
increased (Figure 2D).
Pronounced HBsAg decline in patients with a host induced flare
Only patients with a host-induced flare achieved substantial HBV DNA decline by 
week 78 (HBV DNA decline from baseline was 4.21, 1.51 and 0.58 log copies/mL, in 
patients with host, virus or indeterminate flares, respectively [p<0.001]). Importantly, 
similar HBeAg reductions were achieved in patients with host and virus-induced 
flares, whereas only patients with a host-induced flare achieved a pronounced 
HBsAg decline at 6 months post-treatment; HBeAg declines were 0.84, 1.02 and 
0.25 log IU/mL at week 78 (p=0.309) in patients with a host-induced, virus-induced 
0 50 100
Off-treatment
Week 24 - 52
Before week 24
Percentage of patients in group
WT
WT
WT
PC/BCP mutants
PC/BCP mutants
PC/BCP mutants
Timing of flare
figure 1: Proportion of patients with wildtype or precore and/or core promoter mutants according 
to the timing of the flare. Twenty-one patients experienced a flare before week 24, 4 between 
week 24 and 52, and 25 between week 52 and the end of the study.
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or indeterminate flare, compared to HBsAg declines of 3.24, 0.25 and 0.31 log IU/mL, 
respectively (p<0.001).
HBsAg decline after flare predicts HBsAg clearance
Mean HBsAg levels at the peak of ALT during the flare were simialr in patients with a 
host-induced, virus-induced or indeterminate flare (p=0.562). However, pronounced 
HBsAg declines immediately after the flare were achieved only in patients with a host-
induced flare: mean declines were 0.78 and 1.29 log IU/mL at 1 and 2 months after 
the ALT peak in patients with a host-induced flare. This contrasted strongly with the 
stable levels of HBsAg observed in patients with a virus-induced or an indeterminate 
flare (mean increase two months after ALT peak 0.02 and 0.16 log IU/mL, respectively, 
p=0.002). The probability of an HBsAg decline of at least 0.5 log IU/mL was 53% in 
patients with a host induced flare, 8% in patients with a virus induced flare and 7% 
in patients with an indeterminate flare (p=0.003). Patients who achieved a decline 
of more than 0.5 log IU/mL during the first month after the peak of the flare had a 
probability of HBsAg clearance of 64% (7 / 11), increasing to 75% (6 / 8) in patients 
with a decline > 1 log IU/mL (p<0.001 for both).
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figure 2: Kinetics of ALT, HBV DNA, HBeAg and HBsAg in two patients with a host-induced flare 
(A and B) and in two patients with a virus-induced flare (C and D). Time in weeks, HBV DNA in log 
copies/mL, HBeAg and HBsAg in log IU/mL and ALT in times upper limit of normal
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diSCuSSion
The current study shows that host-induced flares occur more frequently in patients 
with only WT virus, and result in pronounced declines of HBsAg levels. Frequent 
monitoring of serum HBsAg levels during flares may help predict a favourable out-
come.
Spontaneous elevations of ALT are frequently encountered in the natural history of 
CHB, and may herald progression from the immunotolerant phase of HBV infection to 
immune clearance and eventual HBeAg seroconversion.18 However, flares that occur 
during or after discontinuation of nucleo(s)tide analogues (NA) therapy hardly ever 
lead to virological remission, and may result in hepatic decompensation.19, 20 Flares 
that occur after NA discontinuation do not trigger an adequate immune response10, 
suggesting these flares are different from flares that induce disease remission in 
untreated patients. Flink et al. showed that different types of flares occur during 
PEG-IFN therapy, and showed that where host-induced flares frequently resulted in 
therapy response, virus-induced flares did not.5 The current study shows that these 
virus-induced flares occur more frequently in patients where PC and BCP mutants are 
present before PEG-IFN initiation. Since these mutants have a reduced production of 
HBeAg, they are less susceptible to a PEG-IFN induced immune response against 
HBeAg, which could result in positive selection and a subsequent virus-induced 
flare not unlike those observed in patients with viral breakthrough during NA based 
therapy.19 A relationship between type of flare and the host immune system should 
also be investigated. It has been shown that flares that do not result in viral clear-
ance may result in hepatic decompensation or death, and that presence of PC and 
BCP mutants may more frequently be found in patients suffering from such acute 
exacerbations.4, 19, 21 Given that patients with detectable PC and BCP mutants before 
PEG-IFN initiation are unlikely to achieve a virological response 22 and are more likely 
to experience virus-induced flares, it appears that patients with PC and BCP mutants 
are less suitable candidates for PEG-IFN therapy.
Several studies have shown that the serum level of HBsAg is a good marker for 
immune control, both in the natural history and during PEG-IFN therapy.12 Levels of 
HBsAg are a proxy for intrahepatic transcriptionally active cccDNA, and a reduction in 
HBsAg levels may signify a decrease in intrahepatic cccDNA and induction of immune 
control over HBV.12 In the current study, host-induced flares resulted in pronounced 
HBsAg declines that were sustained during post-treatment follow-up. Importantly, 
close monitoring of serum HBsAg levels during flares revealed that the effect of host-
induced flares in reducing serum HBsAg levels was apparent even on the individual 
patient level. It was also clear that virus-induced flares do not result in a reduction of 
serum HBsAg levels, which is in line with the low response rates observed in these 
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patients. Furthermore, the induction of a decline in serum HBsAg levels during a flare 
appears to herald HBsAg clearance, suggesting that monitoring of HBsAg levels in 
patients experiencing flares during PEG-IFN therapy may give valuable information on 
a patient’s probability of treatment response. We propose to use frequent monitoring 
of serum HBsAg, since it is relatively cheap, may provide information on response 
to PEG-IFN therapy 3, 14 and can help predict outcome of flares. A decline in HBsAg 
levels during the first months after the flare may identify patients with a very high 
likelihood of HBsAg loss.
Importantly, our findings were also valid when extending the window for HBV DNA 
increase or decline from 4 to 6 months before or after the flare, and when increasing 
the ALT level from 3 times to more than 4 times the level at baseline.
Concluding, host-induced flares during PEG-IFN therapy may result in HBsAg decline 
and subsequent clearance, whereas virus-induced flares do not. Monitoring of serum 
HBsAg levels in patients with flares may help identify patients with a high likelihood 
of subsequent HBsAg clearance.
145
9
H
B
sA
g
 levels help
 classify flares d
u
ring
 p
eg
interfero
n therap
y
RefeRenCeS
 1. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in 
combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. 
Lancet 2005; 365: 123-9.
 2. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination 
for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
 3. Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a 
are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus 
genotypes B or C. Hepatology 2011; 54: 1591-9.
 4. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immu-
nologically mediated liver disease. Gastroenterology 2001; 120: 1009-22.
 5. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the 
host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. 
Gut 2005; 54: 1604-9.
 6. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of 
chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment 
viremia? Hepatology 2001; 34: 1021-6.
 7. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decom-
pensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 
1995; 109: 908-16.
 8. ter Borg MJ, Hansen BE, Bigot G, et al. ALT and viral load decline during PEG-IFN alpha-2b 
treatment for HBeAg-positive chronic hepatitis B. J Clin Virol 2008; 42: 160-4.
 9. Kusumoto K, Yatsuhashi H, Nakao R, et al. Detection of HBV core promoter and precore 
mutations helps distinguish flares of chronic hepatitis from acute hepatitis B. J Gastroenterol 
Hepatol 2008; 23: 790-3.
 10. Tan AT, Koh S, Goh W, et al. A longitudinal analysis of innate and adaptive immune profile 
during hepatic flares in chronic hepatitis B. J Hepatol 2010; 52: 330-9.
 11. Sonneveld MJ, Rijckborst V, Cakaloglu Y, et al. Durable hepatitis B surface antigen decline in 
hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-
α2b: relation to response and HBV genotype. Antivir Ther 2012; 17: 9-17.
 12. Janssen HL, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface anti-
gen: is it useful for the management of chronic hepatitis B? Gut 2012; In Press.
 13. Sonneveld MJ, Zoutendijk R, Janssen HL. Hepatitis B surface antigen monitoring and man-
agement of chronic hepatitis B. J Viral Hepat 2011; 18: 449-57.
 14. Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to pegin-
terferon alfa-2b for Hepatitis B e Antigen-positive chronic hepatitis B using on-treatment 
Hepatitis B surface Antigen decline. Hepatology 2010; 52: 1251-7.
 15. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term 
follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 
2008; 135: 459-67.
 16. Hussain M, Chu CJ, Sablon E, et al. Rapid and sensitive assays for determination of hepati-
tis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin 
Microbiol 2003; 41: 3699-705.
146
9
 17. Pas SD, Fries E, De Man RA, et al. Development of a quantitative real-time detection assay 
for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 
2000; 38: 2897-901.
 18. Yuen MF, Yuan HJ, Hui CK, et al. A large population study of spontaneous HBeAg serocon-
version and acute exacerbation of chronic hepatitis B infection: implications for antiviral 
therapy. Gut 2003; 52: 416-9.
 19. Zhang NP, Reijnders JG, Perquin M, et al. Frequency and clinical outcomes of flares related 
to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. J Viral Hepat 2011; 18: 
e252-7.
 20. Rijckborst V, Sonneveld MJ, Janssen HL. Review article: chronic hepatitis B - anti-viral or 
immunomodulatory therapy? Aliment Pharmacol Ther 2011; 33: 501-13.
 21. Aritomi T, Yatsuhashi H, Fujino T, et al. Association of mutations in the core promoter and 
precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan. J Gas-
troenterol Hepatol 1998; 13: 1125-32.
 22. Sonneveld MJ, Rijckborst V, Zeuzem S, et al. Presence of precore and core promoter mutants 
limits the probability of response to peginterferon in HBeAg-positive chronic hepatitis B. 
Hepatology 2012; 56: 67-75.
A comparison of two assays 
for quantification of hepatitis 
B surface antigen in patients 
with chronic hepatitis B 10
Milan J. Sonneveld1, Vincent Rijckborst1, Charles A.B. Boucher2, Louwerens Zwang3, 
Matthias F.C. Beersma2, Bettina E. Hansen1,4 and Harry L.A. Janssen1.
Departments of 1Gastroenterology and Hepatology, 2Virology, 3Clinical Chemistry, and 
4Biostatistics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
Journal of Clinical Virology 2011
148
10
ABSTRACT
Background & Aims
Serum Hepatitis B surface Antigen (HBsAg) levels correlate with hepatitis B virus 
intrahepatic covalently closed circular DNA and may predict response to treatment. 
Currently, 2 commercial platforms are available for HBsAg quantification in clinical 
practice, the Architect HBsAg QT and the Elecsys HBsAg. We aimed to directly com-
pare the results of these assays.
Methods
HBsAg levels were measured in 1427 serum samples from HBeAg-positive chronic 
hepatitis B patients who participated in a randomized trial of peginterferon alfa-2b ± 
lamivudine. Samples were extracted from our serum bank, thawed, and subsequently 
analysed for HBsAg levels using both assays.
Results
Of 1427 samples, 242 (17%) were taken before and 1185 during the treatment phase 
of the study. Distribution of HBV genotypes was 447 (31%) genotype A, 125 (9%) 
B, 210 (15%) C and 534 (37%) D. Correlation between Architect and Elecsys results 
was high (r=0.96, p<0.001). By Bland-Altman analysis, agreement between the two 
assays was close (mean difference between Architect and Elecsys: -0.01 logIU/mL, 
95%CI: -0.55 - 0.52 logIU/mL), also when analysed separately for HBV genotypes 
A-D. Additionally, the performance of our recently published stopping rule for HBeAg-
positive patients treated with peginterferon was comparable: the negative predictive 
values were 96% and 98% for Elecsys and Architect, respectively.
Conclusions
There is a high correlation and close agreement between quantitative HBsAg mea-
surements conducted with the Architect and the Elecsys. Clinical prediction rules 
derived from data from one platform can be applied on the other; both can therefore 
be used in clinical practice.
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Chronic hepatitis B (CHB) is an important global health problem, with over 350 million 
people being chronically infected.1 Hepatitis B surface Antigen (HBsAg) is an estab-
lished marker of infection with the hepatitis B virus (HBV), and is therefore often used 
as a screening tool.1 In addition to its use as a qualitative marker, recent innovations 
have allowed for the quantitative assessment of HBsAg in serum. The clinical relevance 
of HBsAg levels is derived from its correlation with intrahepatic HBV covalently closed 
circular (ccc)DNA, the main replicative template of HBV.2-3 Through this association, 
serum HBsAg is hypothesized to be a marker for immunological response to therapy, 
independent of virological response as measured using HBV DNA levels.
Several clinical applications of HBsAg levels have been described. For example, 
HBsAg levels appear to differentiate patients in the inactive carrier state (persistent 
HBeAg negativity, with HBV DNA <2,000 IU/mL, normal ALT4) from those with active 
disease or from inactive carriers with a high probability of subsequent relapse. 5-7 
Furthermore, recent studies have shown that on-treatment HBsAg levels are predic-
tive of a durable off-treatment response to peginterferon (PEG-IFN), and can accu-
rately identify non-responders early during therapy, both in HBeAg-positive,8-10 and 
HBeAg-negative patients.11-12
MeTHodS
Assays
HBsAg was quantified using the Architect platform (Abbott Laboratories, Abbott Park, 
IL, USA) and Elecsys HBsAg (Roche Diagnostics, Indianapolis, IN, USA). HBsAg test-
ing was performed according to the manufacturer’s package insert and with test kits 
from a single lot. For the Architect, sample material and anti-HBs-coated paramag-
netic microparticles are combined. After a washing step, acridinium labelled anti-HBs 
conjugate is added, and after another washing cycle, pre-trigger and trigger solutions 
are added. The subsequent chemiluminescent reaction is measured in relative light 
units, which can be converted directly to HBsAg units. The range of the assay is 0.05 
– 250 IU/mL, and if results were outside of this range, material was diluted according 
to the manufacturer’s recommendations (package insert HBsAg, Abbott Laboratories 
2008). The Elecsys HBsAg assay is an immunoassay that measures HBsAg using a 
sandwich principle: first a complex is formed with two monoclonal HBsAg-specific 
antibodies, one of which is biotinylated, the other labelled with a ruthenium complex. 
After addition of streptavidin-coated microparticles, the complexes bind to the solid 
phase through interaction of biotyn and streptavidin. The mixture is subsequently 
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aspirated into a measuring cell, where application of a voltage then induces chemilu-
minescent emission, which is measured by a photomultiplier. The measured results are 
compared to a cut-off value obtained through HBsAg calibration. The obtained signal 
to cut-off index may then be converted to IU/mL using a WHO standard conversion 
factor of 0.055 IU/mL (all methodology as per Elecsys package inserts for quantitative 
HBsAg measurement, Roche Diagnostics 2011). All assays were performed at the 
Erasmus MC University Medical Center in Rotterdam, the Netherlands.
Samples
Samples for this study were derived form a multicenter randomized trial investigat-
ing the efficacy of 52 weeks of PEG-IFN alfa-2b ± lamivudine for the treatment of 
HBeAg-positive CHB.14 In- and exclusion criteria for this study have been previously 
published. 14 Samples were stored after the study in a large serum bank. For this 
study, samples were thawed and serum was extracted for quantitative HBsAg mea-
surements using the two assays. HBV genotype was assessed using the INNO-LiPA 
line-probe assay.15
Statistical analysis
After transformation to log(10) IU/mL, the results of the two assays were compared 
using correlation (Pearson) and Bland-Altman analyses. A p value of <0.05 was 
considered statistically significant. Additionally, the results of a previously reported 
stopping rule for PEG-IFN therapy, established using the Architect assay10, were 
applied on the Elecsys data for comparison.
ReSulTS
Samples
A total of 1427 samples were measured using both assays, of which 242 (17%) were 
samples taken before treatment and 1185 (83%) were taken during the treatment 
phase. The samples retested for this study represent a random subset of the original 
study population.10
Comparison between Architect and elecsys measurements
A correlation of measurements conducted with the two assays is shown in Figure 1; 
correlation between the assays was excellent (r=0.96, p<0.001). Using regression 
analysis, it was determined that HBsAgArchitect = 0.979 * (HBsAgElecsys) + 0.074. Bland-
Altman analysis (depicted in Figure 2) revealed a close agreement between the two 
tests: the results of the Elecsys were on average only 0.01 log IU/mL higher than 
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the Architect assay. Overall, the range for the mean difference between the two test 
results (± 2 standard deviations) was -0.55 through 0.52 log IU/mL. Additionally, in 
83.4% of paired samples the difference between the two assays was less than 0.25 
log IU/mL, in 93.6% less than 0.5 log IU/mL and in 98.2% the difference between the 
two test results was less then 1 log IU/mL.
Comparison according to HBV genotype
Of the 1427 samples, 447 (31%) were taken from patients with HBV genotype A, 125 
(9%) from patients with genotype B, and 210 (15%) and 534 (37%) from patients 
with genotypes C and D, respectively. The remaining samples (n=111, 8%) were from 
patients who harboured different or mixed HBV genotypes, and were not considered 
0 2 4 6
0
2
4
6
Architect HBsAg (log IU/mL)
E
le
cs
ys
 H
B
sA
g 
(l
og
 IU
/m
L)
Figure 1
r=0.96
figure 1: Correlation between HBsAg measurements using the Architect HBsAg QT assay and 
the Elecsys HBsAg.
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figure 2: Bland-Altman plot of HBsAg measurements using the Architect HBsAg QT assay and 
the Elecsys HBsAg. Dashed lines represent 95% confidence limits.
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for this part of the analysis. The results of the two assays were comparable, within 
narrow confidence limits, irrespective of HBV genotype (table 1).
Retesting of samples with high divergence
A divergence of >1 log IU/mL was found in 25 samples (1.8%). High divergence was 
not related to HBV genotype or treatment week. Sufficient serum for retesting on both 
platforms was available in 20 (80%). The test results observed in the retested samples 
were highly correlated (0.99, p<0.001), and the mean difference between the results 
for the Architect when compared to the Elecsys was -0.10 log IU/mL, with none of 
the samples with detected HBsAg diverting >0.5 log IU/mL. The mean differences 
between first and second measurement were -0.02 log IU/mL for the Architect and 
0.02 log IU/mL for the Elecsys.
Comparison of the performance of a threshold based stopping-rule
Recently, we have reported a stopping-rule for HBeAg-positive patients treated with 
PEG-IFN, based on the presence or absence of a decline in serum HBsAg levels 
from baseline. Patients without a decline from baseline to week 12 of treatment (log 
(HBsAgweek12) − log (HBsAgbaseline)>0) had a very low probability of response (<5%), 
and we advised to discontinue therapy in these patients.10 For the current study, we 
applied this threshold based rule on the subset of patients that had both Architect and 
Elecsys data available. For this analysis, a representative subset of 181 patients of 
the original study (out of 221, 82%) were included. As shown in table 2, the stopping 
Table 1: Bland-Altman analysis per genotype
genotype Bias 95% limits of agreement
- 2Sd + 2Sd
A (n=447) -0.051 -0.555 0.454
B (n=125) 0.063 -0.414 0.540
C (n=210) -0.053 -0.387 0.281
d (n=534) 0.011 -0.610 0.631
Overview of the results of the Bland-Altman comparison of the Architect versus the Elecsys 
HBsAg data in samples from patients with HBV genotypes A, B, C and D. SD, Standard deviation.
Table 2. Positive and negative predictive values of the stopping-rule.
 Response
Architect elecsys
no yes PPV nPV no yes PPV nPV
Any decline week 12 Yes 97 30 24%  – 101 29 22%  –
 No 53 1  – 98%  49  2  – 96%
Response was defined as HBeAg loss and HBV DNA<10,000 copies/mL 6 months after discon-
tinuation of treatment. NPV, negative predictive value; PPV, positive predictive value.
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rule performed very well within the subset of patients included in this analysis, and 
the positive predictive values (PPVs) and negative predictive values (NPVs) obtained 
with the two assays were very similar (NPVs: 96% for the Elecsys, compared to 98% 
for the Architect).
diSCuSSion
This is the first large study comparing the two major commercial platforms, Architect 
and Elecsys, for HBsAg quantification in patient sera. We found a very close agree-
ment between the assays, irrespective of HBV genotype. Both assays can therefore 
be used for HBsAg quantification in clinical practice in HBeAg-positive patients.
Presence of HBsAg is commonly used as a screening tool for infection with HBV, 
and is often detectable in serum before evidence of liver inflammation is present.16 
However, recent technological advancements have allowed for the quantification of 
HBsAg in serum. The clinical relevance of these HBsAg levels is derived from the 
apparent correlation with intrahepatic cccDNA levels, which are strong predictors of 
sustained response to treatment, but can only be assessed invasively through a liver 
biopsy.3, 17
Recent studies have shown that HBsAg levels may be used in the monitoring of HBV 
therapy. During therapy with nucleos(t)ide analogues (NA), HBV DNA is potently sup-
pressed to undetectable levels in a majority of patients after 48 weeks of treatment, 
but only moderate declines in HBsAg levels are achieved.8, 11, 18 HBsAg and HBV DNA 
therefore seem largely uncorrelated during antiviral therapy, and HBsAg decline may 
signify an immunological response that is independent of HBV DNA suppression 
as achieved with NA based treatment. Monitoring of HBsAg levels during antiviral 
therapy for CHB may therefore provide additional information when compared to 
HBV DNA levels alone. One year of PEG-IFN therapy induces a pronounced decline 
in HBsAg levels, especially in patients who achieve an off-treatment sustained 
response.8, 11-12, 19-20 The differences in HBsAg decline between responders and non-
responders can be used to predict success of therapy.10, 12, 20 Additionally, HBsAg 
decline during therapy with NA may be used to predict subsequent loss of HBsAg 
through prolonged follow-up.21-22
Most of the recent studies on HBsAg quantification were conducted using the Archi-
tect platform, but the manual for HBsAg quantification on the Elecsys was recently 
released (HBsAg Quant, Roche Diagnostics 2011).23 The comparability of the results 
of the two assays was however still unknown, and the limited insight into the agree-
ment between the two assays prohibited extrapolation of data and findings from 
studies using either platform to studies or clinics that use the other. The current study 
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was designed to address these issues, and we have now shown that the two assays 
provide comparable results. Importantly, there is a very close agreement between the 
two platforms, within ± 0.5 log IU/mL in 94% of the samples that were tested, and this 
close agreement is independent of HBV genotype.
In addition to the use of HBsAg in monitoring therapy efficacy, several reports have 
now provided stopping-rules for PEG-IFN therapy for CHB. A post-hoc analysis of the 
phase 3 study of PEG-IFN alfa-2a showed that lower HBsAg levels during treatment 
were associated with a sustained off-treatment response.8 Similarly, we showed that 
HBeAg-positive patients without a decline at week 12 of therapy had a low probability 
of sustained response, and no chance of HBsAg loss, even through long term follow-
up.10 The current study shows that our findings reported from data gathered using 
the Architect can be extrapolated to measurements conducted with the Elecsys. This 
implies that published threshold or decline based prediction rules established using 
either platform may be used on the other as well, without losing predictive accuracy. 
Furthermore, our findings can also be extended to measurements conducted with 
other Cobas serology systems, which share characteristics with the Elecsys. This 
should make quantitative HBsAg diagnostics more easily accessible around the 
globe.
In summary, the current study shows a high correlation and agreement between 
quantitative HBsAg measurement conducted with the Architect and Elecsys assays, 
irrespective of HBV genotype. The performance of a clinical stopping rule established 
using Architect measurements was excellent when applied on Elecsys data. Both 
assays can therefore be applied for HBsAg quantification in clinical practice
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ABSTRACT
Background
Hepatitis B e antigen (HBeAg) levels may predict response to peginterferon (PEG-IFN) 
but are also influenced by presence of precore(PC) and core promoter(BCP) mutants.
Methods
HBeAg was measured in 214 patients treated with PEG-IFN±lamivudine for 52 weeks. 
Patients were classified at baseline as wildtype (WT) or non-WT (detectable PC/BCP 
mutants). Combined response (HBeAg loss with HBV DNA <2,000 IU/mL), HBeAg 
response (HBeAg loss with HBV DNA >2,000 IU/mL) or non-response was assessed 
at week 78.
Results
Mean baseline HBeAg levels were 2.65 log IU/mL in combined responders, 2.48 in 
non-responders and 2.24 in HBeAg responders (p=0.034). Baseline HBeAg levels 
were not associated with combined response after stratification by WT/non-WT. 
Within the PEG-IFN monotherapy group (n=104), patients with HBeAg <1 log IU/mL at 
week 24 had a higher probability of combined response (29% versus 12%, p=0.041). 
After stratification by WT/non-WT, WT patients with HBeAg <1logIU/mL at week 24 
had a probability of combined response of 78% (versus 19% in patients with >1log 
IU/mL, p<0.001), whereas no difference in response rates was observed in non-WT 
patients (p=0.848).
Conclusions
The relationship between HBeAg levels and response to PEG-IFN depends upon the 
presence of PC/BCP mutants. HBeAg levels should therefore not be routinely used to 
select patients for PEG-IFN, nor for monitoring of therapy.
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inTRoduCTion
Chronic hepatitis B virus (HBV) infection may ultimately result in severe liver-related 
morbidity and mortality, and treatment of chronic hepatitis B (CHB) is therefore 
indicated in patients with signs of persistent liver inflammation.1 Current treatment 
options for CHB consist of nucleo(s)tide analogues (NA) and (pegylated) interferons 
(PEG-IFN). Despite the recent registration of potent NA that are able to maintain 
undetectable HBV DNA levels through prolonged therapy, PEG-IFN remains an impor-
tant first-line treatment option, especially in hepatitis B e antigen (HBeAg)-positive 
disease, as finite PEG-IFN therapy results in an off-treatment sustained response 
in about 25-30% of patients.2-5 Response to PEG-IFN therapy in these patients is 
accompanied by high rates of hepatitis B surface antigen (HBsAg) seroclearance, a 
reduced incidence of hepatocellular carcinoma (HCC) and prolonged survival.6, 7
The clinical application of PEG-IFN is limited by high costs, frequent occurrence of 
side-effects, and relatively low probability of response.5 Selecting patients for PEG-
IFN based on an individual’s probability of response would help optimize application 
of this agent, but published prediction models, incorporating host and viral factors, 
provide only limited discrimination.8, 9 Recent studies have therefore focused on on-
treatment predictors of response, including serum HBV DNA and HBsAg levels.10-15 
Yet another study focused on the use of HBeAg levels to predict response to PEG-IFN 
for HBeAg-positive CHB, and showed that patients with low HBeAg levels at baseline 
had a higher probability of HBeAg seroconversion 6 months after treatment discontin-
uation.10 Unfortunately, several independent studies have shown that a considerable 
number of patients who achieve clearance of HBeAg have persistently high HBV DNA 
levels.2, 16 We recently showed that presence of viral mutants harboring mutations in 
the precore (PC) and basal core promoter (BCP) regions may prohibit achievement of 
virological response after HBeAg clearance.17 Presence of these mutants may also 
influence HBeAg production and thus HBeAg levels in serum.18 We therefore hypoth-
esized that presence of PC and BCP mutants influences the association between 
HBeAg levels and response to PEG-IFN therapy.
The aim of the current study was therefore to investigate the association between 
HBeAg levels and response to PEG-IFN in relation to the presence of PC and BCP 
mutants.
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PATienT And MeTHodS
Patients
HBeAg levels were assessed in HBeAg-positive CHB patients who were previously 
enrolled in an investigator-initiated international multicenter randomized controlled 
trial.2, 3 In- and exclusion criteria for this study have previously been described 
elsewhere.3 Patients were treated with PEG-IFN alfa-2b 100 μg weekly (PegIntron, 
Schering-Plough, Kenilworth, NJ, USA) in combination with placebo or lamivudine 
(LAM) 100 mg (Zeffix, GlaxoSmithKline, Greenford, UK) daily for 52 weeks. Inclusion 
criteria for the present analysis were completion of the 26-week follow-up phase of 
the main study, availability of data on presence of PC or BCP mutants at baseline and 
availability of a baseline serum sample for HBeAg measurements. Of the 266 patients 
in the initial study, 214 fulfilled these criteria.
The study was conducted in accordance with the guidelines of the Declaration of Hel-
sinki and the principles of Good Clinical Practice. All patients gave written informed 
consent according to standards of the local ethics committees.
laboratory measurements
Serum HBeAg was quantified in samples taken at baseline, during the treatment 
period (weeks 4, 8, 12, 24 and 52) and during follow-up (week 78) using the ELECSYS 
HBeAg assay (Roche Diagnostics, range 0.2 – 100 IU/ml). HBV DNA quantification 
was performed using an in-house developed TaqMan polymerase chain reaction 
(PCR) assay (lower limit of quantification 400 copies/mL) based on the EuroHep stan-
dard. HBsAg was measured using the ARCHITECT HBsAg assay (Abbott laboratories; 
range 0.05 - 250 IU/mL). 11, 19 The presence of PC (at nucleotide position G1896) and 
BCP (at nucleotide positions A1762 and G1764) mutants was assessed using the 
INNO-LiPA HBV PreCore assay (Innogenetics, Ghent, Belgium).17
Statistical analysis
Response was defined as HBeAg loss with HBV DNA <2,000 IU/mL (~10,000 cop-
ies/mL; combined response), HBeAg loss with HBV DNA >2,000 IU/mL at week 78 
(HBeAg response) or non-response.8 Because therapy outcomes did not differ across 
the treatment arms, associations between baseline HBeAg levels and response were 
analysed for the pooled cohort. For on-treatment analyses only the patients treated 
with PEG-IFN monotherapy were analysed. Associations between variables were 
tested using Student’s t-test, Chi-square, Pearson correlation or their non-parametric 
equivalents when appropriate. SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) and 
the SAS 9.2 program (SAS Institute Inc., Cary, NC, USA) were used to perform statis-
tical analyses. All statistical tests were two-sided and were evaluated at the 0.05 level 
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of significance. The ability of HBeAg levels to discriminate between patients with and 
without a response was evaluated by Radio Operator Charateristic (ROC) analyses, 
and quantified using the area under the ROC curve (AUROC).
ReSulTS
Baseline characteristics
Patients were predominantly male (78%), of Caucasian (73%) or Asian origin (19%), 
and harboured HBV genotypes A (35%), B (9%), C (14%) or D (40%). Other charac-
teristics are shown in table 1. Median baseline HBeAg levels were 501.8 IU/mL (IQR 
125 – 924) in the 214 patients, and HBeAg levels were log transformed for further 
analysis. Mean HBeAg levels significantly varied by HBV genotype; 2.59 log IU/mL 
for genotype A, 2.68 for B, 2.56 for C and 2.30 log IU/mL for genotype D (p=0.021 by 
ANOVA). Baseline HBeAg levels did not correlate with age (r=0.11, p=0.10), or ALT 
(r=-0.01, p=0.95), but did correlate with baseline HBV DNA (r=0.39, P<0.001) and 
HBsAg levels (r=0.31, P<0.001).
Relationship between presence of PC and/or BCP mutants and 
HBeAg levels
Baseline HBeAg levels were highest in patients with WT (2.77 log IU/mL), and 2.56 log 
IU/mL in patients with PC mutants, 2.04 log IU/mL in those with only BCP mutants, 
and 2.26 in patients with both PC and BCP mutants (p<0.001 by ANOVA, p<0.001 
for WT versus non-WT). When adjusted for HBV genotype distribution, HBeAg levels 
were still higher in patients with WT versus those with PC and/or BCP mutants (2.81 
versus 2.33 log IU/mL, p<0.001). To further explore the relationship between baseline 
HBeAg levels and presence of PC and/or BCP mutants, patients were allocated into 
groups according to baseline HBeAg levels: quartile 1 (baseline HBeAg <2.098 log 
IU/mL), quartile 2 (>2.098, <2.70 log IU/mL), quartile 3 (>2.70, <2.97 log IU/mL) and 
quartile 4 (>2.97 log IU/mL). Patients were also classified as WT only (n=76), or non-
WT (PC and/or BCP mutants, n=138). As shown in figure 1A, the proportion of patients 
harboring only WT virus increased as baseline HBeAg level was higher (figure 1A).
Baseline HBeAg levels in relation to response
Among the total population of 214 patients 77 (36%) cleared HBeAg, 41 (19%) 
achieved a combined response of HBeAg loss with HBV DNA <2,000 IU/mL, and 
17 (8%) cleared HBsAg at week 78. Baseline HBeAg levels were highest in patients 
who achieved a combined HBeAg and HBV DNA response (2.65 log IU/mL), and 
lowest in patients who cleared HBeAg but did not achieve HBV DNA <2,000 IU/mL 
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(HBeAg responders, 2.24 log IU/mL). Non-responders had intermediate levels of 2.48 
log IU/mL (p=0.034 by ANOVA). Analysis of the probability of response across HBeAg 
quartiles revealed that patients with the lowest (quartile 1) and the highest (quartile 
4) HBeAg levels at baseline had a somewhat higher probability of HBeAg clearance 
at week 78 (42% and 43%, respectively), compared to 32% and 28% for patients in 
quartiles 2 and 3 (figure 2, p=0.259 by Chi-square). However, combined HBeAg and 
HBV DNA response was most frequently achieved in patients in the highest quartile of 
Table 1: Characteristics of the study cohort
Characteristics Peg-ifn
(n=104)
Peg-ifn + lAM
(n=110)
overall
(n=214)
demography
 Mean (SD) age, years 34.3 (13) 33.4 (12) 33.8 (13)
 Male 84 (81%) 83 (76%) 167 (78%)
Race
 Caucasian 77 (74%) 80 (73%) 157 (73%)
 Asian 21 (20%) 19 (17%) 40 (19%)
 Other 6 (6%) 11 (10%) 17 (8%)
laboratory results
 Mean (SD) ALT* 4.4 (3.1) 4.2 (3.0) 4.3 (3.0)
 Mean (SD) HBV DNA, log c/mL 9.2 (0.80) 9.1 (0.98) 9.1 (0.90)
 Mean (SD) HBsAg, log IU/mL 4.4 (0.54) 4.4 (0.65) 4.4 (0.60)
 Mean (SD) HBeAg, log IU/mL 2.5 (0.70) 2.4 (0.70) 2.5 (0.70)
HBV genotype
 A 40 (39%) 34 (31%) 74 (35%)
 B 9 (9%) 10 (9%) 19 (9%)
 C 15 (14%) 14 (13%) 29 (14%)
 D 39 (38%) 46 (42%) 85 (40%)
 Other/mixed 1 (1%) 6 (6%) 7 (3%)
inno-liPA result
 Wildtype 40 (39%) 36 (33%) 76 (36%)
 Precore 25 (24%) 31 (28%) 56 (26%)
 Core promoter 20 (19%) 27 (25%) 47 (22%)
 Precore and core 19 (18%) 16 (15%) 35 (16%)
Response at week 78
 Combined response# 18 (17%) 23 (21%) 41 (19%)
 HBeAg loss 36 (35%) 41 (37%) 77 (36%)
 HBsAg loss 6 (6%) 11 (10%) 17 (8%)
*Multiples of upper limit of the normal range P<0.231
#HBeAg loss and HBV DNA <2,000 IU/mL at week 78
All comparisons of peginterferon alone versus peginterferon with lamivudine p > 0.23
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HBeAg levels at baseline (30%, p=0.036, figure 1B). Similarly, patients in the highest 
quartile of HBeAg levels tended to have a higher probability of HBsAg clearance; 
probabilities were 4%, 7%, 9% and 11% across quartiles 1 through 4, respectively 
(p=0.14). Stratification by WT versus non-WT showed that within these groups, base-
line HBeAg levels were not associated with combined HBeAg and HBV DNA response 
to PEG-IFN (figure 2).
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figure 1: Baseline HBeAg levels; relation to presence of mutants and probability of response. 
The proportion of wildtype (WT) and non-WT (precore and/or core promoter mutants) by baseline 
HBeAg level (quartile 1 (baseline HBeAg <2.098 log IU/mL), quartile 2 (>2.098, <2.701 log IU/mL), 
quartile 3 (>2.701, <2.966 log IU/mL) and quartile 4 (>2.966 log IU/mL)) (figure 1A) and relationship 
between baseline HBeAg levels and response to PEG-IFN at 6 months post-treatment (figure 
1B). Combined response was defined as HBeAg loss with HBV DNA <2,000 IU/mL at 6 months 
post-treatment.
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HBeAg levels during therapy
Mean baseline HBeAg levels were 2.53 and 2.42 log IU/mL in the monotherapy 
and combination therapy groups (p=0.23). HBeAg levels declined in both treatment 
groups, and end of treatment levels were 1.45 and 0.57 log IU/mL in the monotherapy 
and combination therapy groups, respectively (p<0.001, figure 3A). The more pro-
nounced reduction in the patients receiving combination therapy was not sustained 
post-treatment; week 78 levels were 1.46 and 1.37 log IU/mL in the monotherapy and 
combination therapy groups, respectively (p=0.61).
on-treatment changes in HBeAg level according to response: 
comparison with HBsAg levels
The relationship between on-treatment changes in HBeAg level and off-treatment 
response at week 78 was analysed only in patients treated with PEG-IFN monotherapy 
(n=104). Baseline HBeAg levels were highest in patients who achieved a combined 
response, and declined progressively through 52 weeks of therapy and during the 
0
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figure 2: Baseline HBeAg levels and combined response. Relationship between baseline HBeAg 
levels and combined response (HBeAg loss with HBV DNA <2,000 IU/mL) at week 78, stratified 
by presence of wildtype virus or non-wildtype (precore and/or core promoter mutants). Combined 
response was defined as HBeAg loss with HBV DNA <2,000 IU/mL at 6 months post-treatment. 
WT, wildtype.
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figure 3: On-treatment HBeAg and HBsAg levels by treatment and response. HBeAg levels at 
baseline and during therapy across treatment arms (A), and levels of HBeAg (B) and HBsAg (C) 
in combined responders (HBeAg clearance with HBV DNA <2,000 IU/mL at week 78), HBeAg 
responders (HBeAg loss with HBV DNA >2,000 IU/mL) and nonresponders for patients treated 
with PEG-IFN monotherapy.
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figure 4: HBeAg and HBsAg levels at week 24 and response to treatment. Probability of response 
at week 78 by HBeAg (A) or HBsAg (B) level at week 24 stratified by presence of wildtype or 
non-wildtype (precore and/or core promoter mutants) at baseline.
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off-treatment follow-up phase. Importantly, HBeAg levels remained higher in combined 
responders versus non-responders during the first 3 months and HBeAg levels were 
lower in combined responders versus HBeAg responders only after week 24 of treat-
ment (figure 3B). HBeAg levels could therefore not be used to differentiate between 
HBeAg responders versus those with a combined response. For comparison, the 
HBsAg levels at the same time-points14 are shown in figure 3C. Serum levels of HBsAg 
only showed a pronounced decline in patients with a combined response, whereas 
no or only a limited decline was observed in HBeAg responders or non-responders.14
Predicting response using on-treatment HBeAg or HBsAg levels
The use of on-treatment HBeAg levels for prediction of response at week 78 was 
again only evaluated in patients treated with PEG-IFN monotherapy. By ROC analy-
sis, week 24 HBeAg levels were superior to week 12 levels (AUC 0.694 versus 0.503). 
Of the 97 patients with available serum at week 24, 31 (32%) had an HBeAg level 
less than 1 log IU/mL. Patients with an HBeAg level less than 1 log IU/mL at week 
24 had a higher probability of HBeAg clearance (65% versus 23%, p<0.001), HBeAg 
seroconversion (58% versus 18%, p<0.001), combined response (29% versus 12%, 
p=0.041) and HBsAg clearance at week 78 (10% versus 3%, p=0.167). However, 
stratification by WT/non-WT status at baseline revealed that the higher probability of 
combined response in patients with HBeAg levels under 1 log IU/mL at week 24 was 
confined to those with WT virus at baseline, and absent in those with PC and/or BCP 
mutant virus (figure 4A). In contrast, low levels of HBsAg at week 24 (< 1500 IU/mL 
20, 21) were associated with a higher rate of combined response, irrespective of the 
presence of mutants (figure 4B).
diSCuSSion
In this investigator initiated study, we have shown that the relationship between 
HBeAg levels and response to PEG-IFN therapy is highly dependent upon the pres-
ence of viral strains with mutations in the PC and BCP domains. HBeAg levels should 
therefore not be routinely used to monitor PEG-IFN therapy.
PEG-IFN is an effective treatment option for HBeAg-positive CHB, but the limited 
probability of response to this agent necessitates careful selection of patients.1, 5 
Baseline serum HBeAg levels were previously shown to be associated with HBeAg 
seroconversion after PEG-IFN therapy, suggesting they may be used to select patients 
for PEG-IFN treatment.10 Several long-term follow-up studies of patients treated with 
PEG-IFN have however shown that a considerable number of patients do not achieve 
low (< 2000 IU/ml) HBV DNA levels after HBeAg seroconversion.2, 16 These patients 
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are considered to have progressed to HBeAg-negative CHB,22, 23 and are thus at risk 
for the development of cirrhosis, liver cancer and death.24-28
For this reason we investigated whether serum HBeAg levels predict achievement of a 
combined HBeAg and HBV DNA response to PEG-IFN. Our study shows that patients 
who will achieve such a combined response have higher baseline HBeAg levels than 
patients who fail to clear HBeAg or those who achieve HBeAg loss but have persis-
tent HBV DNA more than 2000 IU/mL. These somewhat counter-intuitive findings 
may be explained by the influence of PC and BCP mutant strains. We have previously 
reported that these mutants can be detected in a considerable number of HBeAg-
positive patients17, and the current study shows that patients with detectable mutants 
have lower HBeAg levels than those who do not. Since patients without detectable 
mutants at baseline have a high probability of HBV DNA and HBsAg clearance after 
HBeAg loss17, absence of these mutants may explain the association between high 
HBeAg levels and a high probability of a response to PEG-IFN. Furthermore, we also 
hypothesize that the patients with the lowest HBeAg levels were already experiencing 
spontaneous transition of HBeAg-positive to HBeAg-negative CHB, with selection 
for PC and BCP mutants. This translated to the high rate of HBeAg loss, but low rate 
of subsequent HBV DNA clearance, in these patients. Our findings therefore show 
that HBeAg levels cannot be used to select patients for PEG-IFN therapy without 
considering the presence of viral mutants.
Considering the difficulty of selecting patients with a high probability of response, 
several recent studies have focussed on on-treatment predictors. We have previously 
reported that patients who achieve a combined response to PEG-IFN achieve strong 
HBsAg declines during treatment, and that patients who fail to achieve a decline have 
a low probability of response.11, 13-15 Fried et al reported a very strong association 
between low HBeAg levels at week 24 of treatment and HBeAg seroconversion at 6 
months post-treatment. In concurrence with that study, we showed that a reduction 
of HBeAg levels to less than 1 log IU/mL by week 24 confers an increased probability 
of HBeAg clearance or seroconversion, as well as combined response and HBsAg 
clearance. These findings are in line with a previous report that suggested that early 
HBeAg clearance during PEG-IFN therapy predicts subsequent HBsAg clearance.29 
However, the current study also points out that the relationship between low HBeAg 
levels at week 24 of therapy and subsequent off-treatment response is confined to 
patients with WT virus, and virtually absent in those with PC and/or BCP mutants 
at baseline. Importantly, low serum levels of HBsAg remained a strong predictor of 
response, even among patients with PC and BCP mutants. Taken together, our find-
ings do not support the routine use of HBeAg levels when monitoring response to 
PEG-IFN therapy, whereas they provide further evidence for the excellent predictive 
capabilities of HBsAg levels.
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A possible caveat of our study pertains to the method we used to classify patients 
as WT/non-WT. The INNO-LiPA line probe assay is a sensitive method, but can only 
detect a few often encountered and widely acknowledged mutations, while others 
less frequently observed in previous studies are ignored.
In conclusion, we have shown that HBeAg levels do not adequately predict a com-
bined HBeAg and HBV DNA response to PEG-IFN for HBeAg-positive CHB. Our find-
ings are probably explained by the influence of PC and BCP mutant strains which are 
associated with both low HBeAg levels and failure to achieve a combined response. 
The relationship between HBeAg levels and response to PEG-IFN is therefore unpre-
dictable, limiting the use of HBeAg levels as a sole predictor of treatment response 
in CHB. In contrast, serum levels of HBsAg were able to predict response in patients 
with and without detectable mutants.
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inTRoduCTion
Chronic hepatitis B infection is a global health problem affecting more than 350 mil-
lion people worldwide.1 Prolonged liver inflammation caused by active infection with 
the hepatitis B virus (HBV) may result in progression to liver fibrosis, cirrhosis and 
ultimately hepatocellular carcinoma (HCC) and death.1
Hepatitis B Virus Surface Antigen (HBsAg) represents, since the ‘60s, the hallmark 
of HBV infection because its concentrations can reach several hundred micrograms 
per milliliter.2. Recently, studies with newly available automated quantitative assays 
showed that serum HBsAg levels vary significantly during the different phases of 
chronic HBV infection and are inversely correlated with the immune control of HBV: 
the higher control, the lower HBsAg level.3-6 These findings are consistent with the 
hypothesis that HBsAg serum levels reflect the complex interplay between virus and 
immune system and provide complementary information to viral load as measured 
using HBV DNA levels. Actually, serum HBsAg levels result not only from virions (42 
nm, Dane particles), but mainly from non-infectious HBsAg particles (20 nm diameter 
filaments of variable length and 20-22 nm spheres) which do not contain viral nucleic 
acids and exceed virions by a factor ranging between 102 and 105.. The ratios between 
defective HBsAg particles and virions are not stable, but change over time. Filaments 
and spherical particles are produced in large excess in highly viremic HBeAg positive 
carriers. While filaments decline in parallel with virions, spherical particles remain in 
moderate excess in low viremic HBeAg negative carriers. 7, 8 Thus, HBsAg production 
varies both quantitatively and qualitatively over time and appears to be dynamically 
regulated during different phases of the infection. HBsAg derives mainly from the 
intrahepatic viral minichromosome (cccDNA) by translation of specific RNAs, that 
are distinct from pregenomic RNA (pgRNA), and HBsAg synthesis follows a pathway 
that is distinct from viral replication 9. Accordingly, the correlation between HBsAg 
serum levels and HBV replication (serum and liver HBV DNA) is mostly but not always 
present in HBeAg-positive carriers, in whom HBsAg serum levels correlate with the 
amount of intrahepatic cccDNA and reflect the overall burden of HBV infection.10 It is 
however absent in HBeAg-negative patients, in whom serum HBsAg circulates mainly 
as defective particles, reflecting the residual transcriptional activity of cccDNA, that is 
differently regulated in this phase of HBV infection.10-12
Thus, in clinical practice HBsAg quantification cannot be proposed as a substitute for 
viral load: on the contrary the combined use of the two markers may be very useful to 
define the specific condition of the single HBV carrier throughout the highly dynamic 
phases of chronic HBV infection.
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MeASuReMenT of SeRuM HBSAg leVelS
Several automated assays have been developed for the qualitative assessment of 
HBsAg and 2 are commercially available for HBsAg quantification: the Architect 
HBsAg assay (Abbott Diagnostics)13 and the Elecsys HBsAg II quant assay (Roche 
Diagnostics) 14-16 Both are fully automated chemiluminescent immunoassays and, 
using manual or on board pre-dilution steps, provide a wide dynamic range of quantifi-
cation of HBsAg levels in International Units (IU)/mL. Quantification in IU/mL is recom-
mended by World Health Organization and uses as reference the Second International 
Standard, that is produced from heat inactivated HBsAg plasma.17 Importantly, the 
results acquired with both platforms are very highly correlated (r≥0.9614) and in close 
agreement across all major HBV genotypes. The performance of a threshold based 
prediction rule for patients treated with peginterferon (PEG-IFN) established using 
Architect measurements was excellent when applied on Elecsys data, suggesting 
that prediction rules derived from studies conducted with one platform may be used 
confidently on the other. The choice of platform should therefore primarily be based 
on availability and local costs.
HBSAg in THe nATuRAl HiSToRy of HBV infeCTion
During the natural history of chronic HBV infection HBsAg serum levels decline pro-
gressively from the immune-tolerant to the low-replicative phase (3, 4, 6, Figure 1).
Concordantly, all studies have reported higher and more stable HBsAg levels in 
HBeAg-positive immune-tolerant carriers, with values about half a log higher than 
those observed in HBeAg positive patients in the immune-clearance phase. Never-
theless, in different studies among immune tolerant patients the median values show 
some variability with levels of about 5 log IU/ml in cohorts from Europe (4.9 log IU/
ml) and Hong Kong (4.9 log IU/ml), but only 4.5 log IU/ml in another study from Asia 
3, 4, 6. Different criteria in the definition of the infection phases, immune-tolerance and 
immune-clearance, may account for such a discrepancy. In addition, the influence of 
HBV genotype may be of significant importance.
In HBeAg-positive patients who are in the immune clearance phase median HBsAg 
levels are about half a log lower, ranging from 3.7 to 4.3 log IU/ml. However, sig-
nificant differences may be found across individual patients in the same phase of 
infection.3, 4, 6. Nevertheless, the combined presence of HBsAg ≥ 5 log IU/ml with 
HBV DNA ≥ 8 log and normal or minimally elevated ALT values may be suggestive 
of sustained immune tolerance. The available data suggest that HBsAg serum levels 
are similar between patients who achieve spontaneous HBeAg seroconversion and 
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those who fail to clear HBeAg during the immune clearance phase.6 Once HBeAg to 
anti-HBe seroconversion occurs, HBsAg levels begin to decline, usually with very 
slow kinetics as compared to the sharp and pronounced reduction of HBV DNA 
levels.6 A recent study from Hong Kong reported that a 1 log decline of HBsAg was 
only achieved in a subset of patients, and then only after several years of follow-
up 6. However, a recent Taiwanese study reports that a rapid HBsAg decline below 
1000 IU/ml within one year from spontaneous HBeAg to anti-HBe seroconversion 
could predict HBsAg clearance within 6 years, with hazard ratios of 4.4 and 24.3 
for patients who achieve HBsAg levels of 100-999 or ≤100 IU/ml, respectively 18. It 
remains to be clarified whether a less pronounced HBsAg decline (about 1 log) after 
spontaneous HBeAg to anti-HBe seroconversion might also indicate the achievement 
of an effective immune control of HBV infection, and could help distinguish HBsAg 
carriers who will become inactive from those who will develop HBeAg negative CHB. 
In fact, HBsAg serum levels are significantly lower, as compared to HBeAg positive 
patients, not only in the inactive carriers but also in HBeAg negative CHB patients, 
who show median levels ranging from 2.5 to 3.8 log IU/ml 3-6, 19. In low replicative, 
inactive carriers HBsAg serum levels are even lower, but vary in the different cohorts 
ranging from 1.4-1.7 log IU/ml to 2.8-3.3 log IU/ml 3-6. Such variability depends, at 
least in part, on HBV genotypes and stringency of criteria classifying the inactive 
carriers. A major influence of HBV genotypes on HBsAg secretion is suggested by 
several reports both in vivo and in vitro, where the highest levels has been observed 
for genotype A20. Accordingly, in a cohort of 375 patients with HBeAg negative CHB, 
HBsAg levels were higher in genotype A and D than genotype B and C patients, 
with values (4.1 log IU/ml for genotype A and 3.8 log IU/ml for genotype D) similar 
to those reported by Jaroszewicz et al.19. Moreover, Nguyen et al. found lower levels 
in genotype B than in genotype C inactive carriers (2.2 log IU/ml vs 3.3 log IU/ml) 4. 
In addition to this virological explanation, the high variability could be caused by the 
difficulty to identify at a single time point true inactive carriers from HBeAg negative 
patients in temporary replicative remission 21. Jaroszewicz at al. indeed showed that 
individuals classified as inactive at baseline, but with evidence of active infection 
during follow-up had HBsAg serum levels three-fold higher than those who remained 
inactive 3. In a cohort of 209 genotype D HBeAg negative HBV carriers, the individuals 
with true inactive infection after one year of monthly follow-up of HBV DNA levels had 
baseline HBsAg levels significantly lower than patients who had baseline HBV DNA 
< 2000 IU/ml, but showed fluctuations of viremia above 2000 IU/ml thereafter. In the 
same cohort the diagnostic accuracy and positive predictive value to identify inactive 
carriers of single point measurement of quantitative HBsAg was 92 % and 93% when 
using 650 IU/ml as cut-off and 88% and 75% with 1000 IU/ml, as compared to 89% 
and 70% for a baseline HBV DNA level < 2000 IU/ml. By combining HBsAg (<1000 
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IU/ml) and HBV DNA (< 2000 IU/ml) the diagnostic performance was optimized with 
a diagnostic accuracy of 94% and a positive predictive value of 87% 5. A preliminary 
report on a cohort of 165 HBeAg negative patients infected by different genotypes (A 
to E) indicates a positive predictive value of 100% for cut-offs of 2000 IU/ml for both 
HBsAg and HBV DNA 22.
Overall, these fi ndings suggest that the diagnostic accuracy of single point observa-
tion can be ameliorated only by combining the quantifi cation of HBsAg and HBV 
DNA, where the signifi cant improvement stems from the additional information on the 
status of immune control of HBV infection provided by HBsAg serum levels (Figure 1).
HBSAg in PeginTeRfeRon TReATMenT
PEG-IFN has limited direct antiviral effi cacy, but stimulates the induction of a host 
immune response against HBV. A successful immune response causes the destruction 
of infected liver cells, resulting in a decline of intrahepatic HBV DNA and cccDNA.23, 24 
Importantly, the concentration of infected cells at the end of treatment predicts the 
risk of relapse after therapy discontinuation.24 However, the intrahepatic HBV DNA 
and cccDNA concentrations can only be assessed invasively with liver biopsy, limiting 
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figure 1. Serum levels of HBV DNA, HBsAg and ALT during the different phases of hepatitis B 
virus infection.
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their clinical use. Several independent studies have shown that the decline of serum 
HBsAg levels during PEG-IFN therapy mimics that of intrahepatic cccDNA, suggesting 
that a decline in serum HBsAg levels is associated with the induction of an effective 
anti-HBV immune response.23, 25, 26
HBeAg-positive patients
In a study of 221 HBeAg-positive patients treated with PEG-IFN alfa-2b ± lamivu-
dine (LAM), one year of PEG-IFN induced a pronounced decline in serum HBsAg 
levels.27 Patients treated with a combination of PEG-IFN and LAM achieved a some-
what more pronounced on-treatment decline, but the difference was not sustained 
post-treatment.27 As expected through the association with intrahepatic markers of 
HBV replication, the decline in serum levels of HBsAg was strongly associated with 
the occurrence of a response to PEG-IFN.27-29 Patients who achieved a combined 
serological and virological response to PEG-IFN (HBeAg clearance and HBV DNA 
levels <2,000 IU/mL at 6 months post-treatment) experienced the most pronounced 
declines, whereas non-responders achieved little to no decline in serum HBsAg 
levels.27 Importantly, serum HBsAg decline in responders to PEG-IFN appears to 
be durable, signifying true off-treatment sustained immune control with a low prob-
ability of relapse. The relationship between achievement of immune control and 
on-treatment HBsAg decline during PEG-IFN therapy is illustrated by the limited dif-
ference in HBsAg decline between patients who achieved HBeAg clearance but failed 
to achieve HBV DNA levels below 2.000 IU/mL, i.e. those patients who progressed to 
active HBeAg-negative CHB, and those who failed to clear HBeAg altogether.30
Since decline in serum HBsAg during PEG-IFN therapy is largely confined to patients 
who achieve a response to PEG-IFN, monitoring of HBsAg levels may help distinguish 
patients likely to achieve a response from those who will not. Lau et al. showed that 
patients with low HBsAg levels (<1,500 IU/mL) at week 12 or 24 of therapy have an 
increased likelihood of HBeAg seroconversion, whereas patients with levels >20,000 
IU/mL have a very limited probability of success.28 These findings were recently con-
firmed in other studies of Asian patients treated with PEG-IFN (table).31, 32 However, 
an HBsAg level <1,500 IU/mL can only be used to motivate patients to continue 
therapy, and it remains to be determined whether HBsAg levels >20,000 IU/mL can be 
used as a stopping-rule in non-Asian patients.28 Sonneveld et al. used HBsAg decline 
at week 12 of therapy to identify patients with a limited likelihood of HBeAg clearance 
with HBV DNA levels <2,000 IU/mL at 6 months post-treatment in a predominantly 
Caucasian population, and showed that failure to achieve a decline in serum HBsAg 
from baseline to week 12 reduced the probability of response to <5% and the prob-
ability of HBsAg clearance through 3 years of post-treatment follow-up to 0%.27 
Importantly, HBsAg kinetics appear to be a more reliable predictor of response than 
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HBV DNA kinetics in the same study cohorts.33 A combination of the two markers has 
so far not been investigated in HBeAg-positive patients.
It has become increasingly clear that proposed cut-offs from one study cannot be 
reliably extrapolated to other study populations.34 A possible explanation for the 
reduced performance of prediction rules in other cohorts may be the influence of 
HBV genotype on HBsAg kinetics. Although patients with a combined serological 
and virological response to PEG-IFN achieve substantial HBsAg decline, irrespec-
tive of HBV genotype, considerable differences in HBsAg kinetics were reported 
in non-responders across HBV genotypes A through D.30 The performance of any 
Table: Prediction of response to peginterferon therapy using HBsAg levels and declines at week 
12 of treatment.
Patient population Cut-off Accuracy n Most 
common
HBV 
genotypes
Ref.
HBeAg-positive
Treatment failure No decline
No decline
NPV: 97%
NPV: 71-82%
202
526
A and D
B and C
27
34
>20,000 IU/mL NPV: 84% 399 B and C 28
>20,000 IU/mL NPV: 100% 114 B and C 31
Treatment success# <1,500
<1,500
<1,500
<1,500
PPV: 57%
PPV: 55%
PPV: 46%
PPV: 58%
399
202
92
114
B and C
A and D
B and C
B and C
28
27
32
31
HBeAg-negative
Treatment failure No decline and HBVDNA decline 
<2 log
NPV: 100% 102 A and D 36
No decline and HBVDNA decline 
<2 log 
NPV: 95% 160 A and D 39 
<0.5 log decline NPV: 90% 48 A, B and D 38
<10% decline NPV: 84% 120 B, C and D 37
Treatment success# >0.5 log decline PPV: 89% 48 A, B and D 38
>10% decline PPV: 47% 120 B, C and D 37
Proposed cut-offs for prediction of response for HBeAg-positive and HBeAg-negative patients 
treated with peginterferon using HBsAg levels at week 12 of treatment. *>70% of cohort. #defined 
differently in the various studies. For HBeAg-positive patients, response was defined as HBeAg 
seroconversion in 28, 31, as HBeAg clearance with HBV DNA <2,000 IU/mL in references 27, 34 
and as HBeAg seroconversion with HBV DNA <2,000 IU/mL in 32 . In HBeAg-negative patients, 
response was defined as HBV DNA <2,000 IU/mL with normal ALT at 6 months post-treatment in 
36, 39, as HBV DNA <2,000 IU/mL at one year post-treatment in 37 and as HBV DNA clearance in 38. 
PPV, positive predictive value; NPV, negative predictive value.
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prediction rule incorporating HBsAg levels in HBeAg-positive disease therefore 
probably depends upon the HBV genotype distribution and HBV genotype specific 
prediction rules appear to be required.30
HBeAg-negative patients
Treatment with PEG-IFN alfa-2a with or without LAM induces a decline in serum 
HBsAg levels of 0.7 log IU/mL after one year of treatment 19 and similar declines were 
reported in another study.35 The potential use of HBsAg levels in the management of 
HBeAg-negative patients treated with PEG-IFN is appealing, because only a minority 
of patients achieves a sustained response and many of them achieve undetectable 
HBV DNA during therapy but relapse post-treatment. This leaves quantitative HBsAg 
the only detectable marker in serum during treatment.19, 36
HBsAg decline during PEG-IFN therapy for HBeAg-negative CHB is associated with 
an off-treatment sustained response in a manner similar to that observed in HBeAg-
positive patients. HBeAg-negative patients who achieve a response to therapy 
achieve more HBsAg decline than do non-responders.19, 36, 37 Several groups have 
attempted to formulate prediction rules using HBsAg levels or declines. Moucari et 
al. showed that patients who failed to achieve a decline of 0.5 logIU/mL by week 12 
of therapy had a low probability of HBV DNA clearance after PEG-IFN therapy. This 
study, however, lacked sufficient power for a reliable algorithm and results could not 
be confirmed in another PEG-IFN alfa-2a study.36 A post-hoc analysis of the PEG-
IFN alfa-2a registration trial reported that achievement of at least a 10% decline in 
HBsAg concentration by week 12 predicts response (HBV DNA <2,000 IU/mL at one 
year post-treatment).19, 38 Rijckborst et al. have subsequently shown that prediction of 
response in HBeAg-negative patients may be optimized by combining HBsAg decline 
and HBV DNA decline.36 In their study of HBeAg-negative patients treated with PEG-
IFN alfa-2a, mostly infected with HBV genotype D (85%), the investigators showed 
that patients who failed to achieve a decline in HBsAg levels, and who did not achieve 
an HBV DNA decline >2 log IU/mL, had no chance of achieving a sustained response 
(HBV DNA <2,000 IU/mL and normal ALT at 6 months after treatment).36 Importantly, 
this stopping-rule was subsequently validated in two large independent cohorts 
of HBeAg-negative patients treated with 48 or 96 weeks of PEG-IFN alfa-2a.39 Its 
performance was best among patients infected with genotype D, with a negative 
predictive value of 100%, although non-responders with other genotypes could also 
be identified. It is not clear yet whether the limited differences in HBsAg kinetics 
across HBV genotype in HBeAg negative disease warrant exploration of genotype 
specific prediction rules in these CHB patients as well 40.
Another recent study on patients participating in the PEG-IFN alfa-2a phase 3 trials 
investigated the relationship between end-of-treatment HBsAg levels and a sustained 
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off-treatment response.19 Brunetto et al. showed that patients with HBsAg levels <10 
IU/mL (23 of 194 patients) at the end of PEG-IFN therapy had a 52% probability 
of HBsAg clearance through 3 years of post-treatment follow-up, compared to only 
2% in patients with higher levels. Interestingly, the predictive capabilities of HBsAg 
levels at week 48 were higher than that of HBV DNA levels. Of those patients with 
undetectable HBV DNA at week 48 (n=161), only 15% achieved HBsAg clearance. 
Furthermore, patients with a HBsAg level more than 19 IU/mL at week 48 (or a decline 
from baseline less than 0.46 log IU/mL) had such a low probability of an off-treatment 
sustained response that retreatment seems necessary.19
HBSAg in nuCleo(S)Tide AnAlogue TReATMenT
The most recently approved NA, entecavir and tenofovir, can induce and maintain 
undetectable levels of HBV DNA through prolonged therapy. Treatment with NA aims 
at competitively inhibiting HBV polymerase activity, which is part of a replication 
pathway that is separate from HBsAg production.4 Consequently, while treatment 
with NA may induce pronounced HBV DNA declines, the effect of NA therapy on 
serum HBsAg levels is very limited and HBsAg decline during treatment with NA is 
considerably slower than that observed for HBV DNA.19, 41, 42 Several independent 
studies have assessed HBsAg kinetics in patients treated with NA, and these studies, 
including patients treated with lamivudine, adefovir, telbivudine, entecavir and teno-
fovir, have shown that a reduction in HBsAg levels is largely limited to HBeAg-positive 
patients.19, 41, 43 This is in line with the absence of HBsAg clearance during short term 
treatment of HBeAg-negative patients with NA.43 HBsAg decline was also shown to 
be more pronounced in patients with HBV genotype A and is related to a patient’s 
age.41, 44 In addition, Zoutendijk et al. described that in HBeAg-positive patients 
treated with entecavir, HBsAg decline is limited to patients with an elevated ALT (>2 
times the upper limit of normal) before therapy initiation. Taking into consideration the 
limited direct effect of NA on HBsAg production and the absence of HBsAg decline in 
patients with low levels of ALT, it is likely that a host immune response against HBV is 
required to induce a decline in HBsAg levels in HBeAg-positive patients treated with 
NA.41 This concept is supported by the finding that patients with a successful immune 
response against HBV, namely those who clear HBeAg, achieve HBsAg declines that 
are similar to those found in patients with HBeAg clearance during PEG-IFN therapy41.
While fascinating from a research standpoint, the clinical applications of HBsAg levels 
in patients treated with NA are limited thus far. In the registration study of tenofovir, 
Heathcote et al. found that HBeAg-positive patients who achieved HBsAg clear-
ance through 144 weeks of treatment experienced steeper HBsAg declines during 
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the first 6 months of treatment, suggesting that early decline of HBsAg levels may 
predict immune control in patients treated with NA. 43 One small study suggested a 
relationship between HBsAg levels at the end of telbivudine therapy and a sustained 
off-treatment response.45 However, the proposed cut-off of <2 logIU/mL is achieved 
in a very small number of patients, limiting the clinical use. It is therefore likely that 
the majority of patients treated with NA will require long-term therapy at least until 
HBsAg clearance
Several groups have investigated the use of HBsAg levels to approximate the dura-
tion of continuous therapy required to clear HBsAg. The estimated duration until 
HBsAg clearance spanned several decades, and in concordance with the proposed 
requirement for a host immune response, was reduced only in patients who were 
HBeAg-positive, and shortest in those with high ALT values.
ConCluSionS
Serum HBsAg levels probably reflect intrahepatic transcriptionally active cccDNA and 
provide complementary information to HBV DNA monitoring alone.
Within the natural history of the disease high levels of HBsAg and HBV DNA are 
indicative of a highly productive phase of HBV infection, namely HBeAg positive 
immune-tolerance. On the other hand very low levels of both markers are indicative 
of inactive HBV infection. In between, during immune activation where serum HBV 
DNA fluctuates fast and widely any significant and steady decrease of HBsAg serum 
levels is associated with a stepwise increase of the host immune control of HBV 
infection that may lead to the switch from active disease to the inactive carrier status 
and eventually to HBsAg loss and anti-HBs seroconversion.
Within the setting of HBV therapy a decline in serum HBsAg levels in patients treated 
with PEG-IFN may also herald the successful induction of immune control over HBV 
and can consequently be used to predict response. However, HBsAg kinetics are also 
influenced by HBV genotype, suggesting the requirement for HBV genotype specific 
stopping-rules. The first stopping-rule for HBeAg-negative patients has recently been 
validated in several independent cohorts and appears ready for clinical use. HBsAg 
decline in patients treated with NA is largely confined to HBeAg-positive patients with 
an elevated ALT, suggesting the requirement for a pre-existing immune response to 
HBV in achieving HBsAg decline and subsequent clearance. Current clinical applica-
tions for HBsAg monitoring in patients treated with NA are limited.
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Dear editor,
In a recent issue of Hepatology, Lampertico et al. present a study of mostly HBV 
genotype D HBeAg-negative chronic hepatitis B (CHB) patients treated with (PEG-)
IFN, and show that HBsAg loss was significantly associated with IL28B genotype.1 
Our group recently published a study on the association of IL28B genotype with 
response to PEG-IFN in HBeAg-positive CHB patients. Favourable IL28B genotypes, 
CC for rs12979860 and AA for rs12980275, were associated with higher rates of 
HBeAg seroconversion and HBsAg loss.2 Taken together, these findings provide 
mounting evidence for the importance of IL28B genotype for prediction of response 
to PEG-IFN in CHB, although these findings require further confirmation.
There is however an important pitfall that should be taken into consideration. In our 
study, IL28B genotype distribution varied across ethnicity; 90% of Asian patients were 
genotyped CC, compared to 50% of non-Asians.2 Response to PEG-IFN in CHB also 
depends upon HBV genotype: patients with HBV genotype A achieve higher rates of 
response than those with HBV genotypes B, C or D.3 Importantly, HBV genotypes A 
and D predominate in Caucasians, and nearly all Asian patients are infected with HBV 
genotypes B or C. Since IL28B genotype is associated with ethnicity, it is also associ-
ated with HBV genotype. In our study of HBeAg-positive patients, the favourable IL28B 
genotype was present in 42% of HBV genotype A patients, in 88-90% of patients with 
HBV genotypes B or C, and in 52% of HBV genotype D patients.2 If differences in 
HBV genotype distribution are ignored, analyses of the association between IL28B 
genotype and HBsAg loss in a cohort of patients with mixed ethnicities could result 
in an overrepresentation of Asian patients (with “poor response” HBV genotypes B or 
C) in the favourable CC group, and an overrepresentation of Caucasians and black 
Africans (with “good response” HBV genotype A) in the unfavourable CT/TT groups. 
This could result in a biased estimate of association, or failure to detect one. This 
issue is particularly relevant for studies conducted in countries with mixed ethnicities, 
such as those in Western Europe and the United States, where the HBV infected 
population comprises Caucasians, Asians, and black Africans.
In conclusion, the study by Lampertico et al. provides fascinating new data and urges 
further studies of IL28B genotype and response to PEG-IFN in CHB. However, the 
association of IL28B genotype distribution with that of HBV genotype may introduce 
an important pitfall. Therefore, we strongly recommend that future studies of IL28B in 
CHB be stratified by, or adjusted for, HBV genotype.
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Dear editor,
We thank Dr. Piratvisuth and Dr. Marcellin for their valuable contribution to the debate. 
First of all, it is important to note that our findings of a more pronounced HBsAg 
decline in HBeAg-positive patients with a response to peginterferon were confirmed 
in their study, reflecting the induction of an immune response in these patients.1
Their analysis shows that failure to achieve a decline in HBsAg levels through 12 
weeks of therapy does not predict non-response as well in their cohort as it did 
in our study. Possible explanations for these discrepant findings could be the type 
of peginterferon or duration of therapy, as suggested by Piratvisuth and Marcellin. 
However, the most probable explanation is the difference in HBV genotype distribu-
tion between the study cohorts. Preliminary data from our group show that HBsAg 
decline among HBeAg-positive patients treated with peginterferon is strongly related 
to HBV genotype.2 These differences across genotypes, particularly among patients 
who fail to achieve a response, may be an important determinant of the performance 
of a threshold based stopping-rule. Consequently, the performance of any threshold 
is primarily dependent upon the distribution of HBV genotypes in the study cohort.
The importance of HBV genotype when applying stopping-rules for peginterferon 
therapy in chronic hepatitis B was recently illustrated by a validation study of our 
stopping-rule for HBeAg-negative patients. This stopping-rule, recommending dis-
continuation of peginterferon in patients who fail to achieve a decline in HBsAg and a 
decline in HBV DNA of >2log at week 12, was based on a cohort of mostly genotype 
D patients.3 When validated in two independent study cohorts, performance was best 
in genotype D patients treated with either 48 or 96 weeks of peginterferon.4
Concluding, monitoring of HBsAg levels during peginterferon therapy of chronic 
hepatitis B may provide valuable insight into a patient’s probability of achieving a 
response. However, it appears that differences in HBsAg decline across HBV geno-
types have to be taken into consideration. A pooled analysis of the data from our 
respective studies, stratified by HBV genotype and possibly incorporating HBV DNA 
levels, appears to be a crucial next step.
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Current treatment options for CHB consist of the nucleo(s)tide analogues (NA) and 
(pegylated) interferons (PEG-IFN). Antiviral treatment with NA aims at competitively 
inhibiting viral polymerase activity1, and the most recently approved NA entecavir 
and tenofovir can effectively maintain suppression of HBV DNA levels for prolonged 
periods of time in the vast majority of patients.2-5 Nevertheless, PEG-IFN remains 
an important first-line treatment option for CHB, since an off-treatment sustained 
response can be achieved in a considerable number of patients after a finite treat-
ment course.6-10 Response to (PEG-)IFN-based therapy is accompanied by high 
rates of hepatitis B surface antigen (HBsAg) seroconversion,11 a reduced incidence 
of hepatocellular carcinoma and prolonged survival.12, 13 However, the clinical use 
of PEG-IFN is compromised by the frequent occurrence of side-effects;14 the most 
frequently reported side-effects are a flu-like syndrome, headache, myalgia, fatigue 
and local reactions at the site of injection.7, 10, 15 Selection of patients with the highest 
probability of achieving a response to PEG-IFN is therefore essential to successful 
application of this agent in clinical practice and may help reduce therapy associ-
ated side-effects and costs. Ideally, patients should be selected for PEG-IFN therapy 
based on their individual probability of response; this requires a procedure that 
can accurately predict response using readily available baseline parameters. Once 
therapy is initiated, an individual patient’s probability of response can be updated 
using on-treatment parameters that can accurately identify those patients who are 
likely to become non-responders, while maintaining all future responders on therapy.
Our group has recently published a baseline prediction model based upon a pooled 
dataset from studies of PEG-IFN for HBeAg-positive chronic hepatitis B.16 This study 
identified HBV genotype A, low baseline HBV DNA, high baseline ALT, older age, 
female sex and no previous IFN therapy as factors that predicted a favorable therapy 
response.16 A prediction model based on these variables may help select patients 
for PEG-IFN therapy. However, discrimination was limited, leaving substantial uncer-
tainty on the individual level. Identification of other baseline or on-treatment factors 
that influence the probability of response is therefore required.
ReSPonSe To PeginTeRfeRon RequiReS A SuSCePTiBle 
HoST And A SuSCePTiBle ViRuS
Recently, large genome-wide association studies in hepatitis C virus infected patients 
have revealed an association between sustained virological response to PEG-IFN 
and ribavirin treatment and several single nucleotide polymorphisms on chromosome 
19, located near the IL28B gene.17-20 These studies have convincingly shown that 
favorable IL28B genotypes, such as AA at rs12980275, confer increased probabilities 
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of sustained virological response, independently of other predictors.20 The exact 
biological mechanism or pathway by which these genotypes influence response to 
PEG-IFN is currently unclear. IL28B itself is a member of the IFN-λ family, and IFN-λ 
was recently shown to be active against both RNA and DNA viruses.21-23 Indeed, 
preliminary data from a phase 2 study show that treatment with PEG-IFN-λ is effective 
in HCV infected patients.24 Furthermore, in-vitro studies have shown that IFN-α, such 
as administered in the form of PEG-IFN alfa, may induce IFN-λ production. Since the 
two types of IFN, IFN-α and IFN-λ, have common downstream signaling pathways, 
the two types of IFN may act synergistically in patients treated with PEG-IFN.25-28 In 
Chapter 1, we present the results of a large multicenter study of 205 HBeAg-positive 
patients treated with PEG-IFN in 11 hospitals across the globe.7, 29, 30 All patients were 
genotyped at rs12980275 and rs12979860 near the IL28B. In this study, we found 
that IL28B genotypes were independently associated with the occurrence of HBeAg 
seroconversion after PEG-IFN therapy, and also with HBsAg clearance through 7 
years of follow-up. However, this study also showed that the majority of patients with 
a successful immune response to PEG-IFN (ie. who achieved HBeAg seroconver-
sion) did not achieve low HBV DNA levels (<2,000 IU/mL), nor HBsAg clearance. A 
possible explanation for these observations is the presence of viral strains that have 
mutations in the precore and basal core promoter regions that prohibit the synthesis 
of HBeAg. Presence of these mutants before treatment initiation has been shown to 
predict HBeAg loss after IFN treatment,31 possibly through positive selection during 
antiviral therapy,32 but may predispose patients to persistence of HBV DNA after 
HBeAg clearance.33, 34 In Chapter 2, we therefore investigated whether presence of 
precore and/or core promoter mutants in HBeAg-positive patients who were treated 
with PEG-IFN influenced the probability of response. In this study of 214 patients 
treated with PEG-IFN within a global randomized study7, we found that precore and 
core promoter mutants were most frequently detected in patients with HBV genotypes 
B, C, and D, and in only a subset of patients with the favorable HBV genotype A. 
Patients with detectable mutants had lower levels of HBeAg, and frequently achieved 
HBeAg clearance and seroconversion after PEG-IFN therapy. However, the major-
ity of patients with detectable precore and core promoter mutants who achieved 
HBeAg clearance did not achieve low levels of HBV DNA, nor did they clear HBsAg. 
In contrast, patients with only wildtype virus at baseline had a very high probability of 
achieving either of these endpoints. The lower baseline levels of HBeAg, high rates 
of HBeAg seroconversion but low rates of subsequent disease remission in patients 
with detectable mutants was also apparent in a large cohort of patients treated with 
NA, as shown in Chapter 3.
Given the association of IL28B genotype with serological response and the asso-
ciation between precore and core promoter mutants and failure to achieve low HBV 
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DNA levels after HBeAg clearance, we hypothesized that response to PEG-IFN 
therapy requires both a susceptible host (susceptible to IFN alfa, or an active immune 
response) as well as a susceptible virus (absence of detectable precore and/or core 
promoter mutants). In Chapter 4 we therefore investigated whether a combination of 
markers of an active immune response, serum levels of interferon gamma-inducible 
protein (IP)-10 and ALT, together with confirmed absence of precore and core promoter 
mutants could identify patients with a very high likelihood of response to PEG-IFN 
therapy. The results of this study showed that a combination of high baseline levels 
of IP-10 or high baseline levels of ALT (ie. an active immune response), together with 
presence of only wildtype HBV identified patients with high a priori response chances. 
Possibly, combined use of the described predictors of response to PEG-IFN may 
help select patients with the most favourable characteristics for PEG-IFN therapy, 
resulting in higher overall response rates and a more attractive cost-benefit ratio for 
this treatment option.
ReSPonSe-guided PeginTeRfeRon THeRAPy
While use of baseline predictors may help identify the best candidates for PEG-IFN 
efficacy, the individual probability of response remains limited. Early on-treatment 
identification of non-responders to therapy may help optimize the use of PEG-IFN. 
On-treatment monitoring of viral replication using HBV DNA, HBeAg and HBsAg 
levels may aid decision-making and frequent HBV DNA monitoring is therefore rec-
ommended in treatment guidelines.35 However, modeling of HBV DNA kinetics during 
PEG-IFN therapy has shown only limited clinical utility,36, 37 and reliable prediction of 
non-response is only possible at week 24 of therapy (negative predictive value (NPV) 
86%).38 Recent technical advances have allowed for the quantitative assessment of 
HBsAg in serum. HBsAg is secreted from the hepatocyte during viral replication as 
part of the HBV nucleocapsid, or as part of noninfectious viral particles.39, 40 Several 
studies have reported that serum HBsAg levels correlate with intrahepatic cccDNA 
levels in HBeAg-positive patients.41, 42 Importantly, the concentration of infected cells 
at the end of treatment predicts the risk of relapse after therapy discontinuation.43 On-
treatment HBsAg decline may therefore reflect the efficacy of PEG-IFN in decreasing 
intrahepatic cccDNA and consequently predict a sustained response.
In Chapter 6, we present the results of a study that investigated the kinetics of 
serum HBsAg levels during treatment with PEG-IFN alone or in combination with 
lamivudine. PEG-IFN treatment induced a significant decline in serum HBsAg levels, 
which was sustained post-treatment. Importantly, on-treatment HBsAg decline was 
limited to patients who achieved a sustained response to therapy, suggesting that 
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the on-treatment kinetics of serum HBsAg can be used to monitor therapy efficacy. 
In this study, patients who failed to achieve a decline of serum HBsAg levels during 
the first 3 months of treatment had a probability of response of <5%, suggesting that 
PEG-IFN is not effective and therapy discontinuation can be considered. However, 
patients in this cohort were predominantly of Caucasian origin, and infected with HBV 
genotype A or D. In Chapter 7, we report that HBsAg kinetics are also influenced by 
HBV genotype, suggesting that one prediction rule may not be applicable across all 
major HBV genotypes. Indeed, another study that comprised mostly Asian patients 
infected with HBV genotypes B or C reported that a considerable number of patients 
without a HBsAg decline by month 3 of treatment went on to achieve a response. This 
study proposed a prediction-rule that used an HBsAg levels >20,000 IU/mL at week 
12 or 24 to identify patients with a limited probability of response.44 We were unable 
to confirm the use of this cut-off in our dataset, which may be accounted for by the 
differences in HBV genotype distribution across the study cohorts. In Chapter 8, we 
finally resolved this issue by evaluating the performance of our stopping-rule, as well 
as the stopping-rule based on an HBsAg level >20,000 IU/mL, in a pooled dataset of 
patients participating in 3 of the largest randomized studies of PEG-IFN for HBeAg-
positive CHB conducted worldwide.7, 8, 45 We were able to analyse the individual 
patient data of 803 patients, and found that on-treatment changes in HBsAg levels 
strongly predicted response to treatment across all major HBV genotypes. At week 
24 of treatment, all patients with HBsAg levels >20,000 IU/mL have a low probability 
of response, irrespective of HBV genotype, and PEG-IFN discontinuation is indicated. 
Use of HBV genotype specific stopping-rules may be considered at week 12; patients 
infected with genotypes A or D who do not achieve a decline in HBsAg by week 12 
have a very low probability of response, and for patients with genotypes B or C, those 
with HBsAg levels >20,000 IU/mL at week 12 could be eligible for therapy discontinu-
ation. Our findings may help make PEG-IFN more acceptable to patients, physicians 
and healthcare policy makers and could possibly increase the cost-effectiveness of 
PEG-IFN in HBeAg-positive CHB.
Spontaneous elevations of ALT, or flares, are a well-recognised phenomenon in 
patients treated with PEG-IFN, although the pathogenesis in unclear.46 Flares may 
occur in a considerable number, up to 25%, of patients treated with a one year course 
of PEG-IFN, and have been associated with an increased probability of serological 
response.47, 48 However, flares can also have considerable detrimental effects, and 
may result in hepatic decompensation and death in patients with advanced cir-
rhosis.49 Flink et al. recognised different types of flares during PEG-IFN therapy of 
HBeAg-positive CHB. In this study, host induced flares, characterised by an ALT 
flare followed by a decline in HBV DNA, were associated with response to treatment, 
whereas virus induced flares, or ALT elevations that were preceded by an increase 
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in HBV DNA, were not.47 Since a decline of HBsAg levels may signify induction of 
immune control, close monitoring of HBsAg levels in patients who experience flares 
may provide further insight into the nature of the flare. In Chapter 9, we studied 50 
patients who experienced flares during PEG-IFN therapy, and found that patients 
who experience a host induced flare achieve pronounced declines in HBsAg levels, 
whereas stable or even increasing HBsAg levels were observed in patients with virus 
induced flares. Furthermore, a rapid HBsAg decline during the first weeks after the 
peak of the flare predicts the occurrence of HBsAg loss. Close monitoring of HBsAg 
levels during flares may therefore help classify flares and predict subsequent treat-
ment response.
Several automated assays have recently been developed for the quantitative 
assessment of HBsAg and the most commonly used are the Architect HBsAg assay 
(Abbott Diagnostics)50 and the Elecsys HBsAg II quant assay (Roche Diagnostics). 
To assess whether results obtained using these platforms yield comparable results, 
we measured HBsAg in 1427 samples using both platforms, as reported in Chapter 
10. We found that the results acquired with both platforms are very highly correlated 
(r≥0.96) and in close agreement across all major HBV genotypes. The performance 
of a threshold based prediction rule (as discussed above) for patients treated with 
PEG-IFN established using Architect measurements was excellent when applied on 
Elecsys data, suggesting that prediction rules derived from studies conducted with 
one platform may be used confidently on the other. The choice of platform should 
therefore primarily be based on availability and local costs.
Previous studies have also shown that monitoring of HBeAg levels during PEG-IFN 
therapy may help predict HBeAg seroconversion. Fried et al. showed that achievement 
of low HBeAg levels at week 24 of PEG-IFN therapy accurately identified patients with 
a high probability of HBeAg seroconversion.38 However, as described above, HBeAg 
seroconversion does not result in disease remission in a substantial proportion of 
patients. We therefore investigated whether HBeAg levels, both before and during 
PEG-IFN therapy, could help predict a combined response of HBeAg loss with HBV 
DNA <2,000 IU/mL. In chapter 11, we show that the association between HBeAg 
levels and such a combined response to therapy is unreliable, due to the influence of 
precore and core promoter mutants which are both associated with lower levels of 
HBeAg as well as a reduced probability of combined response to PEG-IFN. Serum 
HBeAg levels should therefore not be used to select patients for PEG-IFN therapy, 
nor for monitoring of treatment efficacy, if presence of precore and core promoter 
mutants is not taken into consideration. In contrast, serum levels of HBsAg were 
able to predict response to PEG-IFN irrespective of presence of precore and core 
promoter mutants.
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ConCluSionS
PEG-IFN is an effective treatment option for a selected group of patients with 
favourable characteristics. Response to PEG-IFN requires both a susceptible host 
(favourable IL28B genotype, high ALT, high IP-10), as well as a susceptible virus 
(absence of precore and core promoter mutants). On-treatment monitoring of viral 
replication using serum HBsAg levels may help optimize decision-making, whereas 
use of HBeAg levels to monitor therapy efficacy is not recommended. Prediction rules 
based on HBsAg levels at week 12 of PEG-IFN therapy require HBV genotyping, but 
discontinuation should be considered in all patients with an HBsAg >20,000 IU/mL 
at week 24.
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De huidige behandelopties voor chronische hepatitis B (CHB) bestaan uit de nucleo(s)
tide analogen (NA) en (gepegyleerd) interferon (PEG-IFN). Antivirale behandeling met 
NA remt het virale polymerase,1 en behandeling met de meest recent ontwikkelde NA, 
entecavir en tenofovir, resulteert in een ondetecteerbaar HBV DNA in het overgrote 
deel van de patiënten.2-5 Desondanks blijft PEG-IFN een belangrijke eerstelijns behan-
deloptie, omdat bij een deel van de patiënten een respons optreedt die ook duurzaam 
is na het staken van de behandeling.6-10 Patiënten die een respons hebben op PEG-
IFN hebben een hoge kans op hepatitis B surface antigen (HBsAg) seroconversie,11 
een lagere kans op het krijgen van een hepatocellulair carcinoom en een gunstige 
prognose.12, 13 Het klinisch gebruik van PEG-IFN wordt echter bemoeilijkt door de 
vaak optredende bijwerkingen;14 de meest voorkomende zijn algehele malaise, 
hoofdpijn, myalgie, vermoeidheid en huidreacties rond de injectieplaats.7, 10, 15 PEG-
IFN dient daarom alleen te worden gebruikt bij patiënten met een hoge kans op 
respons. Idealiter zouden patiënten moeten worden geselecteerd op basis van de 
individuele kansen; hiervoor is echter een methode nodig die de kans op respons 
voldoende betrouwbaar kan vaststellen aan de hand van gemakkelijk beschikbare 
factoren. Daarnaast kan therapie worden bijgestuurd door veranderingen in de virale 
replicatie te monitoren gedurende de behandeling. Voor dit laatste is het belangrijk 
patiënten met een lage kans op succes zo vroeg mogelijk te identificeren, zonder de 
behandeling te staken bij patiënten die toch nog zouden reageren.
Onze groep heeft recent een predictiemodel gepubliceerd dat is gebaseerd op de 
data van patiënten die deel hebben genomen aan 2 grote internationale studies 
naar de effectiviteit van PEG-IFN in HBeAg-positieve CHB.16 Deze studie laat zien 
dat HBV genotype A, lage HBV DNA concentraties, hoge ALT waarden, een hogere 
leeftijd, vrouwelijk geslacht en niet eerder behandeld zijn met IFN de kans op succes 
vergroten.16 Helaas is de betrouwbaarheid op individueel niveau beperkt, en er is 
dan ook nog een grote onzekerheid of de patiënt wel of niet succesvol met PEG-IFN 
kan worden behandeld. Identificatie van andere factoren die het behandelresultaat 
beïnvloeden is daarom essentieel.
de kAnS oP een SuCCeSVolle BeHAndeling MeT 
PeginTeRfeRon HAngT Af VAn de geVoeligHeid VAn de 
dRAgeR en VAn HeT ViRuS
Recent hebben enkele grote genoomwijde associatie studies laten zien dat de kans op 
een succesvolle behandeling van een hepatitis C infectie met PEG-IFN en ribavirine 
beïnvloed wordt door enkele single nucleotide polymorphisms op chromosoom 19, 
nabij het IL28B gen.17-20 Patiënten met een gunstig genotype, zoals AA bij rs12980275, 
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hebben een grotere kans de behandeling succesvol af te sluiten.20 Het biologische 
mechanisme achter de associatie is op dit moment nog onduidelijk. IL28B is een lid 
van de IFN-λ familie, en IFN-λ zelf is effectief tegen zowel RNA als DNA virussen.21-23 
De eerste studie naar de klinische toepassing van PEG-IFN-λ bij patiënten met hepati-
tis C laat veelbelovende resultaten zien.24 Daarnaast hebben in vitro studies laten zien 
dat IFN-α, bijvoorbeeld toegediend in de vorm van PEG-IFN-α, de IFN-λ productie 
kan stimuleren. Omdat de twee typen IFN, IFN-α en IFN-λ, dezelfde reactiecascades 
hebben kunnen ze synergistisch werken bij een behandeling met PEG-IFN-α.25-28
In hoofdstuk 1 beschrijven we de resultaten van een grote multicenter studie waarin 
205 HBeAg-positieve hepatitis B patiënten werden geïncludeerd die behandeld 
waren met PEG-IFN in 11 ziekenhuizen in Europa, Canada en zuidoost Azie.7, 29, 30 
Alle patiënten werden gegenotypeerd voor rs12980275 en rs12979860 nabij het 
IL28B gen. We vonden dat het IL28B genotype van de patiënt een onafhankelijke 
voorspeller was voor de kans op HBeAg seroconversie na de PEG-IFN behandeling, 
en ook samenhing met de kans op HBsAg verlies gedurende een follow-up duur van 
ruim 7 jaar. De resultaten laten echter ook zien dat er bij een aanzienlijk deel van de 
patiënten met een succesvolle immuunrespons (het optreden van HBeAg serocon-
versie) daarna niet een laag HBV DNA (<2,000 IU/mL) of HBsAg verlies gevonden 
werd. Een mogelijke verklaring hiervoor is de aanwezigheid van virale subpopulaties 
met mutaties in het precore of core promoter gebied. Deze virussen maken minder of 
geen HBeAg aan, en de aanwezigheid van dergelijke subpopulaties is mogelijk geas-
socieerd met HBeAg verlies na de behandeling31 ten gevolge van positieve selectie.32 
Echter, aanwezigheid van deze mutanten is ook in verband gebracht met een blijvend 
hoog HBV DNA na HBeAg seroconversie.33, 34
In hoofdstuk 2 hebben we daarom onderzocht of aanwezigheid van precore en 
core promoter mutanten bij HBeAg-positieve patiënten die met PEG-IFN behandeld 
werden samenhing met de kans op respons. Met dit onderzoek, dat werd uitgevoerd 
binnen een grote international gerandomiseerde studie,7 konden wij aantonen dat de 
precore en core promoter mutanten vaak al aanwezig waren bij onze patiënten, en 
dan vooral bij patiënten met HBV genotypes B, C en D. Patiënten met detecteerbare 
mutanten hadden lagere HBeAg concentraties voor de behandeling en hadden een 
goede kans op HBeAg verlies en seroconversie. Echter, het overgrote deel van de 
patiënten met detecteerbare mutanten die HBeAg negatief werden slaagde er niet in 
daarna ook een ondetecteerbaar HBV DNA te krijgen of HBsAg negatief te worden. 
Daarentegen hadden patiënten met alleen wildtype virus juist een hele hoge kans 
op het behalen van deze eindpunten. De lagere HBeAg concentratie bij patiënten 
met detecteerbare mutanten, alsook de hoge kans op HBeAg verlies, hebben we 
vervolgens bevestigd in een cohort patiënten die met NA werden behandeld, zoals 
gerapporteerd in hoofdstuk 3.
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Omdat het IL28B genotype samenhangt met serologische respons (HBeAg serocon-
versie) en aanwezigheid van precore en core promoter mutanten juist iets zegt over de 
kans een blijvend hoog HBV DNA na HBeAg verlies, stelden wij de hypothese op dat 
een succesvolle behandeling met PEG-IFN afhangt van de gevoeligheid van de drager 
en de gevoeligheid van het virus. In hoofdstuk 4 hebben we daarom onderzocht of 
een combinatie van immuunactivatie, gemeten middels de serum concentratie van het 
interferon gamma inducible protein-10 (IP-10) en het ALT, samen met de afwezigheid 
van precore en core promoter mutanten kan helpen patiënten met een grote kans op 
succesvolle PEG-IFN behandeling te identificeren. De resultaten laten zien dat vooral 
patiënten met een hoog IP-10 en een hoog ALT (activatie van het immuunsysteem) en 
met alleen wildtype HBV goede kandidaten zijn voor een behandeling met PEG-IFN. 
De combinatie van bovenstaande factoren kan daarom helpen alleen patiënten voor 
PEG-IFN behandeling te selecteren als zij een hoge kans hebben op succes.
ReSPonS geSTuuRde PeginTeRfeRon BeHAndeling
Naast het gebruik van baseline factoren is het ook mogelijk de behandeling bij te 
sturen aan de hand van veranderingen in de virale replicatie. Het identificeren van 
non-responders gedurende de eerste behandelweken kan helpen het gebruik van 
PEG-IFN verder te optimaliseren. Er zijn 3 belangrijke markers voor virale replicatie: 
HBV DNA, HBeAg en HBsAg.35
De veranderingen van de HBV DNA concentratie tijdens de behandeling heeft maar 
weinig klinische toepasbaarheid,36, 37 omdat betrouwbare responspredictie pas moge-
lijk is na 24 weken behandeling (negatief voorspellende waarde 86%).38 Recent is het 
ook mogelijk geworden het HBsAg kwantitatief te meten in serum. Het HBsAg wordt 
in de hepatocyt geproduceerd gedurende de virale replicatie en wordt uitgeschei-
den als onderdeel van het virale deeltje, maar ook als niet-infectieuze partikels.39, 40 
Enkele studies hebben laten zien dat de HBsAg concentratie in serum samenhangt 
met de intrahepatische cccDNA concentratie in HBeAg-positieve patiënten.41, 42 Een 
hoge cccDNA concentratie is voorspellend voor het optreden van een terugval na het 
staken van de behandeling.43 Het optreden van een daling van het HBsAg is mogelijk 
een weergave van een daling van de intrahepatische cccDNA concentratie en kan 
daarom het succes van de behandeling voorspellen.
In hoofdstuk 6 beschrijven we de resultaten van een onderzoek naar de kinetiek 
van het HBsAg gedurende een behandeling met PEG-IFN. Een daling van de HBsAg 
concentratie trad vooral op bij patiënten met een respons, hetgeen suggereert dat de 
HBsAg concentratie kan worden gebruikt om het succes van de behandeling te moni-
toren. In dit onderzoek hadden patiënten die na 12 weken behandeling geen daling 
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hadden van de HBsAg concentratie een kans op succes van minder dan 5%, zodat 
de behandeling beter gestopt kan worden. Het is echter belangrijk dat dit cohort 
voornamelijk bestond uit Europese patiënten, geïnfecteerd met HBV genotypes A of 
D. In hoofdstuk 7 laten we zien dat de HBsAg kinetiek ook wordt beïnvloed door het 
HBV genotype, en mogelijk moeten er daarom verschillende predictieregels worden 
opgesteld voor patiënten met verschillende HBV genotypes. In een andere studie 
waarin vooral Aziatische patiënten werden bestudeerd, meestal geïnfecteerd met 
genotypes B of C, werd duidelijk dat patiënten met een HBsAg concentratie van meer 
dan 20,000 IU/mL op week 12 een lage kans hadden op succes.44 Wij konden deze 
bevindingen niet bevestigen in ons cohort, wat mogelijk kan worden verklaard door 
de verschillen in HBV genotypes tussen de cohorten.
In hoofdstuk 8 hebben we getracht dit probleem op te lossen door patiënten te 
onderzoeken die behandeld zijn met PEG-IFN in de 3 grootste gerandomiseerde 
studies naar de effectiviteit van PEG-IFN in HBeAg-positieve patiënten.7, 8, 45 In dit 
onderzoek, waarin 803 patiënten vanuit de hele wereld werden geïncludeerd, konden 
we wederom laten zien dat de HBsAg concentratie een sterke voorspeller is van res-
pons op PEG-IFN ongeacht het HBV genotype. Uit deze studie bleek dat de kans op 
succes erg laag werd als de patiënt een HBsAg concentratie had van meer dan 20,000 
IU/mL na 24 weken behandeling, en dat het HBV genotype hierbij niet van belang is. 
Wil men echter na 12 weken behandeling al iets zeggen over de kansen, dan moet 
een HBV genotype specifieke stopregel worden gekozen. Deze bevindingen kunnen 
helpen op de PEG-IFN behandeling verder te optimaliseren, de kosten te verlagen en 
PEG-IFN acceptabeler te maken voor patiënten, artsen en beleidsmakers.
ALT stijgingen (flares) komen vaak voor tijdens een behandeling met PEG-IFN, tot bij 
25% van de patiënten, al is de oorzaak hiervan onduidelijk.46 Patiënten die een ALT 
flare doormaken hebben mogelijk een hogere kans op respons,47, 48 maar de flare kan 
ook resulteren in leverdecompensatie en de dood in patiënten met cirrose.49 Flink c.s. 
hebben verschillende typen flares beschreven: drager geïnduceerd (eerst een ALT 
stijging, gevolgd door een HBV DNA daling) of virus geïnduceerd (eerst een HBV DNA 
stijging, dan een ALT stijging). Drager geïnduceerde flares gingen gepaard met een 
hogere kans op respons, maar dit was niet het geval bij virus geïnduceerde ALT stij-
gingen.47 Omdat de HBsAg concentratie tijdens de behandeling iets kan zeggen over 
de mate van immuuncontrole hebben wij onderzocht of de kinetiek van het HBsAg 
verschilde tussen patiënten met drager geïnduceerde ALT flares en patiënten met 
virus geïnduceerde flares. In hoofdstuk 9 onderzochten wij 50 patiënten die een flare 
doormaakten en vonden dat patiënt geïnduceerde flares een sterke HBsAg daling tot 
gevolg hadden. De HBsAg concentratie bleef stabiel of steeg juist bij patiënten met 
een virus geïnduceerde flare. Verder vonden wij ook dat patiënten met een daling 
van de HBsAg concentratie na een ALT piek een hoge kans hadden om ook HBsAg 
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negatief te worden. Het monitoren van de HBsAg concentratie tijdens flares kan dus 
helpen flares te karakteriseren en behandelsucces te voorspellen.
Recent zijn verschillende geautomatiseerde assays ontwikkeld om het HBsAg te kwan-
tificeren. De twee meest gebruikte zijn de Architect HBsAg assay (Abbott Diagnostics) 
en de Elecsys HBsAg II quant assay (Roche Diagnostics). Om te onderzoeken of de 
twee apparaten vergelijkbare resultaten geven hebben we HBsAg gemeten met beide 
testen in 1427 bloedmonsters. De resultaten hiervan staan beschreven in hoofdstuk 
10. We vonden dat de resultaten van de twee testmethoden zeer vergelijkbaar waren 
onafhankelijk van het HBV genotype. Verder werkte een predictieregel die was ont-
wikkeld met data van de Architect goed toen hij werd toegepast op de meetresultaten 
van de Elecsys. Beide testmethoden kunnen daarom in de klinische praktijk worden 
gebruikt en de keuze moet vooral afhangen van beschikbaarheid en lokale kosten.
Eerdere studies hebben laten zien dat ook het HBeAg een goede voorspeller is van 
respons op PEG-IFN. Fried c.s. publiceerden dat een lage HBeAg concentratie na 
24 weken behandeling een goede voorspeller is voor het doormaken van een HBeAg 
seroconversie. Echter, zoals boven beschreven, lang niet alle patiënten hebben na 
de HBeAg seroconversie een laag HBV DNA. Wij hebben daarom onderzocht of de 
HBeAg concentratie ook samenhangt met het optreden van een lage HBV DNA con-
centratie na de PEG-IFN behandeling. In hoofdstuk 11 laten we zien dat de relatie 
tussen de concentratie HBeAg en respons op PEG-IFN zeer onbetrouwbaar is. Dit 
komt mogelijk door de associatie met aanwezigheid van precore and core promoter 
mutanten, welke samenhangt met zowel lage HBeAg levels alsook een verhoogde 
kans op het falen van de behandeling. De concentratie van HBeAg lijkt daarom afge-
daan te hebben als marker voor het monitoren van de patiënt die behandeld wordt 
met PEG-IFN.
ConCluSie
PEG-IFN is een effectieve behandeling voor een selecte groep hepatitis B patiënten 
met goede karakteristieken. Een succesvolle behandeling met PEG-IFN hangt af van 
de gevoeligheid van zowel de drager (gunstig IL28B genotype, hoog IP-10) als van 
het virus (afwezigheid van precore en core promoter mutanten). Het beloop van de 
concentratie van het HBsAg tijdens de behandeling kan informatie geven over het 
optreden van een respons, en patiënten die een HBsAg concentratie hebben van 
meer dan 20,000 IU/mL na 24 weken dienen de behandeling te staken.
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Dankwoord
Ieder verhaal heeft een begin. Lieve Moniek, jij belde me eind 2008 of ik niet iemand 
wist die jouw promotieplek wilde invullen nu jij het eigenlijk toch niet zo zag zitten. 
The rest is history.
Beste Harry (prof HLA Janssen), onder jouw leiding heeft het HBV onderzoek in 
Nederland een plaats verworven in de absolute wereldtop. Jouw naam, en de kwali-
teit die deze garandeert, heeft veel deuren voor mij geopend en was een essentiële 
component van de successen. Dank voor het in mij gestelde vertrouwen, ondanks 
dat de eerste indruk misschien niet veel goeds beloofde. Ik heb de afgelopen jaren 
waanzinnig veel van je geleerd, over zaken die wel en niet acceptabel zijn, maar vooral 
over hoe belangrijk goed kunnen delegeren is voor het leiden van het bedrijf dat de 
onderzoeksgroep is geworden. De wijze waarop je je promovendi vrijlaat om hun tijd 
en projecten naar eigen inzicht in te vullen is geniaal. Veel dank. In een eerdere versie 
van dit dankwoord eindigde ik met de vraag what’s next? Dat is inmiddels bekend en 
ik wens je alle succes in Toronto.
Daarnaast wil ik dr. De Man, prof. dr. Beuers en prof. dr. Boucher bedanken voor het 
plaatsnemen in de leescommissie. Prof. dr. Osterhaus en prof. dr. Hoepelman, dank 
dat u onderdeel wilt zijn van de commissie. Prof. dr. Wedemeyer: thank you for being 
a part of the committee.
I would like to thank Henry Chan, Vincent Wong and Loredana Regep for their invalu-
able contributions to some of the works included in this thesis.
Angelo Betti, enorm veel dank voor het ontwerpen van de omslag, en natuurlijk voor 
de vele heerlijke pizza-avonden.
De promotieperiode bij de afdeling leverziekten wordt voornamelijk doorgebracht 
in een houten keet die al decennia “tijdelijk” op een van de bijgebouwen van het 
Erasmus MC is geplaatst. Toegang: via een brandtrap. Temperatuur in de zomer: 30 
plus. Mogelijkheden om post te ontvangen: nihil. Toch blijkt het ophokken van een 
groep jonge gemotiveerde onderzoekers een succesformule. Tijdens de afgelopen 
jaren had ik het genoegen om hoogte- en dieptepunten te mogen delen met: Robert, 
Jurriën, Edith, Desiree, Vera, Aria, Celine, Nicoline, Renate, Margot, Aafke, Jorie, 
Edmee, Susanne, Atija, Wouter, Veerle, Wim, Jildou, Leonie, Caroline, Ludi, Femme, 
Lisanne, Wouter en natuurlijk Jeoffrey.
Specifiek wil ik stilstaan bij de collega’s met wie ik intensief heb samengewerkt. 
Roeland, je lijkt zo uit Jiskefet weggelopen. Nadat Vincent vertrok was de HBV groep 
voor de ervaring op ons aangewezen. Het zal even schrikken zijn geweest. We zijn 
vrijwel tegelijk begonnen en binnen 3 maanden lagen we al gezellig in een twijfelaar 
in Boston. We hebben vrijwel het hele traject samen doorlopen en dat schept toch 
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een band. Met je humor, cynisme en kritische blik was je een belangrijk onderdeel 
van mijn mooie tijd op het dak. Dank voor al je input, kritiek en voetbalanalyses. 
Ad, wat heb ik vaak om en met je moeten lachen. Ik heb enorm genoten van onze 
talloze semi-filosofische discussies over wetenschappelijk onderzoek en natuurlijk 
de gezellige borrels en feestjes. Ik ben blij dat ik ook een, uiterst subtiele, bijdrage 
heb mogen leveren aan je succesvolle sollicitatie voor de opleiding tot MDL-arts. 
Heel veel succes met de laatste loodjes, en natuurlijk met het assistentschap! Vin-
cent, op het eerste gezicht lijk je ontzettend serieus. En eigenlijk ben je dat ook. 
Je bent vreselijk minutieus en handhaaft deadlines altijd strikt, en je bent daarom 
een belangrijk leermeester voor me geweest. Toch staan vooral de fantastisch mooie 
congressen, feestjes en ander vertier me het meeste bij. Er zal voor mij nooit meer 
een andere PILF zijn. Veel succes met je gezin en in je verdere carrière! Pauline, je 
moest als vrouw je plekje veiligstellen tussen de B-boys, en daar ben je moeiteloos in 
geslaagd. Veel succes met je promotie, hou vol, het komt goed! Bettina, er zijn maar 
weinig statistici die zo hip zijn als jij. Waar je in Rotterdam de moeilijkste analyses 
moeiteloos uit je mouw schudt draai je je hand er ook niet voor om tot het bittere eind 
de donkerste clubs van Berlijn onveilig te maken. Dank voor al je onmisbare hulp en 
alle gezelligheid!
Ook mijn kamergenoten verdienen natuurlijk een speciale vermelding. Daphne, je bent 
vanaf dag 1 mijn roomy geweest en we hebben ieder hoogte- en dieptepunt van het 
promoveren wel van elkaar meegemaakt. Ik heb enorm genoten van je humor, kooktips, 
glutenvrije hapjes en on-line shopping sprees. Ook jij hebt een ongelooflijk doorzet-
tingsvermogen en ik ben ontzettend onder de indruk van de wijze waarop jij de soms 
moeilijke periodes en tegenslagen hebt overwonnen. Ik ben heel blij dat je inmiddels 
ook in Deventer een thuis hebt gevonden! Paul, jij verliet het dak voordat ik goed en wel 
op stoom was maar ik was toch enorm blij met je hartelijke ontvangst. Veel succes met 
de opleiding en ik hoop dat je de tijd vindt om je boekje snel af te maken. Lisanne, we 
moesten even wennen aan elkaar, maar gelukkig is het helemaal goed gekomen. Ik ken 
weinig mensen die zo gedreven zijn als jij en ongetwijfeld zal je je promotie in recordtijd 
afronden. Veel succes de komende jaren, en wat heerlijk dat je al zeker bent van die 
opleidingsplek! Raoel, we hebben maar kort kamer CA-4.19 gedeeld, maar we hebben 
de periode wel fantastisch kunnen afsluiten in Boston! Wie had kunnen denken dat we 
elkaar na de Wolfert hier weer zouden treffen? Veel succes met je promotie!
De belangrijkste dames van de MDL zijn stafsecretaresses Marion en Margriet. Zon-
der jullie zou de toko als een kaartenhuis in elkaar zakken en zou dit boekje er nog 
niet zijn geweest. Dank voor alle hulp, schuiven met afspraken en mooie verhalen!
Een speciale vermelding verdienen ook de collega’s van de afdeling Virologie die 
de vele duizenden bepalingen waarop mijn onderzoek is gebaseerd uitvoerden en 
zonder wie het onmogelijk was geweest de wereldwijde concurrentie te snel af te 
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zijn. Annemiek en Suzan: bedankt voor alle support als er weer eens een onmogelijke 
deadline moest worden gehaald. Sandra, ook jij hoort hier natuurlijk tussen; vrijwel 
ieder sample waarvan de serologieresultaten in dit proefschrift beschreven staan is 
minstens eenmaal door jouw handen gegaan. Enorm bedankt!
Ook de mensen van het MDL-lab waren onmisbaar. Hanneke, Andrea en André: dank 
voor de support en de hulp om altijd weer alles op tijd af te krijgen. Buddy, Gertine, 
Anthonie, Paula, Martine dank voor alle noeste arbeid die jullie hebben verricht, en 
sorry voor alle keren dat ik weer kwam vragen of de bepalingen al waren gedaan!
Er is een kamer op de afdeling Virologie die ook nog het vermelden waard is: de 
vriezer. Een ruimte van 8 bij 8 met een permanente temperatuur van -20 Celsius, 
waar alle serum monsters van de afgelopen 10 jaar liggen opgeslagen in enorme 
kasten aan claustrofobisch kleine gangetjes. De vele tientallen uren die ik hier heb 
doorgebracht met Vincent en Roeland hebben een band voor het leven geschapen en 
voelen nu nog steeds als een rite of passage.
Het Clinical Research Bureau is de backbone van al het multicenter onderzoek van de 
afdeling. Elke, enorm bedankt voor alle hulp bij het coördineren van de vele (interna-
tionale) projecten, en de hulp bij de vele METC indieningen. Zonder jou was de ARES 
studie nooit een succes geworden. Irene, bedankt voor alle hulp bij het opstellen van 
budgetten. Judith, dank voor al je energie en enthousiasme, vooral bij het opbouwen 
van het online database systeem. Edith, bedankt voor alle hulp bij de METC indiening 
van de IL28B studies. Natuurlijk wil ik ook de research nurses bedanken voor hun 
onmisbare werk; Heleen, Lucille, Melek en Merel: dank voor alle hulp!
Naast mijn collega’s wil ik ook mijn lieve (studie)vrienden bedanken voor de fantas-
tische tijd die ik met jullie heb gehad (en hopelijk nog zal hebben!) en de steun die 
jullie me hebben gegeven in de moeilijkste tijd uit mijn leven (en dan bedoel ik niet 
de promotietijd). Zonder iemand te passeren wil ik enkelen van jullie toch specifiek 
noemen.
Lieve Jacky, we kennen elkaar als sinds de eerste dag van studiegroep 22 en ik 
heb de afgelopen jaren onwijs van je genoten. Ik heb een enorm respect voor de 
wijze waarop jij volledig op eigen kracht de geneeskunde studie hebt gefinancierd 
en cum laude hebt afgerond. Veel succes met de zoektocht naar een opleidingsplek 
gynaecologie en ik hoop dat we elkaar ondanks de verschillende carrière keuzes nog 
vaak blijven zien. Fantastisch dat je mijn paranymf wilt zijn!
Lieve Moniek, zoals hierboven al gememoreerd ben jij de aanstichter van dit boekje. 
Eerste indrukken kunnen misleidend zijn, en ik ben blij dat je openstond voor een 
tweede indruk. Dank voor je vertrouwen en natuurlijk de fantastische tijd die we heb-
ben gehad op Harvard. Succes met de opleiding tot huisarts, je leven met Tejas, en 
ik hoop dat je ondanks je liefde voor Amsterdam toch de weg naar Rotterdam zult 
blijven vinden!
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Lieve Murid, ook jij zat in het illustere groepje 22. Dank voor alle leuke dingen die 
we hebben gedaan de afgelopen jaren, van een weekend weg met 100 eerstejaars 
inclusief ambulances tot gewoon heerlijke avondjes in de kroeg.
Lieve Willem Pieter, we kennen elkaar geloof ik al sinds jaar 1 van de studie. Wat 
fantastisch dat we naast vrienden ook als collega’s hebben kunnen samenwerken! Ik 
ben blij dat alles wat ik achterlaat in zulke goede handen terecht komt! We hebben een 
fantastische tijd achter de rug met congressen, weekendjes Antwerpen en Zeeland, 
een road-trip van San Francisco door de Mojave woestijn en Death Valley naar Las 
Vegas en nu als afsluiter nog een trip naar Boston en New York. Ik heb er alle vertrou-
wen in dat je ARES, de GIANT-B en alle andere projecten tot een succesvol einde zal 
brengen. Succes met je eigen promotie, veel plezier met Lieke, en ik vertrouw erop dat 
we elkaar nog (heel) vaak zullen zien! Waanzinnig dat je me wil bijstaan op deze dag!
Geeske, Telma, Bruno en alle andere geneeskundevrienden: dank voor de fantasti-
sche tijd.
Lieve Jacob en Rianne, wat een mooie jaren hebben we achter de rug! Bedankt voor 
al jullie interesse en support, maar toch vooral voor de talloze heerlijke avonden en 
nachten van Rotterdam tot Ibiza. Heel veel plezier met jullie Eva, het nieuwe grote 
avontuur. Ik hoop dat we nog vaak van jullie kookkunsten mogen komen genieten.
En natuurlijk Kevin en Aart; jullie ken ik al sinds jaar 1 van de Wolfert. Ik ben ontzet-
tend blij dat we ondanks dat we allemaal uitgevlogen zijn toch regelmatig samen 
blijven komen. Ik hoop dat dit altijd zo zal blijven!
Lieve teamgenootjes en andere Trekvogels: dank voor de vele mooie wedstrijden, 
uitjes en natuurlijk jullie begrip als ik er weer eens niet was!
Ik wil ook de mensen bedanken die mijn eerste stappen op het gebied van weten-
schappelijk onderzoek hebben mogelijk gemaakt. Jan (Klein), Markus (Klimek) en 
Frank (Grüne): enorm bedankt voor het in mij gestelde vertrouwen en de begeleiding 
gedurende mijn MSc periode. Gerhard (Visser) en Ingrid (Brussé): dank voor het 
enthousiasme en (mental) support gedurende de ROBRA-2 studie!
Lieve Margreet en Joop, bedankt voor al jullie belangstelling en betrokkenheid.
Suus & Joost, Marlot & Joey: dank voor alle belangstelling, maar vooral alle gezellig-
heid!
Lieve opa’s en oma’s, helaas kunt u niet allemaal aanwezig zijn op deze dag. Dank 
voor alle liefde, mooie verhalen en interesse in al mijn bezigheden.
Lieve Rien, papa, enorm bedankt voor al je liefde, interesse en ondersteuning. Ik vind 
het zeer knap hoe je alle tegenslagen hebt overwonnen. Lieve Marjolein, dank voor al 
je betrokkenheid. Ik ben enorm blij dat jullie elkaar zo gelukkig maken.
Lieve Sonia, mama, het is zo jammer dat je er niet bij kunt zijn als ik dit boekje 
verdedig. Je bent een enorm inspiratie voor me en de reden dat ik altijd het beste uit 
mezelf wil halen. Ik mis je nog iedere dag. Ik hoop dat je trots bent.
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Tot slot, lieve Paula: we zijn al jaren samen en we hebben al talloze hoogte- en 
dieptepunten beleefd. Bedankt voor alle steun die je me hebt gegeven, en voor al je 
belangstelling en enthousiasme voor alles wat ik doe. Zonder jou was dit boekje er 
niet geweest. Ik kan niet wachten om te zien wat de toekomst ons nog voor moois 
gaat brengen.
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Milan Johan Sonneveld werd op 12 januari 1987 geboren te Rotterdam. In 2005 
behaalde hij het atheneum diploma aan de tweetalige VWO opleiding van het Wolfert 
van Borselen Lyceum te Rotterdam. Daarnaast slaagde hij voor het International 
Baccalaureate examen Engels op A1 Standard Level (near-native speaker) en werd 
hij geselecteerd voor deelname aan het Leiden Advanced Pre-University Programme 
for Top-students aan de Universiteit van Leiden in 2004. In 2005 begon hij met de 
opleiding Geneeskunde aan de Erasmus Universiteit Rotterdam, waar hij in 2010 het 
doctoraal examen behaalde. Tijdens zijn studie, van 2006 tot 2009, werkte hij als 
student assistent en later als studententeamleider op de Post Anesthesia Care Unit 
(PACU) van het Erasmus MC. Simultaan aan de Geneeskunde studie startte hij in 
2007 de Research Master opleiding Clinical Research aan het Netherlands Institute 
for Health Sciences (NIHES). Onder begeleiding van dr. M. Klimek en dr. F. Grüne 
(afdeling Anesthesiologie), dr. G. Visser (afdeling Neurologie) en drs. Ingrid Brussé 
(afdeling Verloskunde en Gynaecologie) deed hij onderzoek naar de doorbloeding van 
het brein van zwangere vrouwen met pre-eclampsie, en in 2010 verwierf hij voor zijn 
dissertatie Cerebral Perfusion Pressure remains elevated in pre-eclamptic patients 
with normalized blood pressure de Master of Science titel. Daarnaast nam hij gedu-
rende de zomer van 2009 deel aan het Summer Program van de Harvard School of 
Public Health in Boston, Massachusetts, USA. In 2009 startte hij onder begeleiding 
van prof. dr. H.L.A. Janssen aan een promotietraject op de afdeling Maag-, Darm- en 
Leverziekten van het Erasmus MC met als onderzoeksonderwerp de behandeling van 
patiënten met chronische hepatitis B. Hij woont samen met Paula Clarijs in Rotterdam.
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PhD Portfolio
Summary of Phd training and teaching
Name PhD student: Milan J. Sonneveld
PhD period: 2009-2013
Erasmus MC Department: Gastroenterology and Hepatology
Promotor: Prof. Dr. H.L.A. Janssen
1. Research training
Courses in methodology and biostatistics year Workload
Study design 2007 104 hours
Principals of Research in Medicine and Epidemiology 2007 15 hours
Methods of clinical research 2007 15 hours
Clinical trials 2007 15 hours
Pharmaco-epidemiology 2007 15 hours
Case-control studies 2007 15 hours
Introduction to decision-making in medicine 2007 15 hours
Introduction to data analysis 2008 25 hours
Regression analysis 2008 30 hours
Topics in meta-analysis 2008 15 hours
Survival analysis 2008 30 hours
Modern statistical methods 2008 104 hours
Advanced topics in decision-making in medicine 2008 15 hours
Intervention research and clinical trials 2008 15 hours
Diagnostic research 2008 15 hours
Prognosis research 2008 15 hours
Ethnicity, health and healthcare 2008 15 hours
Scientific writing in English for publication 2009 30 hours
Pharmaco-epidemiology and drug safety 2009 15 hours
Advanced topics in clinical trials 2009 15 hours
Advanced analysis of prognosis studies 2009 15 hours
Principles of epidemiologic data analysis 2009 15 hours
oral presentations at (inter)national conferences
Prediction of sustained response to peginterferon alfa-2b for HBeAg-positive 
chronic hepatitis B using on-treatment HBsAg decline. Twice annual meeting of 
the Netherlands Association of Hepatology, Veldhoven, the Netherlands.
2010 12 hours
Polymorphisms at rs12979860 and rs12980275 near IL28B predict serological 
response to peginterferon in HBeAg-positive chronic hepatitis B. 46th Annual 
meeting of the European Association of the Study of the Liver, Berlin, Germany.
2011 36 hours
230
Presence of precore and core promoter mutants limits the probability of 
achieving a sustained virological response to peginterferon in HBeAg-positive 
chronic hepatitis B. Twice annual meeting of the Netherlands Association of 
Hepatology, Veldhoven, the Netherlands.
2011 12 hours
HBsAg levels at six months post-treatment predict sustained response through 
long-term follow-up in HBeAg-positive patients treated with peginterferon 
alfa-2b.Twice annual meeting of the Netherlands Association of Hepatology, 
Veldhoven, the Netherlands.
2011 12 hours
Presence of only wildtype virus is the strongest determinant of HBV DNA 
undetectability and HBsAg clearance in HBeAg-positive chronic hepatitis 
B patients treated with peginterferon. 47th Annual meeting of the European 
Association of the Study of the Liver, Barcelona, Spain
2012 36 hours
Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg 
clearance – first results from a global randomized trial (ARES study). Twice 
annual meeting of the Netherlands Association of Hepatology, Veldhoven, the 
Netherlands..
2012 12 hours
Response-guided peginterferon therapy in HBeAg-positive chronic hepatitis 
B using serum hepatitis B surface antigen levels: a pooled analysis 803 
patients. Twice annual meeting of the Netherlands Association of Hepatology, 
Veldhoven, the Netherlands.
2012 12 hours
Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg 
clearance – first results from a global randomized trial (ARES study). 63rd 
Annual Meeting of the American Association for the Study of Liver Diseases 
(AASLD), Boston, MA, United States of America.
2012 36 hours
Response-guided peginterferon therapy in HBeAg-positive chronic hepatitis B 
using serum hepatitis B surface antigen levels: a pooled analysis 803 patients. 
63rd Annual Meeting of the American Association for the Study of Liver 
Diseases (AASLD), Boston, MA, United States of America.
2012 36 hours
Poster presentations
HBsAg decline during peginterferon alfa-2b therapy for HBeAg-positive chronic 
hepatitis B depends on HBV genotype: relation to sustained response. 61st 
Annual Meeting of the American Association for the Study of Liver Diseases 
(AASLD), Boston, MA, United States of America.
2010 32 hours
Prediction of sustained response to peginterferon alfa-2b for HBeAg-positive 
chronic hepatitis B using on-treatment HBsAg decline. 61st Annual Meeting 
of the American Association for the Study of Liver Diseases (AASLD), Boston, 
MA, United States of America.
2010 32 hours
Peginterferon alfa-2b induced HBsAg decline is durable through long-term 
follow-up in HBeAg-positive patients. 61st Annual Meeting of the American 
Association for the Study of Liver Diseases (AASLD), Boston, MA, United 
States of America.
2010 32 hours
A comparison of two assays for quantification of hepatitis B surface antigen 
in patients with chronic hepatitis B. 46th Annual meeting of the European 
Association of the Study of the Liver, Berlin, Germany.
2011 32 hours
The performance of HBsAg based stopping-rules for HBeAg-positive chronic 
hepatitis B patients treated with peginterferon depends upon HBV genotype. 
62nd Annual Meeting of the American Association for the Study of Liver 
Diseases (AASLD), San Francisco, CA, United States of America.
2011 32 hours
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HBsAg levels at six months post-treatment predict sustained response through 
long-term follow-up in HBeAg-positive patients treated with peginterferon 
alfa-2b. 62nd Annual Meeting of the American Association for the Study of Liver 
Diseases (AASLD), San Francisco, CA, United States of America.
2011 32 hours
Influence of the presence of precore and core promoter mutants on the 
relationship between hepatitis B e antigen levels and response to peginterferon 
therapy. 62nd Annual Meeting of the American Association for the Study of 
Liver Diseases (AASLD), San Francisco, CA, United States of America.
2011 32 hours
Presence of precore and core promoter mutants limits the probability of 
achieving a sustained virological response to peginterferon in HBeAg-positive 
chronic hepatitis B. 62nd Annual Meeting of the American Association for the 
Study of Liver Diseases (AASLD), San Francisco, CA, United States of America.
2011 32 hours
Peginterferon is superior to prolonger entecavir therapy for serological 
response in HBeAg-positive chronic hepatitis B. 62nd Annual Meeting of the 
American Association for the Study of Liver Diseases (AASLD), San Francisco, 
CA, United States of America.
2011 32 hours
Relationship between precore / basal core promoter mutants and serological 
or virological response in HBeAg-positice chronic hepatitis B patients treated 
with nucleo(s)tide analogues. 62nd Annual Meeting of the American Association 
for the Study of Liver Diseases (AASLD), San Francisco, CA, United States of 
America.
2011 32 hours
Elevated ALT is only predictive for a sustained virological response to 
peginterferon in HBeAg-positive chronic hepatitis B patients with wildtype 
virus. 62nd Annual Meeting of the American Association for the Study of Liver 
Diseases (AASLD), San Francisco, CA, United States of America.
2011 32 hours
Serum levels of interferon-gamma inducible protein (IP-)10 are associated with 
response to peginterferon treatment in genotype D HBeAg-negative chronic 
hepatitis B. 62nd Annual Meeting of the American Association for the Study of 
Liver Diseases (AASLD), San Francisco, CA, United States of America.
2011 32 hours
Prediction of response to peginterferon for HBeAg-positive chronic hepatitis B 
using quantitative serology: HBeAg versus HBsAg. 47th Annual meeting of the 
European Association of the Study of the Liver, Barcelona, Spain
2012 32 hours
Pre-treatment levels of IP-10 predict response to peginterferon in HBeAg-
positive chronic hepatitis B patients. 63rd Annual Meeting of the American 
Association for the Study of Liver Diseases (AASLD), Boston, MA, United 
States of America.
2012 32 hours
Attended (inter)national conferences
44th Annual Meeting of the European Association for the Study of the Liver 
(EASL). Copenhagen, Denmark.
2009 28 hours
The Liver Meeting 2009, 60th Annual Meeting of the American Association for 
the Study of Liver Diseases (AASLD). Boston, MA, United States of America.
2009 28 hours
45th Annual Meeting of the European Association for the Study of the Liver 
(EASL). Vienna, Austria.
2010 28 hours
Twice annual meeting of the Netherlands Association of Hepatology, 
Veldhoven, the Netherlands.
2010 12 hours
The Liver Meeting 2010, 61st Annual Meeting of the American Association for 
the Study of Liver Diseases (AASLD). Boston, MA, United States of America.
2010 28 hours
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46th Annual Meeting of the European Association for the Study of the Liver 
(EASL). Berlin, Germany.
2011 28 hours
Twice annual meeting of the Netherlands Association of Hepatology, 
Veldhoven, the Netherlands.
2011 12 hours
The Liver Meeting 2011, 62nd Annual Meeting of the American Association 
for the Study of Liver Diseases (AASLD). San Francisco, CA, United States of 
America.
2011 28 hours
10th European meeting on HIV and hepatitis. Barcelona, Spain. 2012 14 hours
47th Annual Meeting of the European Association for the Study of the Liver 
(EASL). Barcelona, Spain.
2012 28 hours
63rd Annual Meeting of the American Association for the Study of Liver 
Diseases (AASLD), Boston, MA, United States of America.
2012 28 hours
Awards
Full bursary from the European Association for the Study of the Liver (EASL) 
awarded for the best abstracts by young investigators
2011
Full bursary from the European Association for the Study of the Liver (EASL) 
awarded for the best abstracts by young investigators
2012
Attended seminars and workshops
Tweede Lagerhuisdebat Hepatitis B en C. Amsterdam, the Netherlands 2009 2 hours
7th Post-AASLD symposium. Rotterdam, the Netherlands 2009 2 hours
Derde Lagerhuisdebat Hepatitis B en C. Utrecht, the Netherlands 2010 2 hours
8th Post-AASLD symposium. Rotterdam, the Netherlands 2010 2 hours
9th Post-AASLD symposium. Rotterdam, the Netherlands 2011 2 hours
Het infectieziekten laboratorium van de toekomst. Amsterdam, the Netherlands 2011 8 hours
10th Post-AASLD symposium. Rotterdam, the Netherlands 2012 2 hours
Reviewer for scientific journals
Including Gastroenterology, Hepatology, Gut, Journal of Hepatology
2. Teaching
lecturing
Baseline predictors of response of chronic hepatitis B patients to 
peginterferon: HBV genotype. HBV Preceptorship Program. Rotterdam, the 
Netherlands
2010 6 hours
Een nieuwe toekomst voor oude markers bij de behandeling van hepatitis B. 
Het infectieziektenlaboratorium van de toekomst. Amsterdam, the Netherlands
2011 6 hours
Management of chronic hepatitis B: immune modulation or antiviral action? 
Lecture for second year student participating in a MSc programme in Infection 
and Immunity.
2012 6 hours
Debate: Interferons for treatment of hepatitis B. Pro standpoint. 10th European 
meeting on HIV & Hepatitis. Barcelona, Spain.
2012 14 hours
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Behandeling van chronische hepatitis B en de rol van kwantitatief HBsAg. 
Landelijke Hepatitis Dag 2012.
2012 14 hours
What’s new in chronic hepatitis B? Post-AASLD symposium 2012. WTC, 
Rotterdam
2012 6 hours
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Abbreviations
ALT Alanine aminotranferase
anti-HBe Antibody against HBeAg
Anti-HBs Antibody against HBsAg
BCP Basal core promoter
cccDNA Covalently closed circular DNA
CHB Chronic hepatitis B
CI Confidence interval
ETV Entecavir
HBeAg Hepatitis B e antigen
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
HCV Hepatitis C virus
HDV Hepatitis D virus
HBV DNA Hepatitis B virus DNA
HCC Hepatocellullar carcinoma
HCV Hepatitis C virus
HIV Human immunodeficiency virus
HR Hazard ratio
IL28B Interleukin 28-B
LAM Lamivudine
NA Nucleo(s)tide analogues
PC Precore
PCR Polymerase chain reaction
PEG-IFN Pegylated interferon
TDF Tenofovir disoproxil fumarate
ULN Upper limit of normal
WT Wildtype
